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Summary 
In recent years a new focus has been put on malaria, and elimination and eradication of this 
disease has been brought back to the agenda. While Plasmodium falciparum causes most of 
the disease in Africa, P. vivax is predominant in malaria endemic regions in Latin America, 
Asia and the South Pacific. In the last 10 years increasing reports of severe disease and even 
mortality caused by P. vivax raised new awareness for this parasite. Forty percent of the 
world population lives in areas of P. vivax transmission, and severe disease is caused 
especially in infants and young children. P. vivax has the ability to form semi-dormant liver 
hypnozoites that can relapse and lead to clinical disease after an extended period of time. As 
most currently applied drugs are not effective against hypnozoites, they present a mayor 
obstacle towards malaria control. 
In the lowlands of Papua New Guinea (PNG), malaria prevalence reaches levels similar to 
those in sub-Saharan Africa. Both P. falciparum and P. vivax are frequent, and P. vivax 
reaches prevalence higher than anywhere else in the world. Individuals from these regions 
are often co-infected by both parasite species. Multiple concurrent infections with different 
strains of P. falciparum or P. vivax are common. For this thesis I have genotyped over 3000 
P. vivax positive blood samples collected in a cohort study of 264 children. These children, 
aged 1 to 4.5 years, were followed over 16 months and visited every 8 weeks for collection of 
two blood samples taken 24 hours apart. Additional samples were collected whenever the 
children presented sick to the local health centre. In parallel morbidity data was collected. P. 
vivax was genotyped using two size polymorphic markers, which both distinguished individual 
parasite clones. Genotyping data of P. falciparum clones was available from a previous study. 
Extensive diversity of the genotyping markers and high multiplicity of infection (MOI, the 
number of co-occurring clones per carrier) was observed. Each P. vivax positive child carried 
a mean of 2.7 concurrent infections, mean MOI was nearly twice as high as P. falciparum 
multiplicity in the cohort. We did not detect a seasonal trend in MOI, and only a moderate 
increase of MOI with age, most pronounced in very young children up to 3 years. Most likely 
relapses increase P. vivax mean MOI, and they also lead to high MOI during seasons of less 
transmission. 
The detection of parasitemia in field surveys is imperfect owing to parasite densities below or 
fluctuating around the detection limit of light microscopy or PCR. We have compared >1000 
pairs of samples collected 24 hours apart. The collection of a second sample was found to 
have a limited effect on parasite prevalence: a single PCR missed only 6 to 9% of the 
combined parasite positivity. The proportion of individual clones missed was more 
pronounced. Depending on the marker, 19% or 31% of all P. vivax clones were missed when 
sampling on a single day. As a consequence, mean MOI increased from 2.7 to 3.4 when 
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combining results from paired samples. Detectability does not differ between P. vivax and P. 
falciparum or between age groups. Thus comparisons of prevalence and MOI between 
species and age trends are not biased by detectability. 
To investigate structuring of P. vivax population in PNG, we have typed a subset of samples 
with 13 additional markers. Allele frequencies and haplotypes were compared to those from 
samples collected at other sites in PNG. No differences were detected between parasite 
populations, most likely because of high gene flow between sites. This is in contrast to the 
situation in countries of lower endemicity, and differs from the earlier observed moderate 
structuring in P. falciparum populations from PNG. 
In this cohort study, the incidence of P. vivax malaria decreased with age, whereas the 
incidence of  P. falciparum peaked later at the age of 3.5 years. These contrasting trends are 
in line with results from other countries were both parasites are co-endemic. Differences in the 
parasite biology, e.g. a more limited reservoir of surface antigens of P. vivax compared to P. 
falciparum, might cause faster immunization against P. vivax and thus the different age trends 
in incidence. But also differences in transmission intensity might be responsible. Our typing of 
clones over an extended period of time allowed estimations of the molecular force of infection 
(molFOI), i.e. the number of infections per child per year. Each child acquired 14 P. vivax 
clones per year, but only 6 P. falciparum clones. molFOI did not change with age, suggesting 
that acquired immunity builds up gradually with each new clone, leading to a decrease in P. 
vivax incidence over time. This does not rule out that biological differences between P. vivax 
and P. falciparum also play a role. 
PNG is among the countries with the poorest health infrastructure and the highest prevalence 
of malaria. P. vivax prevalence is in some regions as high as P. falciparum prevalence. High 
MOI and molFOI, as well as high levels of gene flow imply great resilience of P. vivax towards 
antimalarial interventions. Fast acquisition of semi-immunity leads to a large number of 
asymptomatic P. vivax carriers, potentially contributing to transmission, and control is further 
complicated by relapses, occurring in the blood weeks or months after transmission from the 
mosquito. The high proportion of P. vivax will be a major challenge towards malaria control 
and elimination in PNG. 
Zusammenfassung 
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Zusammenfassung 
In den letzten Jahren erhielt die Krankheit Malaria neue Aufmerksamkeit, und ihre Ausrottung 
in einzelnen Ländern oder gar weltweit wird wieder als realistisches Ziel angesehen. 
Plasmodium falciparum verursacht die meisten Krankheitsfälle in Afrika, dagegen ist P. vivax 
der vorherrschende Parasit in Malariagebieten in Lateinamerika, Asien und dem Südpazifik. 
In den letzten zehn Jahren haben Forschungen gezeigt, dass P. vivax häufig schwere 
Krankheit bis hin zum tödlichen Verlauf verursachen kann, insbesondere bei Kleinkindern. 
Dadurch geriet der Parasit nach Jahren mit wenig Beachtung erneut in den Fokus der 
Forschung. Vierzig Prozent der Weltbevölkerung leben in Gebieten mit P.vivax-Übertragung. 
P. vivax hat die Fähigkeit, Ruhestadien zu bilden, welche längere Zeit nach der Übertragung 
zum erneuten Krankheitsausbruch führen können. Die meisten der heute vorhandenen 
Medikamente sind wirkungslos gegen Leberstadien, darum sind diese eine grosse Hürde auf 
dem Weg zur Bekämpfung von Malaria. 
In tief liegenden Gebieten von Papua Neuguinea erreicht die Malariaprävalenz Werte ähnlich 
der in Afrika südlich der Sahara. P. falciparum wie auch P. vivax sind häufig, und die P. vivax 
Prävalenz ist höher als irgendwo sonst auf der Welt. Bewohner dieser Gegenden sind häufig 
gleichzeitig mit beiden Spezies infiziert, sowie mit verschiedenen Linien derselben Art. Für 
diese Arbeit wurden die P. vivax Stämme in über 3'000 positiven Blutproben analysiert, die im 
Rahmen einer Kohortenstudie mit 264 Kindern gesammelt wurden. Diese Kinder im Alter von 
1 bis 4.5 Jahren wurden während 16 Monaten alle 2 Monate besucht um im Abstand von 24 
Stunden zwei Blutproben zu sammeln. Zusätzliche Proben wurden gesammelt, wann immer 
ein Kind eines der Gesundheitszentren aufsuchte. Parallel dazu wurden alle Erkrankungen 
der Kinder registriert. P. vivax Stämme wurden aufgrund von zwei molekularen Markern, bei 
welchen sich die Allele in der Grösse unterscheiden, typisiert. Im Rahmen einer 
vorhergehenden Studie wurden die P. falciparum Stämme in der Kohorte typisiert.  
Die gewählten Marker wiesen eine hohe Diversität auf, und die Multiplizität (die Anzahl 
verschiedener Stämme pro Träger) war hoch. Jedes infizierte Kind trug im Schnitt 2.7 P. vivax 
Stämme, dieser Wert ist fast doppelt so hoch wie derjenige von P. falciparum. Es gab keine 
saisonalen Unterschiede in der Multiplizität, und nur einen geringen Anstieg der Multiplizität 
mit dem Alter der Kinder; dieser war am deutlichsten in sehr jungen Kindern unter 3 Jahren. 
Es ist davon auszugehen, dass wiederausbrechende Leberstadien die Multiplizität erhöhen, 
dies auch während Jahreszeiten mit geringerer Übertragung durch Mücken. 
In Feldstudien ist die Detektion von Parasiten häufig unvollständig, d.h. die Dichte eines Teils 
der Parasiten liegt unter der Nachweisgrenze von Mikroskopie oder molekularen Methoden 
wie PCR. Wir haben über 1000 Blutproben-Paare verglichen, welche im Abstand von 24 
Stunden gesammelt wurden. Die zusätzliche zweite Blutprobe hatte einen eher geringen 
Zusammenfassung 
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Einfluss auf die Prävalenz, mittels PCR wurden nur 6 bis 9% der Proben falsch negativ 
diagnostiziert. Der Anteil der Stämme, die in einer einzelnen Proben nicht detektiert wurden, 
war dagegen ausgeprägter. Je nach Marker wurden 19 oder 31% aller P. vivax Stämme, die 
an mindestens einem der 2 Tage nachgewiesen wurden, am Tag 1 nicht entdeckt. Als Folge 
stieg die Multiplizität von 2.7 auf 3.4 wenn die Resultate von beiden Tagen kombiniert 
wurden. Die Wahrscheinlichkeit, einen Stamm zu detektieren, unterscheidet sich nicht 
zwischen P. vivax und P. falciparum oder in verschiedenen Altersklassen, folglich werden 
Vergleiche der Prävalenz und Multiplizität nicht beeinflusst. 
Um die Populationsstruktur von P. vivax in Papua Neuguinea zu untersuchen haben wir einen 
Teil der Proben aus unserer Kohorte mit 13 weiteren molekularen Markern untersucht. Die 
Allele-Frequenzen und die Haplotypen wurden verglichen mit den-jenigen von drei anderen 
Orten in Papua Neuguinea. Es wurden keine Unterschiede zwischen diesen 
Parasitenpopulationen festgestellt, sehr wahrscheinlich aufgrund eines häufigen genetischen 
Austauschs zwischen den Populationen. Im klaren Gegensatz dazu wurden in Gebieten mit 
geringer P. vivax Prävalenz ausgeprägte Unterschiede zwischen Populationen beobachtet, 
und in früheren Studien wurde auch eine moderat ausgeprägte Populationsstruktur von P. 
falciparum in Papua Neuguinea festgestellt. 
Die Inzidenz von P. vivax, also die Anzahl Erkrankungen, nahm in der Kohorte mit dem Alter 
deutlich ab, dagegen stieg die P. falciparum Inzidenz bis zu einem Alter von 3.5 Jahren. 
Diese gegensätzlichen Trends bestätigen Beobachtungen aus anderem Gebieten, wo beide 
Parasiten endemisch sind. Als mögliche Ursache kommen Unterschiede in der Biologie der 
Parasiten in Frage, z.B. eine kleinere Diversität von Oberflächenproteinen von P. vivax, 
wodurch die Immunisierung schneller verlaufen sollte. Auch sind Unterschiede in der 
Übertragungsrate von P. vivax und P. falciparum möglich. Unsere Typisierung von Stämmen 
über einen längeren Zeitraum ermöglicht, die „molekulare Infektionshäufigkeit“ zu bestimmen, 
also die Anzahl Infektionen pro Kind pro Jahr. Jedes Kind wurde im Schnitt mit über 14 P. 
vivax-Stämmen pro Jahr infiziert, aber nur mit etwa 6 P. falciparum-Stämmen. Die 
Infektionshäufigkeit änderte sich nicht mit dem Alter, dies lässt darauf schliessen, dass die 
Kinder mit der Zeit allmählich Immunität erlangten, und dadurch die Anzahl Erkrankungen 
zurückging. Dies schliesst natürlich nicht aus, dass auch Unterschiede in der Biologie eine 
Rolle spielt im Erlangen von Immunität. 
Papua Neuguinea ist eines der Länder mit dem schlechtesten Gesundheitswesen und 
gleichzeitig einem hohen Auftreten von Malaria. Die Prävalenz von P. vivax ist manchen 
Gegenden gleich hoch wie diejenige von P. falciparum. Die hohe Multiplizität und 
Infektionshäufigkeit, wie auch der hohe Grad von genetischem Austausch zwischen 
Parasitenpopulationen, lässt auf einen hohen Widerstandsgrad gegenüber Massnahmen zur 
Malariakontrolle schliessen. Die schnelle Immunisierung gegen P. vivax führt dazu, dass es 
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eine grosse Zahl von asymptomatischen Trägern gibt, die vermutlich immer noch zur 
Übertragung beitragen. Die Bekämpfung von P. vivax wird weiter erschwert durch die 
Leberstadien, welche noch Wochen oder Monate nach der Übertragung zu 
Krankheitsausbrüchen führen können. Der hohe Anteil von P. vivax an allen Malariafällen 
wird Papua Neuguinea vor grosse Herausforderungen stellen auf dem Weg zur Kontrolle und 
Elimination von Malaria. 
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Abbreviations 
ama1  apical membrane protein 1  
CE  capillary electrophoresis 
csp  circumsporozoite protein  
DALY  disability-adjusted life-year 
dbp  duffy binding protein 
dhfr  dihydrofolate reductase 
DNA  deoxyribonucleic acid 
dNTP  Deoxyribonucleotide triphosphate 
FOI  force of infection 
HE  expected heterozygosity = virtual heterozygosity 
IRB  Institutional Review Board 
ITN  insecticide treated bed net 
LD  linkage disequlibrium  
LDR-FMA ligase detection reaction-fluorescent microsphere assay  
LM  light microscopy 
MOI  multiplicity of infection 
molFOI  molecular force of infection 
MRAC   Medical Research Advisory Committee 
MS  Microsatellite 
msp  merozoite surface protein 
msp1F3 F3 region of the merozoite surface protein 1 
PCR  polymerase chain reaction 
PfEMP-1 P. falciparum Erythrocyte Membrane Protein 1 
PNG  Papua New Guinea 
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PNG IMR Papua New Guinea Institute of Medical Research 
PvAPI  P. vivax annual parasite index 
RBC  red blood cell 
RDT  rapid diagnostic test  
RFLP  restriction fragment length polymorphism 
SNP  single nucleotide polymorphism 
Swiss TPH Swiss Tropical and Public Health Institute 
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Introduction 
 
Malaria: Affecting Humanity from Individuals to the Wealth of Nations 
Malaria is one of the most deadly parasitic diseases in the recent history of mankind (Hay et 
al., 2004). Despite a recent decline in the number of deaths an estimated 781ʼ000 people 
have died from malaria in 2009 (World Health Organization., 2010b). It affects humans from 
the individual level to that of health systems or wealth of nations.  
Many individuals in the tropics are affected by malaria throughout their life. During pregnancy 
millions of mothers and their unborn babies are especially vulnerable to malaria (Dellicour et 
al., 2010), and life starts for many newborns in endemic areas with reduced birth weight 
because of malaria during pregnancy. Early childhood is characterized by repeated clinical 
episodes of malaria. Morbidity and mortality peak in children below 5 years. In school children 
malaria causes repeated absence from school and caretakers are kept away from work. 
Adults, despite developing partial immunity during teenage years in areas of intense 
transmission, still suffer occasionally from sporadic malarial episodes, keeping them away 
from studies or work. Malaria accounts for up to 10% of all disability-adjusted life-years 
(DALYs) in regions of intense transmission (Breman et al., 2006). The United Nations have 
declared to combat malaria and other infectious diseases as one of the millennium 
development goals (www.un.org/millenniumgoals). 
Health costs caused by malaria and loss of income due to disease account for a substantial 
part of household costs in some countries (Russell, 2004), and it has been observed that in 
countries of high malaria prevalence economic growth lags behind that in comparable non-
malarial countries (Sachs and Malaney, 2002). It has been estimated that the growth is 
reduced by 1.3% per year in countries with intensive malaria as compared to non-endemic 
countries (Gallup and Sachs, 2001). 
Malaria has been called “the strongest known force for evolutionary selection in the recent 
history of the human genome” (Kwiatkowski, 2005). The sickle-cell disease, a haemoglobin 
disorder that leads to resistance of severe forms of malaria in heterozygous individuals, but is 
lethal when homozygous, has become a textbook example of adaptation (Barreiro and 
Quintana-Murci, 2010). 
Malaria is caused by different Plasmodium species, unicellular parasites of the Phylum 
Apicomplexa. Parasites are transmitted by mosquitoes of the genus Anopheles and have 
probably infected humans for ten thousands or even million of years (Carter, 2003; Escalante 
et al., 2005; Pick et al., 2011; Silva et al., 2011).  
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Hundreds of Plasmodium species infect mammals, birds and reptiles, and four species – P. 
falciparum, P. vivax, P. malariae and P. ovale – are frequently infecting humans. P. 
falciparum accounts for most of the malaria cases in sub-Saharan Africa, the region suffering 
most from malaria, while P. vivax is the predominant species outside Africa and P. malariae 
and P. ovale account for smaller proportions of cases (Guerra et al., 2010; Hay et al., 2009; 
Mueller et al., 2007; World Health Organization., 2010b). More recently, reports from Malaysia 
have shown P. knowlesi, usually known as an old-world Macaca monkey malaria parasite, to 
infect humans (Cox-Singh et al., 2008; Singh et al., 2004). It is currently unclear whether 
human-to-human transmission of P. knowlesi occurs under natural conditions.  
 
The Burden of Plasmodium vivax Malaria 
It has been estimated that 2.85 billion people, around 40% of the world population, live in 
areas of P. vivax transmission (Figure 1) (Guerra et al., 2010). Estimations of the total number 
of cases per year range from 60-70 million (Mendis et al., 2001) to 391 million (Price et al., 
2007) or up to 435 million (Baird, 2007). Even if the latter numbers represent overestimates 
and no recent publications have come to a similar number, there is no doubt that P. vivax 
accounts for a significant proportion of all human malaria cases. 
 
 
Figure 1: The global spatial limits of Plasmodium vivax malaria transmission in 2009. Red = stable 
transmission (PvAPI (P. vivax annual parasite index) ≥0.1 per 1,000 people p.a.), pink=unstable 
transmission (PvAPI<0.1 per 1,000 p.a.). Areas where the prevalence of the Duffy negative blood group 
(conferring nearly complete resistance to P. vivax) was estimated to >90% are hatched. Source: Malaria 
Atlas Project (Guerra et al., 2010) 
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Despite the high number of P. vivax cases and global distribution in tropical areas, malaria 
research has focussed for most of the 20th century on P. falciparum. P. falciparum is the most 
deadly malaria parasite, and the dominating parasite in sub-Saharan Africa, the region by far 
most affected by malaria. The number of people living in areas of P. falciparum transmission 
is estimated to 1.38 billion (about half of them living in Africa and the other half in Asia) (Hay 
et al., 2009). This number of individuals at risk is much lower than 2.85 billion people living in 
P. vivax transmission areas (Guerra et al., 2010). The number of yearly P. falciparum cases is 
estimated to over 450 million (Hay et al., 2010), and the vast majority of the up to one million 
people that die each year from malaria are infected with P. falciparum, (World Health 
Organization., 2010b). Most of them are children from sub-Saharan Africa below 5 years 
(Snow et al., 1999). The high P. falciparum prevalence and mortality led to neglect of 
research on other Plasmodium spp. Only in recent years intensified research on P. vivax was 
called for, and P. vivax-specific research questions were raised (Carlton et al., 2011; de 
Lacerda et al., 2007; Galinski and Barnwell, 2008; Mendis et al., 2001; Mueller et al., 2009a; 
Price et al., 2007; Sina, 2002). 
 
Comparison of P. vivax and P. falciparum Morbidity 
Numerous reports on severe and even lethal outcome of P. vivax malaria led to a change in 
perception of P. vivax malaria. Traditionally called “benign tertian malaria”, P. vivax proved to 
be far more harmful than earlier appreciated (Anstey et al., 2009; Kochar et al., 2005). 
A number of studies have compared severity of disease caused by P. falciparum and P. 
vivax. Some studies compared patients from areas with sympatric P. falciparum and P. vivax 
transmission who were infected with either species and admitted to the same hospital. This 
allows direct comparison of disease outcome of, with little confounding of external factors 
such as quality of treatment, general level of immunization in the population, use of bed nets 
and history of drugs used in the area. Genton and coworkers analyzed over 9ʼ500 malaria 
cases with confirmed parasitemia in the Wosera area of Papua New Guinea (Genton et al., 
2008). Overall, P. falciparum was over 3 times as frequent as P. vivax based on microscopic 
diagnosis, however, the ratio of cases that lead to severe malaria (defined as parasitemia 
plus a recent history of fits, coma, breathing problems, or anemia) was similar for both 
species: 11.7% for P. falciparum and 8.8% for P. vivax (Genton et al., 2008). Poespoprodjo 
and coworkers have studied 1560 infants that were admitted with malaria to a hospital in 
Papua, Indonesia, with similar numbers of P. falciparum and P. vivax infections 
(Poespoprodjo et al., 2009). The rate of deaths attributed to P. falciparum was higher 
compared to P. vivax (2.2% vs. 1.0%, not significant), while severe anemia was significantly 
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higher in P. vivax patients (Poespoprodjo et al., 2009). In another study in Papua, Indonesia, 
P. vivax-associated coma occurred 23 times less often than in P. falciparum malaria (Lampah 
et al., 2011). In the same hospital, P. falciparum accounted for two out of three hospital 
admissions due to Malaria, but the risk of severe disease was slightly, but significantly higher 
(23% vs. 20%) in patients presenting with P. vivax compared to P. falciparum (Tjitra et al., 
2008). In contrast in northeastern Papua, Indonesia, among all patients admitted to the 
hospital with malaria, the risk of severe disease was about twice as high in patients positive 
for P. falciparum compared to P. vivax (7% vs. 3%) (Barcus et al., 2007). However, the rate of 
fatal outcome in those patients suffering from severe malaria was identical for both species 
(Barcus et al., 2007). Papua New Guinean children aged 5 to 14 years acquired similar 
numbers of P. falciparum and P. vivax infections, but the risk of developing symptomatic 
malaria was 21 times higher in P. falciparum infections (Michon et al., 2007). 
In summary, these studies show the general picture of a more severe outcome of falciparum 
malaria compared to P. vivax infections, however, depending on the symptoms measured and 
on the age group studied, vivax malaria can cause nearly as much morbidity. An age shift 
between P. vivax and P. falciparum incidence illustrates best the different patters of infections 
by both malaria species. P. vivax malaria reaches highest prevalence and causes most 
disease in the fist year of life. P. falciparum becomes the dominating parasite at the age of 2 
to 5 few years and caused most clinical cases throughout childhood and adolescence (Barcus 
et al., 2007; Genton et al., 2008; Kochar et al., 2010; Poespoprodjo et al., 2009). 
 
Specific Aspects of P. vivax Cell Biology, Life Cycle and Epidemiology 
P. vivax and P. falciparum are of different phylogenetic origin. Most probably two independent 
host switches from monkey to human occurred, with the origin of P. vivax in Asia and the 
origin of P. falciparum in Africa (Cornejo and Escalante, 2006; Escalante et al., 2005; Krief et 
al., 2010; Pick et al., 2011; Silva et al., 2011). As a consequence P. vivax differs in many 
aspects from P. falciparum, from molecular and cell biology to epidemiology.  
P. vivax infects only reticulocytes, young erythrocytes that account for only a few percent of all 
red blood cells. As a consequence, parasitemia of P. vivax is usually an order of magnitude 
lower than those of P. falciparum, and rarely reaches values above 0.5%. Furthermore, P. 
vivax was long believed to depend fully on the Duffy receptor for invasion into the red blood 
cell (Miller et al., 1976), while P. falciparum invades cells independently of this receptor. In 
large parts sub-Saharan Africa, over 90% of the population carry the Duffy negative trait, and 
as a consequence, P. vivax is rare in this part of the world. Recent reports showed also Duffy-
negative individuals to become eventually infected with P. vivax (Mendes et al., 2011; 
Mercereau-Puijalon and Menard, 2010). This suggests that P. vivax is more frequent that 
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previously appreciated in Africa. Serological evidence suggests that 13% of the population in 
Congo has been in contact with P. vivax (Culleton et al., 2009), and P. vivax transmission was 
also reported from Uganda (Dhorda et al., 2011). Future research will show whether P. vivax 
has been more common in Africa but has been frequently misdiagnosed as other Plasmodium 
species. 
A consequence of the clear preference of P. vivax for reticulocytes, which are difficult to 
obtain, so far no continuous in-vitro culture could be established (Udomsangpetch et al., 
2008). In spite of intensified efforts to develop culture techniques, for example based on 
human blood enriched for reticulocytes, no continuous in vitro culture system was reported 
yet. 
A further characteristic of P. vivax is the early appearance of gametocytes, the sexual forms 
of the parasite, which are transmitted by mosquitoes. P. vivax gametocytes appear a few 
days after infection, and before the onset of clinical symptoms (reviewed in (Bousema and 
Drakeley, 2011)).  
P. falciparum parasites sequester for part of their 48 hours life cycle, i.e. the infected red 
blood cells cytoadhere in the deep capillaries of inner organs (Garnham, 1966). This prevents 
passage of parasites through the spleen where infected red blood cells are filtered out. P. 
vivax does not sequester as completely as P. falciparum, but partial sequestration has been 
discussed also from P. vivax (del Portillo et al., 2004). The presence of all stages of the red 
blood cell cycle of P. vivax in the blood is one of the characteristics to identify P. vivax by light 
microscopy. Already in 1966 Garnham noted a slight tendency of late P. vivax stages to be 
absent in peripheral circulation (Garnham, 1966), and recently adhesion of P. vivax infected 
erythrocytes to lung endothelial cells was shown, however at a 10-fold lower level than P. 
falciparum adhesion (Carvalho et al., 2010). 
One of the most outstanding hallmarks of P. vivax is its ability to relapse weeks or months 
after the initial transmission by mosquitoes. Semi-dormant liver stages, called hypnozoites, 
are released into the blood stream, leading to blood stage parasitemia and even clinical 
episodes in absence of transmission. Duration between infection and relapse seems to differ 
between regions of different transmission intensity. In regions where transmission only occurs 
during limited time of the year relapses occur after several months or even after a year 
(Mason, 1975). But in regions of intense transmission relapses generally occur within the first 
few months after initial infection. The mechanism to trigger relapses is not known. It has been 
speculated that relapse could be triggered by new Anopheline bites or by an infection with a 
new P. vivax strain, both indicating the potential for transmission to the hypnozoites (Hulden, 
2011). 
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It has long been unclear whether a relapsing parasite clone is genetically identical to the last 
infection. Early studies with limited resolution of molecular markers and low numbers of 
samples have concluded that relapses correspond to the previous blood stage infection (Craig 
and Kain, 1996; Kirchgatter and del Portillo, 1998). More recent studies with larger numbers 
of study participants were conducted in settings were re-infection by mosquitoes could be 
excluded and showed that relapsing parasites differ from those observed at the last infection 
in most of the cases (Imwong et al., 2007b; Restrepo et al., 2011). As a consequence 
relapsing parasites cannot be distinguished from new infection. It is not fully clear whether all 
relapsing parasites had been present as blood stage infection at an earlier time point. It is 
possible that a number of blood stage infections classified as relapses are the result of 
extended latency periods of P. vivax liver stages. 
Genotyping of malaria parasites has become standard in many drug efficacy field studies. 
Genotypes of parasites at baseline are compared to those at the day of recurrent parasitemia 
to distinguish between treatment failure and new infection. Interpretation of results from drugs 
affecting P. vivax blood stage stages are complicated as no differentiation between relapses 
and new infections is possible. Relapsing parasites also add to the complexity of infection. 
When they coincide with transmitted parasites, they add to multiplicity of infection, and thus to 
the potential for sexual recombination between parasite lines in the mosquito. 
Another hallmark of P. vivax is a global distribution (Figure 2). P. vivax transmission occurs in 
the tropics but also in tempered zones, e.g. Middle East and Asia. In the past even large 
areas of Europe, up to England and Sweden, were P. vivax endemic, as well as tempered 
zones of Asia up to Siberia (Hay et al., 2004; Mendis et al., 2001) (Figure 2).  
 
Figure 2: global distribution of malaria from 1900 (prior to malaria control) to 2002 (Hay et al., 2004). P. 
vivax had been transmitted in much of the area that became malaria free during the 20th century in 
Europe, America and Asia. 
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P. vivax Specific Challenges in Malaria Elimination and Eradication 
In October 2007 eradication of malaria was brought back to the agenda at a meeting of the 
Bill and Melinda Gates foundation (Roberts and Enserink, 2007; Tanner and de Savigny, 
2008). Since then, numerous reports, articles and even special editions of entire journals have 
pointed out aspects to consider to achieve elimination (absence of malaria transmission in a 
defined geographical area) and eradication (absence of malaria from the planet) (Das and 
Horton, 2010; Singh, 2009). A detailed research agenda ranging from drugs and vaccines 
over vector control to health system strengthening and monitoring was presented by the 
international “malERA” initiative in January 2011 (Alonso et al., 2011).  
In a first step elimination shall be achieved in countries of comparable low endemicity and 
unstable transmission. It is reasonable to expect fast success by this approach of fighting 
malaria from the boarders of its transmission area, while elimination in countries of very high 
transmission will only be achieved at a later time point (Feachem et al., 2010). Many countries 
with lower transmission are found in Latin America and Asia, and in most of these countries 
P. vivax is the dominant cause of malaria.  
Thus P. vivax will likely play a key role on the path to eradication, and intensified research on 
species-specific intervention strategies is needed. In October 2008 the genome of P. vivax 
was published (Carlton et al., 2008) as well as the transcriptome of the red blood cell cycle 
(Bozdech et al., 2008). For transcriptome studies parasites were obtained from patients and 
maintained in short term culture for 48 hours. In 2010 a second genome was published, 
adding a lot to the knowledge on frequency and distribution of polymorphisms between 
different P. vivax genomes (Dharia et al., 2010). These studies provide the basis for research 
towards a better understanding of basic P. vivax biology. 
Biological differences between P. falciparum and P. vivax have implications for control 
strategies. One of the biggest hurdles to stop P. vivax transmission is the presence of 
relapses. So far only one approved drug, Primaquine, eliminates hypnozoites from the liver. 
However, Primaquine can lead to severe side effects in individuals suffering from glucose-6-
phosphate dehydrogenase (G6PD) deficiency (Clyde, 1981), the most common enzyme 
deficiency worldwide (Frank, 2005). Due to high prevalence of G6PD deficiency in some 
malaria endemic regions, it has been speculated that it confers some resistance to malaria 
(Ruwende and Hill, 1998). As a consequence of its side effects primaquine is not 
recommended for use in G6PD deficient patients (World Health Organization., 2010a). 
As primaquine is not used as standard treatment against P. falciparum malaria even in 
regions of P. vivax co-endemicity, relapsing P. vivax parasitemia is frequently observed after 
P. falciparum treatment (Douglas et al., 2011). Presence of P. falciparum gametcytes seems 
to promote P. vivax relapse. A recent study from Cambodia has shown P. vivax to be present 
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in 47% of patients at 28 days after initial treatment for falciparum malaria and presence of 
gametocytes at baseline (Lin et al., 2011). As P. vivax was not detected by PCR diagnosis in 
most of the samples at day 0, most likely relapsing parasites led to the high numbers of P. 
vivax infections during follow-up (Lin et al., 2011).  
A further complication in P. vivax control is the development of gametocytes before the onset 
of clinical disease. As a consequence even non-immune individuals might transmit P. vivax 
before they even know that they are infected and before drugs to eliminate blood stage 
parasites can be applied. On the other hand, as a proportion of gametocytes is transmitted 
before drug pressure selects for potentially resistant strains, it is expected that P. vivax drug 
resistance develops slower compared to P. falciparum (Mendis et al., 2001).  
 
Malaria in Papua New Guinea 
Papua New Guinea comprises of a number of very diverse ecosystems, from tropical 
lowlands and islands to the tempered zones of the highlands and mountains reaching above 
4500 m. Also biodiversity and cultural diversity is extraordinary high in PNG, with over 800 
languages spoken in an area of about 460ʼ000 km2 (Attenborough and Alpers, 1992). In 
concordance with the geographic diversity malaria prevalence ranges from low to very high 
levels, with temperature as main determinant of transmission intensity (Cattani, 1992; Mueller 
et al., 2003). Four human malaria species are present in PNG, P. falciparum, P. vivax, P. 
malariae and P. ovale (Mehlotra et al., 2002; Mehlotra et al., 2000; Mueller et al., 2002; 
Peters, 1960), with mixed species infections frequently observed (Burkot et al., 1987; Mueller 
et al., 2009b). It is believed that P. vivax was the dominating parasite before the start of vector 
control programs in the middle of the 20th century (Cattani, 1992; Hairston et al., 1947; Muller 
et al., 2003). Pesticide spraying and mass drug administration have meanwhile changed the 
pattern, today P. falciparum is predominant in most part of the country except some regions in 
the lowlands (reviewed in (Mueller et al., 2003)). 
It has even been speculated that population distribution in PNG is a direct consequence of 
malaria prevalence (Riley, 1983). The PNG population of approximately 6.7 million people 
resides mainly in the lowlands, which are highly endemic for malaria, and in the highlands at 
an altitude of around 1500 m, where little malaria transmission prevails. Intermediate altitudes 
are less populated. The population distribution hypothesis suggested that this pattern is a 
consequence of malaria transmission. In the lowlands, high malaria prevalence leads on the 
one hand to high infant mortality, but on the other hand to high human fertility rates and fast 
immunization of individuals that survive early childhood. Malaria prevalence in highland 
valleys is too low to substantially influence population growth. In intermediate zones malaria is 
frequent enough to lead to repeated disease, but immunity does not develop rapidly. 
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In the tropical lowlands malaria prevalence is usually high with perennial transmission 
(Cattani et al., 1986; Genton et al., 1995), leading to high morbidity and mortality. In 1960, an 
infant mortality rate of 571/1000 was reported from Maprik, a region of high malaria 
endemicity (Peters, 1960), and today malaria is the most frequent outpatient diagnosis and 
the second most frequent cause of hospital admission in PNG (Mueller et al., 2003). In the 
highlands at altitudes of 1300 to 1600 m prevalence is lower and transmission usually peaks 
at the end of the rainy season in April to July (Mueller et al., 2003). During local outbreaks 
prevalence can reach high levels of above 60%, and very high morbidity and mortality is 
observed (Mueller et al., 2005). 
In 2009 a total of 1.36 million malaria cases were reported from PNG, although most of them 
were not confirmed parasitologically (World Health Organization., 2010b). Malaria prevalence 
in PNG reaches levels similar to those in sub-Saharan Africa, and P. vivax in PNG reaches 
higher levels than anywhere else in the world.  
Malariologist Robert Koch has made fundamental discoveries in PNG at the turn of the 20th 
century (Stanisic et al., 2010). Even today several aspects make malaria research in PNG 
highly relevant, many of which highlight the specific role of P. vivax: (i) P. vivax prevalence is 
higher than anywhere else observed in the world, (ii) P. vivax is a mayor public health burden 
(iii) different levels of transmission and different species composition can be studied in close 
proximity, and (iv) frequent mixed species infections allow studies on how parasites influence 
each other (multiple-species multiple-clones interactions). 
 
Context of this PhD Project 
This thesis is part of a larger study conducted by an international group of collaborators under 
the leadership of PNG IMR. The aim of this study is to obtain a profound understanding of the 
relationship between prevalence of different malaria parasites and development of disease. 
For this purpose a cohort study was conducted over 16 months in PNG. Blood samples from 
a large number of children were collected in a site of high prevalence of P. falciparum and P. 
vivax, and of lower prevalence of P. malariae and P. ovale. Samples were collected by active 
follow-up and by passive case detection at the local health centres. In parallel parameters 
such as health status and bed net use was recorded every second week from each child. 
 
Study site, sampling, parasite detection and incidence of disease 
The cohort study was conducted in several villages in the Ilahita area, Maprik district, Papua 
New Guinea from March 2006 to July 2007. Maprik district is located at the north coast in the 
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tropical lowlands of PNG, the climate is tropical with high temperatures year round. The study 
consisted of an active follow up with blood samples taken every two months from every child, 
and of passive case detection during the whole period. Two hundred sixty-four children aged 
0.5 to 3 years at age of enrolment were included in the study, after written parental consent 
was obtained from the parents or legal guardians. Details of the study site, enrolment and 
sample collection were published previously (Lin et al., 2010). 
In brief, the active follow up consisted of 2-monthly cross sectional surveys repeated 9 times 
and was carried out as follows: At baseline and in the last round of the study 5 ml venous 
blood was taken. In between, children were visited every eight weeks and 250 µl finger prick 
blood was taken regardless of presence of symptoms for malaria. With the exception of the 
first and the last round, two blood samples were taken 24 hours apart from the same child. In 
addition children were visited every two weeks and checked for signs of malaria using a 
questionnaire. In case of presence of symptoms (fever above 37.5°C) or if fever during the 48 
hours prior to the visit was reported, a 250 µl finger prick blood sample was taken. From all 
febrile children two blood slides were examined and rapid diagnostic test (RDT) was made. 
Children with confirmed parasitemia were treated with Coartem. In few cases other 
antimalarials (amodiaquine, chloroquine, sulphadoxine, artesunate, quinine and primaquine), 
received from health posts outside the study area, were given to the children; treatment 
details were recorded. 
In parallel to the periodical active follow-up, passive case detection was maintained at the 
Ilahita health centre and Sikamo aid post. Regardless of the cause of presentation to the 
health centre or the clinic, all study participants attending these health facilities were 
examined for malaria. A blood sample was taken and children were treated in case of positive 
blood slides or RDT. 
Four Plasmodium spp. were found in the study population. Species detection was done by 
light microscopy (LM) (at least two independent reads by expert microscopists), as well as by 
ligase detection reaction-fluorescent microsphere assay (LDR-FMA), a molecular method to 
detect human malaria parasites (McNamara et al., 2006). Prevalence at baseline was as 
follows: P. vivax 53.0% by LDR-FMA and 44.3% by LM, P. falciparum 49.6% by LDR-FMA 
and 32.6% by LM, P. malariae 9.9% by LDR-FMA and 4.2% by LM, P. ovale 2.7% by LDR-
FMA and 0.0% by LM (Lin et al., 2010). Incidence of P. falciparum and P. vivax malaria was 
similar, however age trends were contrasting: P. falciparum incidence peaked at around 3 
years of age with approx. 3.5 clinical episodes per child per year, P. vivax incidence dropped 
throughout the age group studied from approx. 3.5 clinical episodes per child per year in the 
youngest age group of 1 year old children to 1.5 episodes in the oldest children (Lin et al., 
2010). 
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Genotyping 
In recent years genotyping based on size polymorphic markers has become the method of 
choice for many epidemiological studies, where differentiation between individual clones is 
needed (Collins et al., 2006; Falk et al., 2006; Sutherland, 2008; World Health Organisation, 
2008). In addition it is well known that Plasmodium densities are often below the detection 
limit of light microscopy, and PCR – either to distinguish species or for genotyping – reveals 
substantially higher prevalence than microscopy alone (reviewed in (Okell et al., 2009)). Also 
in drug trials, were persisting infections (i.e. drug failure) must be distinguished from new 
infections or relapses, genotyping polymorphic markers has become a standard method 
(Gatton and Cheng, 2008; Juliano et al., 2010). This PCR correction of drug trial outcomes 
often shows that a substantial proportion of patients with recurrent parasitemia at day 28 have 
acquired new infections, hence the drug applied was more effective than estimated based on 
microscopy results only (Hwang et al., 2011; Karunajeewa et al., 2008; Ratcliff et al., 2007; 
Yavo et al., 2011). 
The prime criteria for genotyping markers for this study were high diversity and robust PCR 
amplification. A small number of markers (ideally a single marker) with a large number of 
alleles is preferred to the combination of several markers with limited diversity. Although 
guidelines define the procedure for drug efficacy genotyping based on three markers (World 
Health Organisation, 2008), the laboratory workload to analyze a single markers is lower. In 
epidemiological studies, genotyping is used to differentiate between clones and to track them 
over time. High diversity of markers is a special advantage in situations of multiple clone 
infections, when construction of haplotypes by compiling genotyping data from different loci is 
not possible or error prone.  
The P. falciparum parasites in this cohort have been genotyped using the merozoite surface 
protein 2 (msp2) as marker, results have been published (Schoepflin et al., 2009). A number 
of size polymorphic molecular markers have been identified in P. vivax (Imwong et al., 2007a; 
Imwong et al., 2005; Imwong et al., 2007b; Karunaweera, 2006). In a preliminary study we 
have assessed the diversity of nine size polymorphic molecular markers in P. vivax samples 
from PNG (Koepfli et al., 2008). Based in this study, we have selected the most diverse 
coding sequence, the F3 region of the merozoite surface protein I gene, and the most diverse 
microsatellite, MS16, for genotyping. There is no need that markers for epidemiological 
studies are neutral, as long as high diversity is maintained, markers under selection (such as 
genes coding for surface proteins of the parasite) can be used for genotyping. Care is needed 
with markers that are linked to drug resistance phenotypes. Instead of the overall diversity of 
the parasite populations they will more likely represent the history of drug use. 
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Goal and Objectives of the Thesis 
The main goal of this thesis was to describe the genetic diversity of the population of P. vivax 
parasites in the cohort study in PNG and to use the genotyping data to investigate the 
infection dynamics of P. vivax. To make further statements on population genetic parameters 
the parasite population from the cohort study was compared to P. vivax populations from 
other locations in PNG. The specific research objectives and the rationale were:  
 
I. Determine parameters of P. vivax epidemiology in a highly endemic region  
a) Over 5000 blood samples were collected in the course of the cohort study, and over 
3000 of them were diagnosed P. vivax positive by light microscopy or LDR-FMA. By 
genotyping these samples we aimed at assessing the diversity (number and 
distribution of alleles per locus, number of haplotypes) and the number of concurrent 
infections per patient (multiplicity of infection, MOI). Incidence of falciparum and vivax 
malaria show clearly contrasting age trends in our cohort (Lin et al., 2010). Hence a 
special focus was put on the investigation of age dependency of these molecular-
epidemiological parameters. 
b) For the first time for P. vivax a new parameter was to be established: the “force of 
infection” (molFOI), i.e. the number of new P. vivax infections per child per year. FOI is 
a central parameter in the study of any infectious disease. Disease is a consequence 
of infection, and many interventions to control malaria, such as administration of 
preventive drugs or bed nets, aim at reducing the number of new infections. In areas 
of lower endemicity estimates of FOI can be made based on parasite positivity, 
without genotyping clones. In situations of high endemicity, as in our cohort, infections 
usually overlap and genotyping is needed to obtain reliable estimates of FOI. 
 
II. Estimate the share of parasites that are not detected in standard 
epidemiological surveys 
Every field survey of parasitemia is confronted with the fact that a number of parasites are 
not detected, because their density is below the detection limit at the time point of 
sampling. This applies for microscopical detection of parasites as well as for molecular 
methods. Due to the combined effect of sequestration and fast asexual replication in the 
red blood cell, the number of parasites detected in the peripheral blood can change 
dramatically from one day to the other. The acquisition of a new infection or the loss of an 
infection (in absence of drug treatment) is neglectable within a 24 h period.  
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We have compared samples collected 24 hours apart from the same individual, with both 
respect to species detection of P. falciparum and P. vivax by light microscopy and PCR, 
and with respect to composition of individual clones as determined by molecular 
genotyping. This allows estimations of the detectability of parasites, and as both P. vivax 
and P. falciparum are highly prevalent in the study population, we can make direct 
comparisons between species. The parameter “clone detectability” is of great importance 
in malaria epidemiology where multiple clone co-infections are the rule. 
 
III. Compare the genetic composition of P. vivax populations in PNG  
Differences between parasite populations can reflect historic changes in epidemiology 
(such as recent expansions of populations), influence emergence and spread of drug 
resistance, and inform intervention strategies. In the third part of my thesis I aimed at 
investigating the population genetic differences between a subset of the samples of the 
study in Ilahita and three other sites in PNG. Based on multi-locus genotyping, 
parameters such as the extent of linkage disequilibrium, differences in allelic frequencies, 
levels of gene flow and population size were assessed. 
 
In the course of this thesis a further practical application of our P. vivax genotyping led to a 
collaboration on PCR correction of results from a drug trial. Results are presented in the 
appendix (manuscript published in “Antimicrobial Agents and Chemotherapy”). Four different 
drug regimens were tested in 195 children in PNG, and in a substantial number of cases 
recurrent parasitemia on day 28 or day 42 was observed (Karunajeewa et al., 2008). 
Comparison of genotyping results of day 0 samples with samples taken on the day of 
recurrent parasitemia allows distinction from true treatment failure (same genotype in both 
samples) and new infection or relapse (different genotype). 
Beside these scientific goals technology transfer to PNG and training of local researchers in 
genotyping has been an additional aspect of this thesis. Training was provided in workshops 
at the Papua New Guinea Institute of Medical research in Goroka and in Madang, as well as 
for a visiting student from PNG at the Swiss Tropical and Public Health Institute. 
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Abstract
Background: In malaria endemic areas, most people are simultaneously infected with different parasite clones. Detection of
individual clones is hampered when their densities fluctuate around the detection limit and, in case of P. falciparum, by
sequestration during part of their life cycle. This has important implications for measures of levels of infection or for the
outcome of clinical trials. This study aimed at measuring the detectability of individual P. falciparum and P. vivax parasite
clones in consecutive samples of the same patient and at investigating the impact of sampling strategies on basic
epidemiological measures such as multiplicity of infection (MOI).
Methods: Samples were obtained in a repeated cross-sectional field survey in 1 to 4.5 years old children from Papua New
Guinea, who were followed up in 2-monthly intervals over 16 months. At each follow-up visit, two consecutive blood
samples were collected from each child at intervals of 24 hours. Samples were genotyped for the polymorphic markers
msp2 for P. falciparum and msp1F3 and MS16 for P. vivax. Observed prevalence and mean MOI estimated from single
samples per host were compared to combined data from sampling twice within 24 h.
Findings and Conclusion: Estimated detectability was high in our data set (0.79 [95% CI 0.76–0.82] for P. falciparum and,
depending on the marker, 0.61 [0.58–0.63] or 0.73 [0.71–0.75] for P. vivax). When genotyping data from sequential samples,
collected 24 hours apart, were combined, the increase in measured prevalence was moderate, 6 to 9% of all infections were
missed on a single day. The effect on observed MOI was more pronounced, 18 to 31% of all individual clones were not
detected in a single bleed. Repeated sampling revealed little difference between detectability of P. falciparum and P. vivax.
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Introduction
Detection of malaria parasites is essential for many malariolog-
ical investigations. For instance, the detailed maps of global
malaria risk created by the Malaria Atlas Project (MAP) use
parasite prevalence as the main indicator for transmission
[1,2,3,4]. Prevalence is also the key malariological measure
assessed in Malaria Indicator Surveys (MIS) [5,6]. Within
populations, the identification of individual parasite clones by
PCR based genotyping techniques has substantially increased
knowledge of the infection dynamics of malaria by providing
estimates of multiplicity of infection, incidence and clearance rates
[7,8,9,10]. In addition, it allows classification of drug failures into
recrudescences and new infections.
However, all DNA based techniques for detection of malaria
parasites in a blood sample are imperfect. Parasites can remain
undetected because their densities fall below the detection limit of
the diagnostic technique. PCR based methods generally have a
better detection limit compared to microscopy [11], but both
methods likely miss a proportion of clones.
Several biological factors add to the probability of low numbers
of parasite in the blood stream and subsequently of missing clones.
In P. Falciparum infections late blood stage forms cytoadhere to the
endothelial wall of blood vessels. This sequestration of P. Falciparum
in deep organs lasts for 24–28 hrs of the 48 hrs blood stage cycle.
During this period parasites are absent from the peripheral
circulation and escape detection. A parasite clone defined by a
shared genotype and by common ancestry is completely absent
only if all individual parasites belonging to this brood are tightly
synchronized. By rare chance a clone might be superinfected by
another clone sharing the same genotype. The probability of this
occurring is determined by the resolution of the typing scheme and
the mean multiplicity of infection in the study area [12].
In blood stage schizogony a single schizont divides into
numerous merozoites [13] within a few hours. This has particular
implications for P. Vivax, because these parasites usually divide
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synchronously. As a result the number of DNA copies of a given
clone may drastically increase from one day to another. In
addition, parasite densities of P. Vivax are usually lower than those
of P. Falciparum [14,15]. Taken these factors together, imperfect
detection of P. Vivax clones is likely, however, only for P. Falciparum
this has been suspected because of sequestration.
Besides these issues of parasite biology, also methodological
constraints may add to the risk of missing clones. These causes
equally apply for both parasite species. In multi-clonal infections
minority variants constituting a small proportion of the total
parasite load, might be missed by PCR-based detection, because in
competition for primers or other constituents of the reaction mix,
they are outcompeted by the more abundant clones.’’
Although sequestration of P. Falciparum has been reported
several decades ago [16,17], low parasite densities in P. Vivax and
the sensitivity threshold of both light microscopy and PCR-based
diagnostic methods have been well studied [18,19,20], the
consequences of imperfect detectability for estimates of prevalence
and other epidemiological parameters have often not been
addressed adequately.
The daily dynamics of P. Falciparum clones has been investigated
previously in a longitudinal study with daily follow up bleeds
collected over a period of 14 days from 20 children from Tanzania
[21]. A complex dynamics of P. Falciparum clones was observed.
The composition of infecting clones found in a single host was
found to be unstable over time or even changing from one day to
another [21]. In a drug efficacy trial in Tanzania children were
sampled on two consecutive days and the results were compared to
the standard protocol with single bleeds. An increased number of
multiple clone infections and additional recrudescence cases were
detected [22]. Several studies have described statistical models to
estimate infection dynamics of P. Falciparum allowing for this
imperfect detection [23,24,25,26]. The model by Sama et al. [23]
was applied for a longitudinal field study in Ghana, where blood
samples were collected once at each of 6 cross sectional surveys
conducted in 2-monthly intervals. Statistical models indicated that
at any time of sampling on average only 47% of all parasite clones
present in a host were detected by genotyping [23].
Back in 1966 Garnham reported a slight tendency of late P.
Vivax stages to retreat from the peripheral circulation [27], but
sequestration is generally thought to be absent in P. Vivax. This
view was questioned only recently when cytoadherence of P. Vivax
was shown in vitro [28]. Few studies have addressed the infection
dynamics of individual P. Vivax clones [7]. Daily fluctuations in
detectability of P. Vivax clones have not yet been investigated.
To obtain a more precise picture of the parasite population
present in a host, blood sampling should be repeated within short
time intervals. However, collection of consecutive blood samples
from a study participant will translate into considerably increased
efforts in the field and laboratory, added costs, and additional
discomfort for participants. Limited knowledge has been gathered
so far on the effect of such a sampling scheme on epidemiological
measures, such as prevalence or multiplicity of infection.
Here we present data from a large set of paired samples that
were collected 24 hours apart. Within this time interval re-
infection with a new parasite clone is very unlikely and may be
ignored. Samples were derived from a cohort study performed in
Papua New Guinean children 1 to 4.5 years of age living in an
area highly endemic for both P. Falciparum and P. Vivax. Parasites
of both species were genotyped to calculate the detectability of
infection and to investigate the benefit of collecting 24 h bleeds on
basic and molecular measures of epidemiology such as prevalence
and multiplicity of infection. Figure 1 gives a schematic overview
on the effect of combining results obtained on two consecutive
days.
Methods
Ethics Statement
Scientific approval and ethical clearance for the study was
obtained from the Medical Research and Advisory Committee
(MRAC) of the Ministry of Health in PNG and from the
Ethikkommission beider Basel in Switzerland. Informed written
consent was sought from all parents or guardians prior to
recruitment of each child.
Field survey and patients
This study was conducted in a rural area near Maprik, East
Sepik Province, Papua New Guinea. A detailed description of the
study was given previously [15]. Briefly, 269 study participants
were enrolled at an age of 1 to 3 years starting in March 2006 and
regular follow-up visits were conducted over a period of 16 months
until July 2007. At seven time points separated by 8-weekly
intervals two consecutive 250 ml finger prick blood samples were
Figure 1. Dynamics of parasite clones over 24 hours. Schematic overview of possible outcomes of 24 h bleeds. A sample is positive as soon as
a parasite is detected on either day. Different colors of PCR results indicate different clones detected. The combined multiplicity of infection includes
all clones detected in two corresponding bleeds.
doi:10.1371/journal.pone.0019010.g001
Probability of Detection of Human Plasmodia
PLoS ONE | www.plosone.org 2 April 2011 | Volume 6 | Issue 4 | e19010
collected at intervals of 24 hours (in the following termed: 24 h
bleed) from each study participant. Two blood slides were made
and a rapid diagnostic test was performed upon presentation of
malaria symptoms. Antimalarial treatment with CoartemH
(Novartis, Switzerland) was administered upon a positive test plus
iron and folate supplementation if haemoglobin levels were
,7.5 g/dl. Children that were treated on day 1 of the 24 h bleed
were excluded from the analysis (n = 97). Over the 16 months
follow up period, study participants adhered to 93 to 94% of all
study visits.
Laboratory procedures
Diagnosis of the different malaria species was performed in
parallel by two methods, light microscopy (LM) and post-PCR
Ligase Detection Reaction (LDR) [29]. Only samples positive by
light microscopy and/or LDR were genotyped for our markers.
All finger prick blood samples were separated into plasma and
cells. DNA was extracted from cell pellets using QIAampH 96
DNA Blood Kit (Qiagen, Australia) according to the manufactur-
er’s instructions. All samples were genotyped for the polymorphic
marker gene merozoite surface protein 2 (msp2) by use of capillary
electrophoresis (PCR-CE) for fragment sizing as previously
described by Falk et al. [18] with some minor changes and
adaptations of PCR conditions for highly purified DNA as
described by Schoepflin et al. [12].
P. vivax genotyping was performed as described previously [30]
with the following modifications: A multiplex primary PCR was
done with the primers for the 2 markers msp1F3 and MS16
followed by individual nested PCRs for msp1F3 and MS16.
Primary PCR was performed in a volume of 20 ml containing 1 ml
template DNA, 0.25 mM of each primer (Eurofins MWGOperon),
0.3 mM dNTPs (Solis BioDyne), 2 mM MgCl2, 2 ml Buffer B
(Solis BioDyne) and 5 U Taq FIREPol (Solis BioDyne). 1 ml
primary PCR product was used as template for nested PCR
performed in a volume of 20 ml containing 0.25 mM of each
primer (Applied Biosystems), 0.2 mM dNTPs (Solis BioDyne),
2 mM MgCl2, 2 ml Buffer B (Solis BioDyne) and 1.5 U Taq
FIREPol (Solis BioDyne). The forward primers for the nested
PCR were labelled with fluorescent dyes: 6-FAM for msp1F3, NED
for MS16. Cycling conditions were as follows: Initial denaturation
95uC for 1 minute, then 30 cycles (primary PCR) or 25 cycles
(nested PCR) with 15 seconds denaturation at 95uC, 30 seconds
annealing at 59uC and 30 seconds elongation at 72uC plus a final
elongation of 5 minutes at 72uC.
All samples negative after the first round of PCR amplification
were repeated once. Repeats and all microscopy negative samples
(due to an expected lower parasitaemia) were done under similar
conditions with the exception that 2 ml DNA solution were used as
template for the primary PCR. Capillary electrophoresis was done
as described earlier [30]. As the msp1F3 nested PCR in general led
to more amplification product compared to the MS16 PCR, twice
as much MS16 PCR product (2.5 ml of 1:10 dilution of PCR
product) was analysed by capillary electrophoresis.
All alleles were grouped into bins of 3 base pairs according to
the possible size of insertions and deletions in coding regions and
the repeat size of the microsatellite.
Data analysis
Analysis of 24 h interval bleeds. Sample pairs collected
24 hours apart from the same patient were compared. Sample
pairs were excluded from the analysis if antimalarial treatment was
given on the first day of paired sampling. Individual genotypes
were classified by positivity on each of two consecutive days,
leading to two categories for each genotype: one day positive
(genotype observed on either day of paired sampling, n1) and both
days positive (n2). An estimate ~q of the detectability q was
calculated as suggested by Bretscher et al. [31]:
~q~
2n2
n1z2n2
An approximate confidence interval was calculated as follows: CI
[q61.96 se(q)], where the standard error is:
se(q)~
2
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
n1n2(n1zn2)
p
(n1z2n2)
2
Comparison of detectability between day 1 and day 2 was done by
McNemar’s exact test for paired data. Detectability was calculated
for different age groups of patients, for samples with different MOI
(combined over 24 h) and for different parasite densities at day 1.
Comparison of different groups was done by nonparametric test
for trend across ordered groups. Statistical analysis was performed
using STATAH 9.1 statistical analysis software (Stata Corporation,
College Station, TX).
Results
Parasite detection by light microscopy and PCR-capillary
electrophoresis
For the analysis of paired samples collected in 24 h interval,
1019 pairs, equal to 2038 individual blood samples, were eligible.
LM diagnosed P. falciparum in 398 samples, in 362 samples (91%)
this was confirmed by PCR-CE. Additional 210 microscopy-
negative samples were P. falciparum positive by PCR-CE, leading to
a total of 572 samples for which P. falciparum genotyping results
were obtained. P. vivax was diagnosed in 1001 samples by LM, 987
(98.6%) of them were also positive by PCR-CE. Additional 187
samples were positive by PCR-CE, leading to a total of 1174 blood
samples with P. vivax genotyping results. Thus, sensitivity of LM
was lower than that of PCR based diagnosis. Detection of P. vivax
by MS16 PCR (1161 positive samples) was more sensitive than by
msp1F3 PCR (1120 positive samples). This difference was
significant (McNemar’s test: x2 = 9.48, p = 0.002).
Effect of repeated sampling on observed parasite
prevalence
By light microscopy 242 and 563 out of 1019 pairs were positive
for P. falciparum and P. vivax, respectively, at least on either day
(Table 1). Observed prevalence did not differ between individual
days but it increased when both days were combined. P. falciparum
parasites were detected in 19.1% of samples at day 1 and 20.0% at
day 2 (McNemar’s test: x2 = 0.65, p = 0.42). Overall, parasites
were detected in 23.7% of sample pairs. Observed prevalence of P.
vivax was 48.6% on day 1 and 49.7% on day 2 (McNemars test:
x
2 = 0.88, p = 0.35), and 55.3% when both days were combined.
The 1019 sample pairs were genotyped using msp2 as marker for
P. falciparum and both msp1F3 and MS16 as markers for P. vivax.
After PCR the number of pairs positive at least on one of both
consecutive days increased to 311 for P. falciparum and 616 for P.
vivax. Table 1 summarizes the detection of parasites by PCR on
day 1 and 2 of paired samples. Again the observed prevalence of P.
falciparum as well as P. vivax infection did not differ significantly
between both days (P. falciparum: 27.8% on day 1 vs. 28.5% on day
2, McNemar’s test: x2 = 1.0, p= 0.3; P. vivax: 58.5% on day 1 vs.
60.5% on day 2, McNemar’s test: x2 = 2.21, p= 0.14). When
typing results from both days were combined, the observed
Probability of Detection of Human Plasmodia
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prevalence increased only marginally: from 28% to 30.6% for P.
falciparum and from 59.3% to 64.0% for P. vivax.
Effect of repeated sampling on detection of individual
clones
When assessing the persistence of individual alleles on the
consecutive days of sampling, considerable turn-over in allele
composition was observed (Table 2). Examples from 2 patients are
given in Figure 2. For P. falciparum msp2 64.7% of the infecting
clones were observed on both days. For P. vivax, 57.0% of the
msp1F3 alleles and 43.5% of the MS16 alleles were observed on
both consecutive days. These two markers differed slightly in their
genetic diversity, with MS16 (virtual heterozygosity HE= 0.98)
showing greater polymorphism than msp1F3 (HE= 0.88).
Combining the genotyping results from 24 h bleeds made it
possible to assess the effect of repeated sampling on other
molecular epidemiological parameters, i.e. prevalence and MOI.
In P. falciparum combining results from both days lead to a small
increase in observed mean MOI to 1.68 compared to an observed
mean MOI of 1.52 at day 1. In P. vivax the observed mean MOI
based on msp1F3 increased from 2.21 detected on a single day to
2.60 detected on two days. For the more diverse marker MS16, the
observed mean MOI increased from 2.43 to 3.10. When both
markers were considered to establish mean MOI, i.e. for each pair
the highest number of clones observed was counted, observed
MOI increased from 2.78 based on a single day bleed to 3.37
based on results of both consecutive days (Table 2).
Detectability, ~q, was in the same range for both Plasmodium
species: for P. falciparum clones detectability was 0.79 and for P.
vivax detectability was 0.73 based on msp1F3 marker and 0.61
based on microsatellite MS16.
The relationship of clone detectability with age, MOI and
parasite density was determined. Figure 3 depicts detectability by
age group (0–2 years, 2–3 years, .3 years) for light microscopy
and PCR-CE detection. No major difference was observed except
for P. vivax detection by microsatellite marker MS16, which
revealed a slightly lower detectability in children above 3 years
compared to younger children (no overlap of 95% CI).
The influence of MOI on detectability was investigated
(Figure 4). All markers showed a significant decrease in
detectability with increasing MOI (nonparametric test for trend
across groups, P. falciparum msp2: z =24.36, P,0.001; P. vivax
msp1F3: z =23.72, P,0.001; P. vivax MS16: z =24.82, P,0.001).
Detectability increased with parasite density for both parasite
species (Figure 5). P. falciparum msp2 detectability increased with
increasing density. P. vivax detectability increased with density until
5000 to 10’000 parasites/ml and decreased thereafter. In samples
negative by LM detectability was very low, 0.69 for P. falciparum
msp2, 0.48 for P. vivax msp1F3 and 0.36 for P. vivax MS16.
Discussion
Genotyping of malaria parasites has become an integral part
of many malariological field studies. Since more than a decade
genotyping has been considered imperative for clinical trials of
antimalarials performed in endemic countries, The hallmark of
PCR correction of clinical trial outcomes is discrimination of
new infections versus recrudescences. Quantification of clone
detectability at any time point of blood sampling contributes
relevant information on the reliability of PCR corrections.
Furthermore, the number of newly acquired clones per time
interval might be a suitable outcome measurement of antima-
larial interventions; the parameter ‘‘clone detectability’’ might
also correct this estimate.
Imperfect detectability for P. falciparum has been common
knowledge, but to date this effect has been quantified only in few
molecular epidemiological studies. The detectablity of P. vivax
clones has been largely ignored due to the reported absence of
sequestration. However, the generally lower parasite densities in P.
vivax compared to P. falciparum has potential to contribute to
compromised detectablity in a major way. The precise estimation
of the detection probabilities of both species, undertaken in the
Table 1. Effect of repeated sampling on P. falciparum and P. vivax prevalence by light microscopy or PCR.
P. falciparum P. falciparum P. vivax P. vivax P. vivax P. vivax
Microscopy msp2 PCR Microscopy msp1F3 PCR MS16 PCR
PCR 2
markers1
No. of positive samples
1st day pos., 2nd day neg. 39 (16.1%) 21 (6.8%) 57 (10.1%) 39 (6.3%) 49 (7.8%) 40 (6.1%)2
1st day neg., 2nd day pos. 47 (19.4%) 28 (9.0%) 68 (12.1%) 56 (9.1%) 58 (9.1%) 55 (8.4%)3
Both days positive 156 (64.5%) 262 (84.2%) 438 (77.8%) 521 (84.6%) 527 (83.1%) 557 (85.5%)
Total no. of pairs positive at least on one day 242 311 563 616 634 652
Prevalence (parasite positivity)
Prevalence on 1st day (n = 1019 samples) 0.19 (195/1019) 0.29 (283/1019) 0.49 (495/1019) 0.55 (560/1019) 0.57 (576/1019) 0.59
(597/1019)
Prevalence on 2nd day (n = 1019 samples) 0.20 (203/1019) 0.28 (290/1019) 0.50 (506/1019) 0.57 (577/1019) 0.57 (585/1019) 0.60
(612/1019)
Prevalence 2 days combined (n = 1019 pairs) 0.24 (242/1019) 0.31(311/1019) 0.55 (563/1019) 0.60 (616/1019) 0.62 (634/1019) 0.64
(652/1019)
Detectability ~q [95% CI] 0.78 [0.74–0.83] 0.91 [0.89–0.94]4 0.88 [0.86–0.89] 0.92 [0.90–0.93]4 0.91 [0.89–0.93]4 0.92
[0.91–0.94]4
1A sample was defined positive for P. vivax if any of the two markers msp1F3 or MS16 was amplified.
2These samples are positive on day 1 for at least one marker and negative on day 2 for both markers.
3These samples are negative on day 1 for both markers and positive on day 2 for at least one marker.
4Detectability refers to PCR positivity at day 1 versus day 2.
doi:10.1371/journal.pone.0019010.t001
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same field study and under perfectly matching experimental
conditions, allows assessing the combined effects of parasite
sequestration, synchronicity and low parasitaemia and differences
among Plasmodium species. It is clear that the individual factors,
contributing jointly to detectability, cannot be determined by our
genotyping approach.
Our analysis of samples collected 24 hours apart revealed
limited day-to-day fluctuations in the detection of P. falciparum and
P. vivax infection. This indicates that short-term sampling has only
a small impact on prevalence estimates – regardless of whether
infections are detected by light microscopy or PCR. For both
species the observed prevalence by PCR increased, when 2 days
were combined, by less than 10%. A more pronounced difference
in prevalence based on one versus two days of sampling was only
observed for microscopic detection of P. falciparum, where
prevalence increased by 24%. It is unclear in how far the effect
Figure 2. Examples of results obtained on two consecutive days by PCR-capillary electrophoresis. Capillary electrophoresis
chromatograms obtained with the P. vivax marker msp1F3 from two patients on two consecutive days. X-axis: size of PCR product in base pairs.
Y-axis: relative fluorescent units. In patient 1 one clone was detected on day 1, and two additional clones were detected on day 2, combined MOI= 3.
Patient 2 was negative on day 1, but one clone was found on day 2, combined MOI = 1.
doi:10.1371/journal.pone.0019010.g002
Table 2. Effect of repeated sampling on molecular detection of parasite clones and on multiplicity of infection.
P. falciparum P. vivax P. vivax P. vivax
msp2 msp1F3 MS16
2 markers
combined1
Detection of parasite clones
No. clones detected only on day 1 93 (18.0%) 382 (23.8%) 495 (25.2%)
No. clones detected only on day 2 90 (17.4%) 307 (19.2%) 617 (31.3%)
No. clones detected on both days 335 (64.7%) 912 (57.0%) 855 (43.5%)
Total No. of clones 518 1601 1967
Detectability ~q [95% CI] 0.79 [0.76–0.82]2 0.73 [0.71–0.75]2 0.61 [0.58–0.63]2
Multiplicity of infection
MOI on day 1 1.53 2.31 2.34 2.78
MOI on day 2 1.47 2.11 2.52 2.77
MOI on both days 1.68 2.60 3.10 3.37
1The highest value for MOI of either marker msp1F3 or MS16 was used.
2Detectability refers to individual genotypes at day 1 versus day 2.
doi:10.1371/journal.pone.0019010.t002
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of parasite synchronization and sequestration add to this
discrepancy between PCR and microscopy in P. falciparum
detectability. These finding suggests that for Plasmodium species
conducting repeated sampling within 24 h does not substantially
increase the observed prevalence.
Detection of individual clones was very high in P. falciparum
(~q=0.79). Accordingly, combining genotypes from both days
resulted in a small increase in observed mean MOI rising from
1.52 based on one day to 1.68 for both days. Children ,5 years
have not yet developed a strong immunity to P. falciparum [15] and
therefore carry high parasite densities (mean parasite density: 2558
parasites/ml), which leads to a better chance to detect by PCR
most of the parasite clones present. Recently in a similar study in
Ghana blood samples from individuals up to 20 years were
repeatedly collected in intervals of 1, 4, 5 and 7 days [31].
Detectability was calculated using the same approach as in our
study. Clone detectability was around 0.6 in sample pairs collected
24 hours apart [31].
In contrast to P. falciparum, sequestration of late stage parasites
has not been reported from P. vivax. Despite this biological
difference, the detectability of individual parasite clones was lower
in P. vivax than in P. falciparum. A larger number of P. vivax clones
was only detected on either day for both P. vivax markers analyzed.
In P. vivax parasite densities are generally much lower than in P.
falciparum, in our study mean P. vivax density was 498 parasites/ml
compared to the 5-fold higher P. falciparum density. Our results
suggest that the overall low parasitaemia combined with
synchronized replication, as generally seen in P. vivax, has a larger
impact on detectability than sequestration plus sporadic low
parasitaema, as observed in P. falciparum.
The number of concurrent P. falciparum or P. vivax infections had
a pronounced effect on detectability: Increasing MOI lead to
decreasing detectability. It has been suggested that in multiple-
clone infections, clones representing a minority of the total parasite
population in a host might escape detection by PCR [32]. In
experimental mixtures of DNA from two different P. falciparum
clones up to ratios of 1:100, both genotypes were detected by
PCR-CE [33], as well as in mixtures of DNA from two different P.
falciparum clones in a ratio of 1:5 [34]. However, our observation
that detectability decreased with increasing MOI, suggests
impaired amplification of minority clones. Hence, the higher
Figure 3. Detectablity of Plasmodium infections and parasite clones in different age groups. Values for microscopy and ‘‘P. vivax PCR any
marker’’ refer to detection of parasites without distinction of clones. Values for the molecular markers P. falciparum msp2, P. vivax msp1F3 and P. vivax
MS16 refer to the detection of parasite clones. Larger 95% CI of P. falciparum detectability are mainly caused by smaller sample size.
doi:10.1371/journal.pone.0019010.g003
Figure 4. Detectablity of parasite clones vs. multiplicity of
infection.
doi:10.1371/journal.pone.0019010.g004
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mean MOI in P. vivax (MOI= 3.37) compared to P. falciparum
(MOI= 1.68) could be seen as a further reason for the slightly
lower detectability in P. vivax.
Detectability of the two P. vivax markers msp1F3 (~q=0.73) and
MS16 (~q=0.61) differed. Overall, more samples were positive for
P. vivax and more clones were detected with the MS16 PCR. This
suggests a higher detection threshold of the msp1F3 PCR in
combination with a lower influence of fluctuations in parasite
density on detectability. In addition, a difference in the genetic
diversity of these markers could add to the discrepant values: two
independent clones are expected to share more often the same
msp1F3 allele.
Our results highlight that a single bleed does not reflect the full
complexity of concurrently infecting P. vivax clones. The true MOI
of P. vivax is underestimated to a greater extent than the MOI of P.
falciparum. The effect of repeated sampling on prevalence,
however, was in the same range in P. falciparum and P. vivax: for
both species 6 to 9% of all infections were missed on any single
day. The known biology suggests that low parasite densities should
have different causes in P. falciparum and P. vivax. P. falciparum
parasites sequester periodically but a clone is absent from the
peripheral circulation only if its erythrocytic cycle is tightly
synchronized, which according to our data seems not to be the
rule. P. vivax generally occurs at lower densities, and the timing of a
parasite clone within the erythrocytic cycle seems to be well
synchronized. These are major differences between both species,
but with respect to detectability of parasite clones in the blood
stream, both species differ less than previously thought.
In our study participants parasite densities for P. vivax dropped
with increasing age, while for P. falciparum densities remained at
the same level [15]. If parasite densities would directly impact
detectability, a similar decrease in detectability with increasing age
would thus be expected for P. vivax. However, we did not observe a
clear effect of parasite density or age on detectability. Despite the
fact that we did not detect an age trend in detectability in our
study participants aged 1 to 4.5 years, this relationship might be
different in older individuals. It remains open whether the often
observed decrease of prevalence over the entire age range in
moderate to high levels of transmission might be due at least
partially to lower detectability associated with decreasing parasite
densities.
Our P. falciparum results were generated by using a similar
experimental and analytical approach as in a previous study,
conducted in a highly endemic area in Ghana, and results can thus
be compared. When all age groups were included in the Ghana
study a strong age-dependency of detectability was noted, with a
detectability of over 60% in younger individuals and only 10% in
adults [24]. Overall, only 35% of all clones present in the host
were detected in a single blood sample [18]. In individuals of the
same age group as our participants, detectability ranged from 0.51
to 0.55 [31]. This lower detectability in Ghana could be affected
by higher malaria endemicity and higher mean MOI. A lower
transmission and therefore slower acquisition of immunity in PNG
might lead to lower age dependency in detectability. It remains
open whether in older children the often-observed decrease of
prevalence by age in moderate to high levels of transmission might
be due at least partially to lower detectability associated with
decreasing parasite densities. Our current results reflect the
situation in children harbouring high parasite densities. The
situation in adults might be different.
In conclusion, when both 24 h bleeds were combined, we
observed an increase in precision of estimates of epidemiological
parameters in our study for both P. falciparum and P. vivax. While
the increase in observed prevalence was limited, the effect on
detection of individual alleles was more pronounced. Especially in
highly endemic countries where most patients carry multiple clone
infections repeated sampling substantially increases the precision
of observed epidemiological parameters such as MOI. There was
surprisingly little difference between the two parasites; just as
studies of P. falciparum should recognize that they only detect a
proportion of infections, the same is true for P. vivax.
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Abstract
Plasmodium vivax is highly endemic in the lowlands of Papua New Guinea and accounts for a large proportion of the malaria
cases in children less than 5 years of age. We collected 2117 blood samples at 2-monthly intervals from a cohort of 268
children aged 1 to 4.5 years and estimated the diversity and multiplicity of P. vivax infection. All P. vivax clones were
genotyped using the merozoite surface protein 1 F3 fragment (msp1F3) and the microsatellite MS16 as molecular markers.
High diversity was observed with msp1F3 (HE = 88.1%) and MS16 (HE = 97.8%). Of the 1162 P. vivax positive samples, 74%
harbored multi-clone infections with a mean multiplicity of 2.7 (IQR = 1–3). The multiplicity of P. vivax infection increased
slightly with age (P= 0.02), with the strongest increase in very young children. Intensified efforts to control malaria can
benefit from knowledge of the diversity and MOI both for assessing the endemic situation and monitoring the effects of
interventions.
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Introduction
Malaria caused by Plasmodium vivax infection is increasingly
recognized as a public health burden. The worldwide population
at risk is estimated to be 2.85 billion, with high prevalences
observed in locations throughout Southeast Asia and the Pacific
[1]. Even though P. vivax epidemiology is less well studied and
understood compared to that of P. falciparum, it is thought that P.
vivax will present a greater challenge on the way to elimination of
malaria outside Africa. Papua New Guinea (PNG) presents a
variety of different climatic and ecological zones which have
differing levels of malaria transmission [2] with a high burden of P.
vivax in the tropical lowlands. The occurrence of high prevalence
and morbidity marks locations in PNG as suitable field sites for P.
vivax drug trials [3,4] and potentially also for future vaccine trials
[5].
In Maprik in northern PNG, both P. vivax and P. falciparum are
highly prevalent [6]. The incidence of P. vivax clinical episodes has
been shown to peak in the second year of life, while that of P.
falciparum increases until the fourth year [7,8]. Children between
one and five years are considered to be a target age-group for P.
vivax vaccine trials [5]. While previous studies have provided
baseline data on clinical incidence rates, epidemiological patterns
and the age-distribution of disease [8,9], genotyping data on
individual P. vivax clones describing their diversity and molecular
epidemiological parameters are scarce. For P. falciparum, the mean
number of concurrent infections per patient (multiplicity of
infection, MOI) has been used as one of several measures of the
impact of interventions. MOI is crucial to assess the risk that an
individual carries a drug resistant parasite and to evaluate levels of
inbreeding [10].
Here we describe the genetic diversity and multiplicity of
infection of a P. vivax population in an area of high malaria
prevalence in the Maprik District in PNG. Data were obtained
from children aged 1 to 4.5 years who were followed-up over 16
months [8]. We make use of two markers to genotype individual P.
vivax clones, one a microsatellite and the other a region of the msp1
gene, encoding the Merozoite Surface Protein 1. While the
microsatellite MS16 (located on NCBI contig XM_001615468.1)
is considered a neutral marker that has been used in a number of
population genetics studies [11,12], msp1 (XM_001614792)
encodes a potential vaccine candidate (reviewed in [13]) and its
diversity has been studied in different settings [14,15,16]. In a
previous study, the two markers showed robust PCR amplification
and high diversity with a risk of less than 1% that two clones share
the same two-loci haplotype [17].
Methods
Ethics statement
The cohort study was approved by institutional review boards
of the PNG Medical Research Advisory Committee (approvals
05.19 and 09.24), University Hospitals Case Medical Center
(Cleveland, Ohio USA), and the Ethikkommission beider Basel
www.plosntds.org 1 December 2011 | Volume 5 | Issue 12 | e1424
(approval 03/06). Informed written consent was provided by the
parents or legal guardians of each child.
Study site and design
The cohort study was conducted in the Ilaita area, Maprik
District, East Sepik Province, PNG between April 2006 and
August 2007. The study area has hyper- to holoendemic perennial
transmission with moderate seasonal variation [8,18,19,20]. P.
vivax infections are the most prevalent infection in young children
and remain frequent into adulthood, while P. falciparum is the
predominant infection in children over 4 years of age [6,21].
268 children aged 1 to 3 years at enrolment were followed-up
over a period of 16 months. As part of the cohort study, the
children were visited every two months with blood samples taken
at least for one and, for some surveys, on two consecutive days. In
the analysis presented here, only blood samples taken on the first
day were included. The prevalence of Plasmodium species by
microscopy in the study population was 44.3% for P. vivax, 32.6%
for P. falciparum and 4.2% for P. malariae [8]. Defining clinical
episodes as the presence of fever .37.5uC (axillary temperature
measured twice and a third time if the difference was above 0.3u)
or history of fever during the last 48 hours together with
parasitaemia observed by light microscopy, the clinical incidence
rates were 2.56 P. falciparum and 2.46 P. vivax episodes per child per
year [8]. Children presenting with parasitologically confirmed
malaria (i.e. positive blood slide or RDT) were treated with
Coartem. Details of the study have been published previously [8],
as well as genotyping data of the population of P. falciparum clones
in this cohort [22].
Species detection, genotyping and data analysis
Finger prick and venous blood samples were collected and DNA
was extracted as previously described [8]. The presence of P.
falciparum, P. vivax, P. ovale and P. malariae was detected by light
microscopy as well as by post-PCR Ligase Detection Reaction
(LDR) [8], a molecular method for the detection and species
identification of malaria parasites [23]. All samples which were P.
vivax positive by light microscopy or LDR plus 88 negative baseline
samples were selected for genotyping.
The selection of highly diverse molecular markers is crucial for
assessing MOI in molecular epidemiology studies. Based on our
previous results [17], we selected the polymorphic marker gene
msp1F3 and the microsatellite MS16 for genotyping. In contrast to
population genetic studies, where large numbers of neutral
markers of moderate to high diversity (e.g. microsatellites) are
generally analyzed, a small number of highly polymorphic markers
are ideal for tracking clones in epidemiological studies for two
reasons Where concurrent infections with several clones are
common construction of haplotypes combining data from several
PCR amplified markers is difficult. In addtion, when MOI is
defined as the maximum number of clones by any of the markers
typed, the risk of overestimating MOI due to PCR artefacts
increases with the number of markers analyzed, in particular for
microsatellite amplification where PCR artefacts caused by
polymerase slippage are of concern [24] (Tables A and B in Text
S1). Any highly polymorphic marker is suitable for studying the
epidemiology of multiple infections. As long as high diversity is
maintained, there is no need for selective neutrality.
In this molecular epidemiological study, the coding sequence
msp1F3 was chosen because it harbours a more complex repeat
structure than microsatellites. This has the advantage that PCR
artefacts due to slippage are rare for msp1F3. Our second marker
was MS16, a highly polymorphic microsatellite that lacks
dominant alleles.
PCR and capillary electrophoresis were performed with slight
modifications of the published protocol [17] to save costs and
labour time: a multiplex primary PCR was done with the primers
for the 2 markers msp1F3 and MS16 followed by individual nested
PCRs for msp1F3 and MS16. The primary PCR was done in a
volume of 20 ml containing 1 ml template DNA, 0.25 mM of each
primer (Eurofins MWGOperon), 0.3 mM dNTPs (Solis BioDyne),
2 mM MgCl2, 2 ml Buffer B (Solis BioDyne) and 5 U TaqFIREPol
(Solis BioDyne). As we expected low parasitemia in samples
negative by microscopy, 2 ml DNA instead of 1 ml were used for
the primary PCR. 1 ml primary PCR product was used as the
template for the nested PCR, which was performed in a volume of
20 ml containing 0.25 mM of each primer (Applied Biosystems),
0.2 mM dNTPs (Solis BioDyne), 2 mM MgCl2, 2 ml Buffer B
(Solis BioDyne) and 1.5 U TaqFIREPol (Solis BioDyne). The
forward primers for the nested PCR were labelled with fluorescent
dyes: 6-FAM for msp1F3, NED for MS16. Cycling conditions were
as follows: initial denaturation 95uC for 1 minute, then 30 cycles
(primary PCR) or 25 cycles (nested PCR) with 15 seconds
denaturation at 95uC, 30 seconds annealing at 59uC and
30 seconds elongation at 72uC plus a final elongation of 5 minutes
at 72uC. Subsequently, capillary electrophoresis was performed as
described [17].
The PCR data was analysed using the GeneMarkerH pro-
gramme version 1.85 (SoftGenetics). Based on experience from
preliminary studies, peaks above a cut off of 1000 units relative
fluorescent intensity (RFU) were considered true amplification
products, all peaks below this cut off were considered background
noise as well as lesser peaks in the vicinity of strong peaks reaching
40% (msp1F3) and 70% (MS16) of their height. Occasionally the
fluorescence intensity differed between plates or samples as
indicated by varying signal intensities of the commercial size
standard. To compensate for this technical shortfall, the standard
cut off value was lowered from 1000 to 300 RFU if signal
intensities of both sample peaks and size standard peaks were low
(generally below 1000 RFU). This practice was justified by a
greater agreement in positivity at both loci. As a consequence, the
proportion of samples positive only for a single marker dropped
from 12% to 10%. All samples were checked visually (after
blinding of samples) for stutter peaks thereby excluding one
msp1F3 and 25 MS16 samples from further analyses.
Author Summary
The parasite Plasmodium vivax is the second most frequent
cause of malaria in humans. In the Maprik area in lowland
Papua New Guinea, P. vivax and P. falciparum are
sympatric each with a prevalence of around 50%.
Longitudinal samples from 268 children aged 1 to 4.5
years over 16 months were collected. The 1162 blood
samples positive for P. vivax were genotyped for two size-
polymorphic molecular markers. A very high parasite
diversity was observed. The number of co-infecting
parasite clones per carrier (multiplicity) was nearly twice
as high for P. vivax as for P. falciparum despite the similar
prevalences of the species. The P. vivax multiplicity
increased with age, with the strongest increase in young
children below 1.5. This is likely to be a consequence of
fast acquisition of immunity against P. vivax malaria and
also of relapses, the release of long-lasting, silent liver
stages to the blood stream. This is the first dataset from a
highly endemic setting that presents data on a large
number of individual P. vivax clones genotyped with
highly diverse markers.
Plasmodium vivax in Papua New Guinea
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The genotyping method was validated by typing a subset of 28
samples for both markers in duplicate. 80% of msp1F3 clones and
88% of MS16 clones were detected in both replicates (Tables C
and D in Text S1). An important reason for the imperfect
detection of clones is the low concentration of template DNA in
samples with scanty parasitemia, where partial amplification of all
templates seems to be governed by chance. In serial dilutions of
DNA in field samples, we have demonstrated this effect by
performing PCR amplification in triplicate for each dilution
(Tables E and F and Figures A and B in Text S1). At low DNA
concentrations, the allelic composition of a blood sample differed
between replicates with individual clones detected in an apparently
random fashion (out of several clones detected in undiluted DNA).
Data analysis
Alleles were grouped into bins of 3 base pairs, defined by the
expected size differences in the two markers: 3 base pairs (bp) for
the coding region of Pvmsp1 as well as for microsatellite MS16
harbouring a 3 bp repeat unit. When a single genotype was
observed with both markers, a blood sample was defined as single
clone infection. In multiple clone infections, the highest number of
clones observed for either marker defined the combined MOI of a
blood sample. We used the kappa statistic to describe agreement
between the molecular markers after correcting for chance
agreement.
The determination of MOI for single and double clone
infections was validated by genotyping a subset of samples with
12 additional markers. MOI= 1 was confirmed in 67/92 (72.8%)
samples and MOI= 2 in 31/32 (96.9%) samples (Tables A and B
in Text S1).
Although the distributions of MOI are skewed, we present the
mean MOI, a common measure, to allow comparisons with other
studies. We estimated the effect of age (at the time of the survey in
6 months age groups) and season on prevalence and MOI using
regression models. To account for multiple visits per child, we
included a random effect for child. The models were implemented
in STATA version 10 [25] and WinBUGS version 1.4 [26].
The genetic diversity of a given locus in a population is
expressed by the virtual heterozygosity HE, i.e. the probability that
two clones taken at random from the population carry different
alleles. HE was calculated using the formula
HE~
n
n{1
(1{
X
pi
2)
where n is the number of clones analysed and p is the frequency of
allele i. HE of msp1F3 and MS16 were determined by using only
the first P. vivax positive sample of each study participant; HE of
msp1F3/MS16 haplotypes by using the first single clone infection
per patient. This procedure prevents potential sampling bias due
to repetition of persisting clones from the same individual. Linkage
between markers was assessed using LIAN 3.5 [27]. Linkage
disequilibrium measured from only two markers cannot provide
information on inbreeding and was used only to provide evidence
that the markers occur independently of each other.
Results
Of the 2117 blood samples collected in cross sectional surveys,
1340 were genotyped since they were positive by microscopy or
LDR. Of the 88 microscopy and LDR negative samples that were
selected for genotyping, only 2 (2.3%) were positive. This low
proportion did not justify genotyping all negative samples.
Nested PCR for the two P. vivax genotyping markers provided
an amplification product from at least one marker from 1162
samples. msp1F3 PCR products were obtained from 1094 samples
MS16 PCR products from 1118 (Table 1). In 1050 samples
(90.3%), positive results were obtained for both markers. The two
markers agreed well on P. vivax positivity (kappa= 0.71), although
the difference in PCR efficiency (McNemar’s test: P=0.026)
suggests a slightly higher sensitivity of the MS16 PCR.
Prevalence
The overall prevalence of P. vivax based on positivity by PCR
was 55%. The prevalence was lowest in children under 1.5 years at
44% and reached 62% in children aged 3 to 3.5 years. The
increase of prevalence by age at the time of the survey was
significant (P=0.005) largely driven by the lower prevalence in
children less than 1.5 years. Without this youngest age group no
evidence of a trend was observed. No major seasonal trend in P.
vivax prevalence was observed with the exception of a slight peak in
September (P=0.17).
Allelic diversity
In 1162 samples positive for P. vivax, 57 different msp1F3 and
103 different MS16 alleles were detected (Figures 1A and 1B).
Virtual heterozygocity HE was 97.8% for MS16, 88.1% for msp1F3
and 99.1% for msp1F3-MS16 haplotypes determined in single-
clone infections (Table 1). In 219 single clone infections from 148
patients, a total of 154 different haplotypes were observed with the
most common haplotype detected in only six individuals
(Figure 1C). We tested this data set for independence of the two
molecular markers. No linkage disequilibrium was observed
(IA
S=20.0001, P=0.53).
Multiplicity of infection
The MOI was determined for each marker separately, as well as
for both markers combined. In P. vivax positive samples, the mean
Table 1. Diversity and multiplicity of infection of P. vivax in Papua New Guinea.
No. of positive
samples No. of clones
Multiplicity of
infection Allelic richness
Virtual Hetero-
zygosity (HE)
msp1F3 1094 (79)* 2480 (173)* 2.27 57 (31)* 0.881 (0.874)*
MS16 1118 (80)* 2542 (175)* 2.27 103 (65)* 0.976 (0.977)*
combined 1162 NA** 2.69 NA** NA**
Single clone infections 219 (25)* 219 (25)* 1 154 (25)* 0.991 (0.96)*
*In brackets numbers for baseline only.
**NA=Not applicable.
doi:10.1371/journal.pntd.0001424.t001
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MOI was 2.27 for each marker individually and 2.69 when
calculated from the maximal number of clones per sample by any
marker. Among samples for which positive results were obtained
from both markers, MOI was concordant in 38% (397/1050)
(kappa= 0.17). A difference of one clone was observed in 38.5%
(404/1050) of samples. The frequency distribution of MOI plotted
separately for msp1F3 and MS16 was compared to the combined
MOI (Figure 2). A single marker slightly underestimated MOI.
Multiple clone infections were observed in 63% of all positive
samples by msp1F3 and in 61% by MS16. When results of both
markers were combined, the proportion of multiple clone
infections increased to 74% (Table S1). Likewise, the proportion
of samples with a MOI of 3 or higher was underestimated based
on a single marker. Of the 531 samples with a combined MOI
between 3 and 9, the combined MOI result was reproduced only
in 279 samples (52%) by msp1F3 alone and in 324 samples (61%)
by MS16 alone.
The mean MOI of P. vivax was associated with age. In children
up to 1.5 years the mean MOI was 2.4 increasing slightly up to 2.8
in children 3.5 to 4.5 years of age (Figure 3, P=0.02). If the
youngest children below 1.5 years were excluded, no significant
trend was observed (P=0.23). The increase of the proportion of
children bearing more than two clones was more pronounced
(Figure 4). In the 18 youngest children aged 300 to 400 days, we
observed a low MOI of 1.67 and only two children (11%) carried
more than 2 clones. There was no significant seasonal variation in
MOI (P=0.50).
Discussion
We have genotyped P. vivax parasites in a cohort of 268 children
from an area of Papua New Guinea with sympatric P. falciparum
and P. vivax with prevalences of 49.6% and 53.0% respectively in
this cohort at enrolment [8]. The ecology and epidemiology of P.
vivax differs from that of P. falciparum in several aspects. Parasite
densities are generally lower, which is likely to affect prevalence
data generated by both microscopically or molecular diagnosis
[28,29]. Gametocytes appear shortly after an infection is
established in a host [30], with implications for transmission and
the frequency of sexual recombination, and the occurrence of
relapses leads to appearance of new genotypes in the blood stream
independent of mosquito transmission.
Our genotyping enables the distinction of individual parasites
within the human host and thus the assessment of MOI. The mean
MOI for P. vivax in our cohort was 2.7 and 73.6% of samples
carried multiple clones (combined results from two independent
markers). This compares to a substantially lower P. falciparum MOI
of 1.5 in the same cohort determined by the marker msp2 and only
35.2% of samples carrying multiple clone infections [31].
The multiplicity of Plasmodium infections depends on a number
of factors including transmission intensity or the duration of
infection as the result of loss of infection and antimalarial
treatment. An additional factor, unique to P. vivax, contributes to
the number of blood stage infections circulating in the blood:
relapses of semi dormant liver stages. Previous studies have shown
that relapses often genetically differ from already present blood
stage parasites [32,33] and thus lead to increased MOI. As
Coartem does not clear liver stage parasites and the level of
treatment in our cohort was high, the combined effect of treatment
and relapses is likely to enhance differences between P. vivax and P.
falciparum MOI. In addition, as mosquitoes biting people
harbouring multi-clone infections are more likely to transmit
several clones concurrently [34,35], the higher MOI among P.
vivax blood-stage parasites will increase the likelihood that multi-
clone P. vivax infections are transmitted in a single mosquito bite.
Under intense transmission such as found in lowland PNG, the
MOI of P. vivax species increases with age, with the increase most
pronounced in children below 1.5 years. In an earlier study, no
evidence of differences between children aged 4 to 14 were found
[36]. This increase in early childhood may at least in part be
related to the increased exposed body surface with child growth
thus leading to higher rates of mosquito bites and consequently
risk of infection [37]. In addition, with rapidly increasing im-
munity fewer P. vivax infections may reach high densities which are
associated with febrile illness and antimalarial treatment [8] and
the average duration of a P. vivax infection may increase with age.
Figure 1. Allelic frequencies of P. vivax genotyping markers. Allelic frequencies of markers msp1F3 (A) and MS16 (B) and the combined
msp1F3-MS16 haplotypes (C). For msp1F3 and MS16 the frequencies of the 3 most frequent alleles and the respective sizes of the amplified product
are given.
doi:10.1371/journal.pntd.0001424.g001
Figure 2. Distribution of multiple clone infections. Distribution of
multiplicity of infection as detected by the markers msp1F3 and MS16
as well as both markers combined. Only samples with positive results
for both markers were included (n = 1050).
doi:10.1371/journal.pntd.0001424.g002
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Both the mean MOI and prevalence using genotyping data
showed no pronounced seasonality, concurring with previous
findings using light microscopy and LDR detection [8]. In
contrast, the incidence of clinical disease increased in the wet
season [8]. The lack of annual fluctuations in P. vivax prevalence
and MOI observed in PNG is likely to be caused by relapses
during periods where there is less mosquito transmission.
The proportion of multiple-clone infections clearly differs from
observations from countries of lower P. vivax endemicity. We
observed polyclonal infections in three out of four samples. Even if
numbers cannot be compared directly to other studies using other
genotyping protocols (higher numbers of markers increase the
chance of observing several clones at least in one marker), this
proportion only reaches 11 to 49% in the Amazon [12,38], 55% in
Sri Lanka [11] but 73% in Myanmar [11].
The molecular markers msp1F3 and MS16 showed a high
degree of genetic diversity. While three msp1F3 alleles reached
frequencies above 10%, the distribution of MS16 alleles is more
homogenous with the highest frequency of 5%. The selected
markers are suitable for studies where high resolution discrimina-
tion between P. vivax clones is required, such as longitudinal
tracking of clones or discrimination between existing and incoming
infections. The probability of two individual clones sharing the
same 2-loci haplotype was below 1%. Analysing additional
polymorphic markers would lead only to a minimal improvement
of discrimination. As the mean MOI increases, the chance that
two clones within a host share the same haplotype increases.
Simulations indicate that mean MOI would be unlikely to be
substantially underestimated with either marker, unless the
mean MOI was greater than 6 (Amanda Ross, manuscript in
Figure 3. Boxplot of MOI by age group. The median is represented by the central line. The box represents the interquartile range from the 25th
to 75th centiles. The whiskers extend to the most extreme data point which is no more than 1.5 times the interquartile range from the box, points
beyond this are plotted individually.
doi:10.1371/journal.pntd.0001424.g003
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preparation). The diversity observed in P. vivax compares well to
the genetic diversity of two P. falciparum markers, msp1 and msp2,
previously determined in the same cohort [22]. MS16 was highly
diverse in our cohort, and has been shown to be almost as diverse
in countries of lower P. vivax endemicity such as Peru [12] and
Vietnam [39] but was lower in Sri Lanka and Ethiopia [11].
In more than half of the samples, the number of clones detected
was discordant for the two markers. Three factors contribute to
such discrepancies, namely (i) differences in the discrimination
power of the two markers, (ii) imperfect detection of clones in
samples with low parasite densities and (iii) mutation of one of the
markers occurring within a host (Text S1). Given the high diversity
of both markers, we expect that limited discrimination power only
accounts for a small fraction of observed discrepancies. More
likely, low parasite densities around the detection limit will cause
imperfect detection of clones. In a previously published analysis of
clone detectability in the same set of samples, we have determined
the contribution of an additional blood sample collected 24 hours
later from the same children. This analysis showed that detection
of genotypes by PCR is equally imperfect for both species, P.
falciparum and P. vivax. Overall, 17 to 31% of all clones were missed
on a single day, and detection of clones was imperfect especially in
samples harboring a high number of concurrent clones [31]. In
addition, in serial dilutions of parasite DNA from field samples we
now show that at very low concentrations, MOI and allelic
composition differed between replicates. In particular minority
clones were lost. It is therefore very likely that such stochastic
amplification of genotypes also occurred in our samples.
Due to its antigenicity and surface exposed location, MSP1 is
considered a candidate for a malaria vaccine (reviewed in [13]).
We identified 57 MSP1F3 alleles with the 3 most abundant alleles
adding up to a frequency of 53%. The predominant alleles
maintained stable allelic frequencies throughout the study. In a
similar number of Papua New Guinean children, 27 haplotypes
were observed for another potential vaccine candidate, the Duffy
Binding Protein II (DBPII, XM_001615397). The 3 most frequent
DBPII alleles were present in 57% of infections [40]. These results
indicate high diversity of P. vivax antigens in PNG. With respect to
vaccine development based on PvMSP1, the allelic frequencies
generated in our genotyping study provide useful information on
genetic diversity of this antigen.
In summary, this study provides one of the first large data sets of
P. vivax genotypes from a highly endemic area. Our high resolution
typing technique accurately determined allelic frequencies and
clone multiplicity. This adds to the knowledge about P. vivax
epidemiology and may serve as reference data for high endemicity
P. vivax populations. The molecular parameters established could
be utilized as one of several measures for effective monitoring of
intervention and control of P. vivax, for surveillance and to
parameterize mathematical models of transmission dynamics [40].
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Table S1: Genotyping results from 1162 P. vivax positive field samples 
using the markers msp1F3 and MS16 
 
MOI as 
detemined 
by 
msp1F3 
MOI as 
detemined 
by MS16 
MOI 
combined 
from both 
markers 
MOI 
identical 
by both 
markers 
MOI=1  404 439 305 230 
MOI=2 291 295 305 95 
MOI=3 208 181 235 50 
MOI=4 118 107 166 18 
MOI=5 50 49 89 0 
MOI=6 16 32 40 4 
MOI=7 5 15 20 0 
MOI=8 1 0 1 0 
MOI=9 1 0 1 0 
Sample negative for one 
marker and positive for the 
other  marker 
67 19 0  
Sample excluded because 
of PCR artifacts 
1 25 0  
Total number of samples 1162 1162 1162 397 
Total number of multiclonal 
infections 
690 
(63.1%)** 
679 
(60.7%)** 
857 
(73.6%)** 
 
Total number of single clone 
infections 
404 
(36.9%)** 
439 
(39.3%)** 
305 
(26.2%)** 
230 
 
* If values from both markers were discrepant, the higher value was accepted 
** Not taking into account samples negative for this marker and samples excluded because of 
PCR artifacts 
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Text S1: Validation of Plasmodium vivax genotyping based on msp1F3 
and MS16 as molecular markers 
 
1. Confirmation of multiplicity of infection in field samples from Papua New Guinea by 
genotyping additional molecular markers 
92 single clone infections and 32 double clone infections (based on combined results from 
msp1F3 and MS16) were typed with 12 additional markers: MS1, MS2, MS4, MS5, MS6, 
MS7, MS8, MS9, MS10, MS12, MS15, MS20 [1] (manuscript in preparation). 
Assessing multiplicity of infection (MOI) based on a large number of markers increases the 
risk that MOI is overestimated because of potential within-host clonal variation [2] or stutter 
artefacts occurring in one marker. Intra-host clonal variation is thought to be the result of 
strand-slippage in a repetitive sequence, such as a microsatellite, during mitotic DNA 
replication. Stutter peaks are PCR artefacts observed especially when microsatellites with a 
simple repeat structure are amplified [3]. Despite visual checking of electropherogrammes for 
stutter peaks and excluding them, some PCR artifacts may be overlooked. Both processes 
lead to higher MOI at one locus, while the other loci remain unchanged.  
To compensate for within-host clonal variation and PCR stutter peaks, we set a cut-off as 
follows: a sample was accepted as multi-clone infection if at least 3 loci indicated a MOI>1. 
Applying this cut-off, MOI=1 (based on msp1F3/MS16 typing) was confirmed in 67/92 
samples (72.8%) (Table A). 
Table A: Confirmation of single clone infections (MOI=1) by genotyping 12 additional 
markers 
Total no. 
of samples 
all markers 
MOI=1 
1 marker 
with MOI>1 
2 markers 
with MOI>1 
3 markers 
with MOI>1 
>3 markers 
with MOI>1 
92 31 (33.7%) 23 (25.0%) 13 (14.1%) 18 (19.6%) 7 (7.6%) 
 
In sample sets typed with many markers it has been frequently observed that the highest MOI 
detected by any marker is not supported by other markers [4,5], suggesting occurrence of 
intra-host clonal variation and PCR stutter peaks. Their frequency is not known. However we 
can estimate it from our data in table A that includes results from 1288 individual PCRs (92 
samples typed with msp1F3, MS16 and 12 microsatellites). In a total of 49 PCRs additional 
alleles were detected (23 samples with 1 PCR indicating MOI >1 and 13 samples with 2 
PCRs indicating MOI > 1). Based on these values, we estimate the frequency of PCR results 
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that overestimate MOI to be 49/1288 = 3.8%. The following calculation illustrates the 
increased risk for overestimating MOI when many markers are analyzed: assuming a 4% 
chance of a false-positive peak for a single marker, 96% of all samples will reveal the true 
MOI for this marker. However, with 14 independent markers, the chance of observing the true 
MOI drops to 56%.  
In addition to single clone infections, we have genotyped 32 samples with MOI=2 revealed by 
msp1F3/MS16 typing for 12 additional markers. Results are given in table B. Applying the 
same cut off as above (maximal two markers with higher MOI), MOI=2 was confirmed in 
31/32 (96.9%) of samples. 
For 4/32 (12.5%) samples, MOI=2 was not confirmed by any additional marker. We cannot 
rule out that these samples are in fact single clone infections with an incorrect result for either 
msp1F3 or MS16. 
Table B: Confirmation of MOI=2 by genotyping 12 additional markers 
Total no. of 
samples 
all markers 
MOI=1 or 2 
1 marker 
with MOI>2 
2 markers 
with MOI>2 
3 markers 
with MOI>2 
>3 marker 
with MOI>2 
32 20 (62.5%) 9 (28.1%) 2 (6.2%) 1 (3.1%) 0 
 
Conclusion: When choosing the number of markers to be genotyped, there is a trade-off 
between number of artefacts, which increases with each additional marker, and limited 
resolution of multiple infections when there are high frequencies of some alleles. Using the 12 
additional markers, we reproduced the msp1F3/MS16 genotyping results for a MOI of 1 or 2 
in a reasonable proportion of the samples.  
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2. Congruence of samples typed in duplicate 
We genotyped 28 samples in duplicate for both markers msp1F3 and MS16. Congruence in 
MOI results and allelic composition in each sample was assessed. 
MOI was identical in 50% (msp1F3) and 71% (MS16) of duplicates (Table C). The agreement, 
estimated using kappa (Table C), was fair to high. 
Table C: Congruence in MOI after genotyping 28 samples in duplicate 
Difference in MOI msp1F3 MS16 Combined results 
0 14 (50%) 20 (71.4%) 15 (53.6%) 
1 10 (35.7%) 4 (14.3%) 9 (32.1%) 
2 4 (14.3%) 2 (7.1%) 2 (7.1%) 
3 0 2 (7.1%) 2 (7.1%) 
kappa 0.33 0.62 0.4 
 
Detection of individual genoptypes was compared between duplicates. The msp1F3 allelic 
composition was identical in 12/28 (42.9%) sample pairs, that of MS16 in 19/28 (67.9%).  
The probability of detecting a clone in the duplicate samples (n=28) was estimated using the 
formula presented by Bretscher et al [6] (Table D). 
Table D: Detection of clones in 28 samples genotyped in duplicate 
  msp1F3 MS16 
Clones detected twice 53 61 
Clones detected only once 26 16 
Detectability [0.95 CI] 0.80 [0.73-0.88] 0.88 [0.0.83-0.94] 
 
The congruence obtained from these 28 samples genotyped in duplicate was compared to 
detectability of clones. Detectability was estimated from sample pairs collected 24 hours apart 
from the same child [7]. Fluctuating parasite densities from one day to another lead to 
differences in bleeds collected within short time intervals, but no gain or loss of infection is 
expected within such a short time period. When day 1 and day 2 bleeds from the same child 
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were analyzed, detectability was 0.73 for msp1F3 clones and 0.61 for MS16 clones [7]. This 
comparison revealed that the congruence of results obtained from duplicated typing of the 
same blood sample was much higher, 0.80, for msp1F3 and 0.88 for MS16. 
Imperfect detectability of parasite clones in field samples is caused by low densities of 
parasites. Depending on the presence or absence of a parasite clone in the DNA template 
added to the PCR reaction mix, PCR detection of low-density parasites leads to a chance 
result [8]. Results obtained at the detection limit of PCR can be exemplified by performing 
serial dilutions of a DNA solution followed by PCR (see paragraph 3 below). 
Conclusion: The agreement of MOI and clone detection in the duplicate samples was 
reasonable and so genotyping the same sample in duplicate is not necessary.  
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3. Detection of clones in serial dilutions of DNA 
Any method to detect parasites at densities close to the detection limit is imperfect. To assess 
the impact of low concentrations of template DNA on the outcome of our P. vivax genotyping 
PCR, DNA from field samples was diluted 1:102, 1:103, 1:104 and 1:105. Subsequently, P. 
vivax genotyping was performed in triplicate using the standard protocol [7]. Six field samples 
were analyzed. MOI and allelic composition in each sample were assessed. Results for 
marker msp1F3 are listed in Table E and for MS16 in Table F.  
Table E: Number of msp1F3 clones detected in triplicates of serial DNA dilutions 
*  Electropherogramms are displayed in Figures A and B. 
 
DNA dilution 1:1 1:102 1:103 1:104 1:105 
triplicate A B C A B C A B C A B C A B C 
Total no. 
of clones 
observed 
Sample 1* 3 3 3 3 2 2 2 2 1 0 0 0 0 0 0 3 
Sample 2 3 4 4 4 3 4 2 1 2 1 0 1 0 0 0 4 
Sample 3 2 2 2 1 1 2 0 1 1 1 0 1 0 0 0 2 
Sample 4* 3 3 3 3 3 3 2 1 1 0 0 0 0 0 0 3 
Sample 5 2 2 2 1 1 2 0 1 0 0 0 0 0 0 0 4 
Sample 6 1 3 1 0 2 0 0 0 0 0 0 0 0 0 0 3 
Total no. of 
pos. samples 
(n=18) 18/18 16/18 12/18 4/18 0/18   
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Table F: Number of MS16 clones detected in triplicates of serial DNA dilutions. 
 
Genotyping results from undiluted and serial dilutions of DNA from field samples 1 and 4, 
done in triplicate, are shown in Figure A and B, respectively. At a DNA dilution of 1:103, some 
clones are no longer amplified, as compared to undiluted DNA. At such low DNA 
concentrations, the distribution of detected genotypes seems to be random, as seen in 
sample 4 (Figure B): one or two genotypes per PCR reaction were amplified at a DNA dilution 
of 1:103, but the allelic composition of the 3 replicates differed. Triplicate A showed two 
fragments of 236 bp and 262 bp, respectively. Triplicate B contained a single 262 bp fragment 
only, and triplicate C a single 274 bp fragment. All 3 clones were amplified when DNA was not 
diluted. 
DNA dilution 1:1 1:102 1:103 1:104 1:105 
triplicate A B C A B C A B C A B C A B C 
Total no. 
of clones 
observed 
Sample 1 3 3 2 2 2 2 2 0 0 0 0 1 0 0 0 3 
Sample 2 2 3 3 2 2 3 1 1 3 1 0 0 0 0 0 4 
Sample 3 2 2 2 0 2 2 2 0 4 1 0 0 0 0 1 5 
Sample 4 4 3 3 4 5 4 3 2 1 1 0 0 0 0 0 5 
Sample 5 4 3 4 2 1 1 0 0 0 0 0 0 0 0 0 4 
Sample 6 3 1 2 0 0 0 0 0 1 0 0 0 0 0 0 4 
Total no. of 
pos. samples 
(n=18) 18/18 
 
14/18 
 
10/18 4/18 1/18  
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Figure A: Electropherogrammes of msp1F3 genotyping PCR performed in triplicate (relicates 
A, B,and C) on serial dilutions of field sample 1. The standard cut-off of 1000 RFU was 
applied for all samples. Alleles above this cut-ff are indicated with a grey line 
X-axis: size of DNA fragment in base pairs 
y-axis: Relative fluorescent units (RFU) 
Red: commercial size standard 
Green: msp1F3 alleles 
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Figure B: Electropherogrammes of msp1F3 genotyping PCR performed in triplicate 
(replicates A, B,and C) on serial dilutions of field sample 4.  
 
Conclusion: When low parasitemia is simulated by serial DNA dilutions, detection of clones 
becomes stochastic and differs between replicates.  
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Abstract 
The clinical burden of Plasmodium vivax malaria is increasingly recognized, and the 
importance of this parasite is highlighted by its predominance in focus areas of intensified 
anti-malaria interventions towards elimination. Yet little is known about its population genetic 
structure, in particular in areas of high P. vivax transmission. Knowledge on genetic exchange 
within and between populations and gene flow has implications for drug and vaccine based 
control strategies. Papua New Guinea (PNG) comprises a variety of P. vivax transmission 
settings, with the worldwide highest transmission ever documented.  
We have genotyped 254 samples from 3 lowland and 1 highland sites in PNG for 14 
microsatellite loci. Diversity is high with expected heterozygosity values ranging from 0.66 to 
0.97 for the different markers.  252 individual multi-locus haplotypes were observed in single 
clone infections or in dominant clones of multiple clone infections. Separation between sites 
was very low (FST=0.0015-0.0251), with the slightly more pronounced difference occurring 
between lowland and highland locations. These findings imply high effective population size 
and levels of high gene flow. The population genetic parameters for P. vivax in PNG are in 
sharp contrast to a strong sub-structuring reported from other countries with low P. vivax 
endemicity. The high level of gene flow in P. vivax, and thus extensive parasite or vector 
migration, strongly argues for country-wide rather than patchy control efforts in order to be 
effectively control vivax malaria in PNG. 
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Introduction 
Papua New Guinea (PNG) is outstanding with respect to biodiversity as well as diversity of 
human cultures and languages (Attenborough and Alpers, 1992). Ecological zones range 
from tropical lowlands to mild and tempered climate zones in the highlands and high mountain 
ranges. PNG harbours four Plasmodium species that infect humans, P. falciparum, P. vivax, 
P. malariae and P. ovale, with probably the highest P. vivax prevalence anywhere in the world 
(Mueller et al., 2003). P. vivax is the predominant cause of malaria outside Africa (Guerra et 
al., 2010), and there are increasing reports of severe outcome of disease, especially from 
PNG and West Papua (Genton et al., 2008; Poespoprodjo et al., 2009; Tjitra et al., 2008). 
Population structure can inform interventions towards malaria elimination, as marked 
differences between parasite populations indicate little gene flow, suggesting restricted 
parasite or vector migration. In such settings with restricted gene flow, antimalarial 
interventions in small areas seem possible. At a later stage, when transmission is reduced to 
a low level, genotyping could play an important part in tracking outbreaks. 
Diversity, population structure, gene flow and linkage disequlibrium (LD) between loci 
influence the emergence and spread of drug resistance and affects efficiency of potential 
future vaccines (Ariey et al., 2003; Buckee and Gupta, 2010; Yuan et al., 2011). LD between 
loci is high in nearly clonal populations with little recombination between strains, but 
associations between markers are quickly reverted in panmictic populations. The extent of LD 
influences the marker density needed for genome wide association studies (Hayton and Su, 
2008; Mu et al., 2005). Likewise LD influences spread of drug resistant parasites. A number 
of current antimalarial drugs combine compounds acting on different targets of the parasite 
metabolism, and as a consequence accumulation of mutations in different genes is needed to 
confer drug resistance (Cammack, 2011). Once emerged by chance, such drug resistance 
haplotypes can persist and spread quickly in conditions of low genetic exchange. But if 
parasites undergo frequent recombination with non-resistant parasites, resistance haplotypes 
may be quickly interrupted (Talisuna et al., 2003).   
Multi-locus genotyping of neutral markers of P. falciparum and P. vivax provide data for the 
analysis of diversity and population structure. Population genetic studies from village- to 
intercontinental level were undertaken with samples from Latin America and several South-
East Asian countries, where P. vivax prevalence is generally lower than in PNG. P. vivax 
populations from these countries have revealed considerable genetic differentiation between 
populations, suggesting limited gene flow (Ferreira et al., 2007; Gunawardena et al., 2010; 
Imwong et al., 2007; Karunaweera et al., 2008; Van den Eede et al., 2010b).  
Because of much higher P. vivax transmission intensity in PNG, a different parasite 
population structure is likely. High diversity has been reported from studies of P. vivax surface 
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antigens in PNG (Bruce et al., 2000; Henry-Halldin et al., 2011; Kolakovich et al., 1996), and 
moderate differences between populations based on the Duffy binding protein gene (Cole-
Tobian and King, 2003), but not on subtypes of the circumsporozoite protein (Henry-Halldin et 
al., 2011). Population genetic analyses based on neutral markers were conducted for P. 
falciparum, which in PNG is equally prevalent as P. vivax. High haplotype diversity and 
moderately structured population were observed at 4 lowland sites (Schultz et al., 2010). 
Results from a local malaria outbreak in the highlands could indicate that species-specific 
differences occur: clonality was confirmed for all P. falciparum infections, however, P. vivax 
samples from this study were highly diverse and included multiple infections (Mueller et al., 
2002).  
Our previous finding of a P. vivax MOI twice as high as that of P. falciparum (Koepfli et al., 
2011) also suggested that sympatric populations of these parasites differ substantially despite 
their similar prevalence. This lead us to investigate the population parameters in 254 P. vivax 
samples collected from patients at three sites in the lowlands and one site in the highlands of 
PNG, using 14 size polymorphic neutral microsatellite markers. Diversity of parasites and 
population structure was assessed village- and country-wide, and compared to results 
obtained from the msp1 gene, a polymorphic surface antigen likely under selection.  
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Methods 
Ethics statement 
This study was performed on archived samples from previous studies with approval from the 
Institutional Review Board of PNG Institute of Medical Research (Amendment to IRB 0919 
and to MRAC 09.24 from the PNG Medical Research Advisory Committee). 
 
Study sites and patients 
P. vivax positive blood samples from four regions in PNG were used. Three study sites (Ilaita, 
Kunjingini and Alexishafen) were located in the tropical lowlands; one site (Sigimaru) was in 
the central highlands at an altitude of 1100 metres (table 1, figure 1).  
At the Ilaita study site (Maprik District, East Sepik Province) cross-sectional sampling was 
done in several villages from April 2006 to August 2007 from 264 children aged 0.5 to 4.5 
years (Lin et al., 2010). Samples were collected in the course of a drug efficacy studies in the 
Kunjingini health center (Maprik District, East Sepik Province) from April 2004 to February 
2005 from children aged 0.5 to 7 years (Marfurt et al., 2007), at the Alexishafen health centre 
(Madang Province) from April 2005 to July 2007 from children aged 0.5 to 5 years 
(Karunajeewa et al., 2008), and in the Sigimaru health center (Karimui area, Simbu Province) 
between 2002 and 2005 from children aged 0.5 to 7 years (Marfurt et al., 2007).  
Large parts of the coastal lowlands of PNG are characterized by high prevalence of P. vivax 
and P. falciparum malaria with perennial transmission and mild seasonal variation. In study 
participants from the Ilaita site, East Sepik Province, prevalence of Plasmodium species by 
microscopy was 44.3% for P. vivax, 32.6% for P. falciparum and 4.2% of P. malariae. 
Incidence rate of malaria was 1.92 episodes per child per year for P. vivax and 1.59 for P. 
falciparum (Lin et al., 2010). In contrast, in Simbu province in the highlands, malaria 
prevalence varies from below 5% at higher altitudes in the northern parts of the province to 
35% in the southern and lower altitude areas, where our study site is located (Mueller et al., 
2004). In a survey in 2001 and 2002 P. vivax prevalence in South Simbu was 8% (Mueller et 
al., 2004).  
From all 4 study sites P. vivax positive samples had been genotyped in the course of previous 
epidemiological and drug efficacy studies, using the two markers msp1F3 and MS16 
(Barnadas et al., 2011; Koepfli, 2011). To facilitate construction of multi-locus haplotypes (see 
below), single clone infections according to these earlier typing results were selected for 
genotyping additional loci. Because the number of single clone infections was not sufficient, 
we also included samples with a multiplicity of 2 or 3. 
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Genetic markers, PCR and genotyping by capillary electrophoresis   
We have selected a panel of 14 well-described and frequently used size polymorphic P. vivax 
markers for genotyping: MS1, MS2, MS4, MS5, MS6, MS7, MS8, MS9, MS10, MS12, MS15, 
MS16, MS20 (Karunaweera, 2006), Pv3.27 (Imwong et al., 2007; Koepfli et al., 2008). In 
addition the polymorphic F3 region of the merozoire surface protein 1 (msp1F3 (Koepfli et al., 
2008)) was types. MS3, that had also been described as polymorphic P. vivax marker 
(Karunaweera, 2006), was excluded after preliminary testing because no amplification 
product was obtained from over 50% of samples. These markers were selected for 
comparability with previous studies in other countries.  
Genotyping results for MS16 and msp1F3 were retrieved from earlier studies (Barnadas et al., 
2011; Koepfli, 2011; Koepfli et al., 2008). For 13 additional microsatellite markers (MS1, MS2, 
MS4, MS5, MS6, MS7, MS8, MS9, MS10, MS12, MS15, MS16, MS20, Pv3.27) a semi-nested 
PCR protocol with 13-plex primary followed by individual reactions for nested PCR was 
applied. Forward primers for the 13 primary PCR assays were designed (supplementary table 
S1) and used in combination with previously published nested primers. Nested PCR primers 
were adopted from earlier publications (Imwong et al., 2007; Karunaweera, 2006). Multiplex 
primary PCR was conducted under conditions optimized for multiplex reactions as follows: 
each 50 µl reaction contained 1 µl template DNA, 5 µl Buffer B (Solis Biodyne), 0.3 mM 
dNTPs, 3 mM MgCl2, 0.25 µM of each primer (MWG Operon, 26 primers in total) and 10 U 
Taq Firepol (Solis Biodyne). Cycling conditions were 1 minute initial denaturation at 95°C 
followed by 25 cycles of 15 seconds at 95°C, 30 seconds at 60°C, 30 seconds at 72°C and a 
final elongation step for 5 minutes at 72°C. The primary product was diluted 1:40 in H2O. 1 µl 
of this dilution was used as template for each of 13 individual nested PCRs, performed in a 
total volume of 20 µl containing 2 µl Buffer B (Solid Biodyne), 0.2 mM dNTPs, 4 mM MgCl2, 
0.25 µM of both primers (Applied Biosystems) and 1.5 U Taq Firepol (Solis Biodyne). Nested 
forward primers were labelled with a fluorescent dye (VIC, NED or 6-FAM, supplementary 
table S1).  Nested reverse primers included a 7 base tail, promoting addition of a terminal 
adenine to amplification products. Nested cycling conditions were 1 minute initial denaturation 
at 95°C, then 35 cycles of 15 seconds at 95°C, 30 seconds at 61°C and 45 seconds at 72°C, 
followed by 5 minutes at 72°C. 
5 µl of each nested amplification product were run on a 1.5% agarose gel. According to the 
intensity of bands on this gel, PCR products were diluted in H2O either in a ratio of 1:10, 1:20 
or 1:40.  If a very weak or no band was observed on the gel (e.g. for microsatellite MS4), the 
PCR product was diluted 1:4. This usually resulted in a detectable peak in capillary 
electrophoresis (CE). 2.5 µl of such diluted amplification product was analysed by CE as 
described (Koepfli et al., 2008). 
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Data analysis 
Data retrieved from CE was analysed using the GeneMarker® programme version 1.85 
(SoftGenetics) as described (Koepfli, 2011). We used a total of 15 markers, 14 of which were 
presumably neutral microsatellites, whereas msp1F3 represents a size polymorphic domain 
of intragenic repeats of the surface antigen MSP1. It is not clear whether this domain is under 
balancing selection, therefore msp1F3 typing results were only included in a separate round 
of our analyses, and results obtained from microsatellite data alone were compared to those 
with msp1F3 data.  
All available single clone infections were used in this study. However, as up to 75% of all 
children in our study sites carried multiple clone infections, a sufficient sample size was not 
reached, and thus samples with multiplicity of 2 and 3 were also included. Samples yielding 
amplification products for <9/13 markers were excluded from further analysis. The full dataset 
included all clones detected per sample by any marker, i.e. the predominant clone plus all 
minority clones from multiple clone infections. For specific analyses the building of multi-locus 
haplotypes was required. In case of multiple clone infections we have used peak heights to 
determine the dominant clone and all minority clones were excluded. This strategy has been 
applied in previous studies (Anderson et al., 2000; Hunt et al., 2005). Due to the likely 
preferred amplification of smaller alleles or minor variation in peak height ratios, this approach 
could be error prone if peaks of 2 clones are of similar height. To rule out ambiguities, we 
have excluded from haplotype building all markers, for which the minor allele reached a peak 
height of >70% of the predominant peak. 
Alleles were binned into 2, 3 or 4 bp bins according to their repeat unit size using TANDEM 
software Version 1.08 (Matschiner and Salzburger, 2009). As TANDEM processes only 
genotyping data from diploid organisms, results from single clone infections were duplicated 
for constructing allele bins. 
The software Dropout was used to detect genotyping errors due to PCR artefacts leading to 
overestimation of the number of haplotypes (McKelvey and Schwartz, 2005). Expected 
numbers of pairwise differences between haplotypes were compared with observed 
differences. The software Lositan was used to detect loci that are under positive or balancing 
selection and thus influence the analysis of population differentiation. To detect non-neutral 
loci 100ʼ000 simulations were run in Lositan under a stepwise mutation model (Antao et al., 
2008). For msp1F3 Lositan suggested populations differentiation in the range of that of 
microsatellite markers. Dropout and Lostian software gave no indication of genotyping errors 
or non-neutral loci, and all samples and markers were included into further analysis. 
The genetic diversity of a locus in a population is expressed by the expected heterozygosity 
HE, i.e. the probability that two clones taken at random from the population carry different 
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alleles. HE was calculated as described (Gatton and Cheng, 2008). Linkage disequilibrium 
(LD) was assessed using the program LIAN 3.5 applying a Monte Carlo test with 100ʼ000 
random resamplings (Haubold and Hudson, 2000; http://adenine.biz.fh-weihenstephan.de/cgi-
bin/lian/lian.cgi.pl). LIAN cannot handle missing data, thus 7 markers and subsequently all 
samples still containing missing data were removed from the data. The remaining dataset 
included the markers MS1, MS2, MS8, MS9, MS10, MS12, MS15 and MS20. The final 
sample size for each study site is shown in table 1. Slightly different datasets of samples 
without missing data, based on different combinations of markers, led to similar estimates of 
LD, indicating that results are not influenced by selection of markers. The standardized index 
of association ISA was calculated as an estimation of LD using the equation 
 
with 
! 
I  being the number of loci analyzed, VD the variance of the number of loci at which each 
pair of haplotypes differs and Ve the expected variance in linkage equilibrium. ISA is zero for 
linkage equlibrium (Haubold and Hudson, 2000). 
To compare allelic frequencies between populations in Ilaita, Kunjingini, Alexishafen and 
Sigimaru, Wrightʼs FST coefficient was calculated using FSTAT (Goudet, 1995). This program 
only allows analysis of diploid data. “Virtual diploids” were created from the full dataset by 
grouping alleles per study site randomly into pairs. This approach can be justified in haploid 
organisms because FST values rely entirely on allele frequencies within populations without 
requiring that an allele pair was derived from the homologous chromosomes of a diploid 
individual (Balding et al., 2007). P-values were adjusted using Bonferroniʼs correction for 
multiple comparisons. FST takes values between 0 (indicating that allelic frequencies in all 
populations are identical) and 1 (indicating maximum differentiation between populations 
without any allele shared) (Balding et al., 2007; Hartl and Clark, 2007). Correlation between 
genetic difference, geographic distance and altitude was assessed by Mantel testing in 
FSTAT with 20ʼ000 randomisations. Distances and altitudes were retrieved from Google 
Earth.  
The samples from Ilaita were collected in cross-sectional surveys in different villages, 
approximately 2 to 5 km from each other. This allowed comparison of allelic differences 
between subpopulations. Five sites were compared according to the detailed map given in 
Figure 2. 
As a complementary approach to assess population structure we have analysed haplotypes 
using the program STRUCTURE version 2.3.2 (Pritchard et al., 2000). This algorithm 
attempts to form groups of haplotypes without prior information on the origin of a sample. 
STRUCTRE is able to detect genetic differences among subgroups that do not correlate with 
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geography. The number of populations (K) was set from 1 to 20 with 3 replications per K, 
each with 100ʼ000 Markov Chain Monte Carlo runs after a burn-in period of 50ʼ000 steps, 
using the admixture model. Principal component analysis (PCA) was done in R using the 
prcomp function. Haplotypes containing missing data were excluded to calculate the 
covariance matrix, but projected into the final plot if not more than 3 data points were missing. 
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Results 
We have genotyped 15 size polymorphic molecular markers in 254 P. vivax positive blood 
samples from different locations in Papua New Guinea. Out of 3810 expected genotyping 
data points (254 samples times 15 markers), 3566 (93.6%) data points were generated. For 
the construction of haplotypes in multiple-clone infections all minority clones were excluded, 
but in 155 electropherogrammes concurrent genotypes yielded peaks of almost equal height 
and thus no dominant genotype could be determined. This led to the exclusion of these data 
points from haplotype building. The final data set comprised 3411 out of a maximum of 3810 
(89.5%) data points. Because these gaps were equally distributed over all samples and 
markers, excluding certain samples or markers would not improve data completeness. All 
markers were highly polymorphic with 8-61 alleles per locus and HE of 0.664-0.997 (Table 2). 
We have assessed population structure using different approaches. FST values were 
calculated in the full dataset, including also minor clones, as use of haplotypes is not required 
for this calculation. Very little differences were observed between lowland populations, but 
comparisons between lowland sites and Sigimaru gave slightly higher FST values (Table 3A). 
The only statistically significant difference was found between Ilaita in East Sepik Province 
and Sigimaru in the highlands (FST=0.0247, P=0.0013), most likely due to the larger sample 
size from Ilaita. Correlation between genetic differentiation and geographical distance or 
altitude was assessed Mantel testing. Distance alone explained only 40% of genetic 
differences (P=0.449), but altitude explained 89.6% (P=0.071), and the combination of both 
explained 96.1%.  
We have then searched for clustering of genotypes in our dataset using the widely used 
software STRUCTURE. STRUCTURE makes it possible to assess population genetic 
structure in groups of samples without prior information on the origin of these samples. No 
structuring was found in our data set, the highland - lowland difference between Ilaita and 
Sigimaru populations was not reproduced.  This suggests that there is either no clustering in 
our data or only very little, as STRUCTURE is not adequate for detection of very low, yet 
significant FST values (Pritchard et al., 2007). Similarly, Principal component analysis using R 
did not reveal any grouping of haplotypes (Figure 3). 
Next we have assessed linkage disequilibrium (LD) between loci. As this analysis cannot 
handle missing data, we have assessed LD in a reduced sample set of 8 markers, only 
including samples without missing data (n=142). No LD was observed when assessed 
separately for all four study sites as well as for all sites in combination (Table 4).  
In addition to the 14 presumably neutral microsatellite markers we have genotyped the marker 
msp1F3, which codes for the intragenic repeat region of the MSP1 surface antigen. This 
marker could be subject to balancing selection. We have repeated our analysis for msp1F3 
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alone and for a combined dataset of the 14 microsatellites and msp1F3. (Table 4B). 
Population structure analysis of msp1F3 only confirmed the difference between Ilaita and 
Sigimaru (FST=0.0332, P=0.00017). Moreover, a difference between Alexishafen and Ilaita 
was observed (FST=0.0299, P=0.00017). When all 15 markers were analyzed in a single 
dataset, the difference between Alexishafen and Ilaita remained significant (FST=0.0251, 
P=0.00167, Table 3C). The number of individual haplotypes (n=252) remained the same after 
inclusion of msp1F3, as well as the result of the analysis using the STRUCTURE software. 
In a study from Peru, using the same markers, significant population differentiation was found 
between villages as close as 2 km (Van den Eede et al., 2010b). Samples from Ilaita were 
collected in individual villages, and we could thus assess population genetic substructuring 
between five villages in the study area (Figure 2), 1 to 5 km from each other. All FST values 
between villages were close to 0 (FST <0.005) and non-significant (P>0.4). Inclusion of 
msp1F3 did not change results, nor were differences between villages observed when only 
msp1F3 was analyzed. 
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Discussion 
All 14 microsatellites showed high numbers of alleles and a genetic diversity similar or higher 
to published results from Asia and Latin America (Imwong et al., 2007; Karunaweera, 2006; 
Van den Eede et al., 2010a; Van den Eede et al., 2010b). The genetic composition of the 3 
lowland P. vivax populations differed only marginally, whereas FST values for comparisons 
between lowland and highland sites were higher. Most likely this was caused by the fact that 
Sigimaru is separated from the 3 lowland sites by a sparsely populated region with little 
malaria transmission. P-values were influenced by different sample sizes, leading only for the 
Ilaita-Sigimaru comparison to a signficnant result. 
This low level of population structuring in P. vivax observed in PNG is in sharp contrast to 
results obtained in Latin America, where P. vivax is the predominant malaria parasite, but 
endemicity is usually low. FST values were 0.4-0.7 between five sites in Colombia (Imwong et 
al., 2007) and 0.03-0.25 between sites in Brazil (Rezende et al., 2009). Large geographic 
distances combined with mountain ranges without malaria transmission might add to the 
genetic differentiation seen in Colombia. But also on a scale of 2 to 50 km distance between 
sites, without geographical barriers to transmission, high population differentiation was found 
(Van den Eede et al., 2010b). P. vivax is the predominant Plasmodium species also in many 
Asian countries. Inter-country FST values were established between populations from India, 
Laos and Thailand and ranged from 0.13-0.45 (Imwong et al., 2007).  
P. falciparum populations from different lowland sites in PNG were investigated previously. P. 
falciparum diversity was equally high at each site and all 318 haplotypes, based on 10 loci, 
were different. Population differentiation in P. falciparum was more pronounced compared to 
the situation of P. vivax, and showed significant differences between all sites with FST values 
of 0.05-0.14 (Schultz et al., 2010).  
The little genetic structuring of P. vivax populations are difficult to explain in view of the 
geographic distance. Transport within PNG is restricted to few roads, often unpaved and 
difficult to travel, and expensive air transport. Only in the past decade inhabitants from the 
East Sepik province migrated to Madang province which could explain the similarity of 
parasites found in Alexishafen. In contrast, human migration between Sigimaru and the 
lowlands is likely more restricted. Yet our data suggest, that mobility along the highland 
lowland trading routes is sufficiently strong to allow genetic exchange among P. vivax 
populations.  
No LD was detected between our markers. LD is a result of inbreeding of parasites and high 
LD in P. vivax has been reported previously from low transmission areas, such as the 
Amazon (Ferreira et al., 2007; Imwong et al., 2007; Rezende et al., 2009; Rezende et al., 
2010; Van den Eede et al., 2010b), Sri Lanka or Ethiopia (Gunawardena et al., 2010; 
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Karunaweera et al., 2008). A report from South Korea, a country with currently emerging P. 
vivax prevalence, showed a decrease of LD paralleled with an increase in prevalence over a 
period of 10 years (Honma et al., 2011). Absence of LD was reported from India, Laos and 
Thailand (Imwong et al., 2007), however LD was observed in neighboring Myanmar 
(Gunawardena et al., 2010). This pattern of strong LD in low transmission, but no LD in high 
transmission follows expectations and is equally true for P. falciparum (Anderson et al., 2000; 
Neafsey et al., 2008) 
Recombination among Plasmodium parasites can occur in the mosquito midgut if genetically 
different gametocytes are taken up at a blood meal. High levels of transmission increase the 
proportion of humans carrying multiple clone infections and thus augment the chance of 
simultaneous transmission of different gametocyte clones in a single mosquito bite. In blood 
samples from our study participants the proportion of children carrying multiple clone 
infections ranged from 63 to 73% (table 1). In areas of low P. vivax transmission this 
proportion ranged from 13% in Sri Lanka (Gunasekera et al., 2007) to 10-34% in South 
America (Imwong et al., 2007; Van den Eede et al., 2010b) and 30-35% in Thailand and Laos 
(Imwong et al., 2007). 
To date it is still unknown whether all P. vivax clones concurrently present in a human host 
produce gametocytes simultaneously, and in how far multiplicity of infection in the host 
correlates with recombination frequency in mosquitoes. All P. falciparum and P. vivax clones 
were genotyped in the Ilaita cohort study (Lin et al., 2010), from which also our P. vivax 
samples derived (Koepfli et al., 2011). Only 33% of P. falciparum positive children carried 
multiple clone infections (Sonja Schoepflin, unpublished), in contrast to 73% multi-clone 
infections for P. vivax (Koepfli, 2011). It is plausible that in P. falciparum the predominance of 
single clone infections, and as a consequence less recombination in mosquitoes, caused the 
more substantial P. falciparum population structuring.  
While our 14 microsatellite markers are presumable neutral, msp1F3 encodes a highly 
polymorphic region of the MSP1 antigen. Coding regions, in particular those of surface 
antigens, are under immune selelction. For P. falciparum MSP1 it was shown that high levels 
of anti-msp1 antibodies protected children from malaria, and that this protection was allele 
specific (Conway et al., 2000). Parasites infecting a semi-immune host will be favored if they 
express an allele that is not recognized by antibodies, and as a consequence large number of 
alleles will be maintained in parasite populations. (Hastings, 1996). Indeed, in P. falciparum 
population genetic differences for a polymorphic msp1 fragment were less pronounced than 
for neutral loci (Conway et al., 2000). Our P. vivax msp1F3 locus is located approximately 1 
kb upstream of the highly antigenic C-terminal MSP119 fragment, that elicits a strong antigenic 
response (de Oliveira et al., 1999; Soares et al., 1997) and is a widely studied vaccine 
candidate (reviewed in (Herrera et al., 2007)). Consequently, balancing selection could be 
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expected to act on msp1F3, but given the low level of population differences we observed 
with neutral loci, we did not detect a different pattern for msp1. We cannot rule out that in 
situations were marked population genetic differences are detected by neutral microsatellite 
markers, balancing selection would be identified to act on msp1F3. 
 
Conclusions 
We present the first comparison of P. vivax populations on small to medium geographic scale 
in a country of generally high endemicity, but also including a site of presumably lower 
transmission intensity. The nearly complete lack of population structuring is in sharp contrast 
to results of low endemic areas. Our results highlight a difference in population structure 
between the sympatric species P. vivax and P. falciparum, with the latter species being more 
structured, possibly owing to its much lower mean MOI. Large population size, high gene flow 
and absence of LD have direct implications for interventions. Single mutations conferring drug 
resistance are expected to spread fast in the country, however multi-locus genotypes 
associated with resistance are expected to break down fast in absence of drug pressure (Dye 
and Williams, 1997). Our results imply frequent migration of parasites between different sites, 
which likely compromises the outcome of interventions in single locations.  
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Figure 1: Location of sites of sample collection in Papua New Guinea 
and altitude above sea level  
 
 
Fig. 4: Sub-structure of the Ilaita study site. Allelic frequencies of the villages in 
the red circles were compared against each other. Adapted from (Lin et al., 2010). 
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Figure 3: Principal component analysis of P. vivax haplotypes genotyped 
with 14 microsatellite markers. 
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Table 1: P. vivax samples included into this study  
Site 
year of 
collection 
No. of P. 
vivax pos. 
samples 
collected 
Mean MOI 
of all P. 
vivax pos.  
samples* 
Proportion of 
multiple clone 
infections in all 
P. vivax pos.   
samples* 
No. of 
samples 
geno-
typed References 
Ilaita 
2006-
2007 2096 2.67 73.1% 132 
(Koepfli, 2011; 
Lin et al., 2010) 
Kunjingini 
2003-
2005 94 2.07 63.8% 38 
(Marfurt et al., 
2007; Marfurt et 
al., 2008) 
Alexishafen 
2005-
2007 150 2.27 72.7 45 
(Barnadas et al., 
2011; 
Karunajeewa et 
al., 2008) 
Sigimaru 
2004-
2005 48 2.6 70.8% 39 
(Marfurt et al., 
2007) 
* based on the markers msp1F3 and MS16 
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Table 2: Diversity of 15 P. vivax markers in PNG 
 
no. of pos. 
samples 
no. of 
alleles 
observed 
size range 
(bp) 
expected 
heterozygosity 
HE 
MS1 237 9 221 - 251 0.692 
MS2 228 24 171 - 379 0.913 
MS4 206 13 155 - 227 0.664 
MS5 213 14 154 - 196 0.866 
MS6 221 10 211 - 253 0.840 
MS7 214 15 141 - 243 0.774 
MS8 225 39 181 - 334 0.965 
MS9 231 8 152 - 173 0.807 
MS10 231 20 156 - 213 0.898 
MS12 237 9 167 - 233 0.666 
MS15 231 20 231 - 291 0.884 
MS16 241 61 194 - 452 0.977 
MS20 240 28 158 - 251 0.927 
Pv3.27 220 33 184 - 460 0.934 
msp1F3 236 28 237 - 372 0.849 
 
Plasmodium vivax Populations in Papua New Guinea 
89 
Table 3: Genetic differentiation of P. vivax populations in Papua New Guinea 
A  Kunjingini Alexishafen Sigimaru 
 Ilaita 0.0012 0.0091 0.0247* 
 Kunjingini  0.0052 0.0207 
 Alexishafen   0.0252 
     
     
B  Kunjingini Alexishafen Sigimaru 
 Ilaita 0.0053 0.0332* 0.0299* 
 Kunjingini  0.0489 0.0267 
 Alexishafen   0.0034 
     
     
C  Kunjingini Alexishafen Sigimaru 
 Ilaita 0.0015 0.0107* 0.0251* 
 Kunjingini  0.0082 0.0211 
 Alexishafen   0.0238 
 
FST values for inter-site comparisons are given.  
(A) results obtained from 14 microsatellite markers  
(B) results obtained from marker msp1F3 only 
(C) results obtained from 14 microsatellite markers and msp1F3 
* significant at the Bonferroni-corrected 5% level (P<0.00833) 
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Table 4: Linkage disequilibrium between 8 markers (MS1, MS2, MS8, MS9, MS10, MS12, 
MS15, MS20), determined by LIAN software 
 
no. of 
samples ISA P 
Ilaita 67 0.0075 0.0613 
Kunjingini 22 0.0271 0.0255 
Alexishafen 31 0.0121 0.13 
Sigimaru 22 -0.0086 0.744 
    
All 142 0.0052 0.023 
 
Supplementary table S1: Primer sequences 
Marker Primer name Sequence 5' - 3' Fluorescent dye 
MS1 primary forward CATCTCGACATGTCGACGTAG  
 nested forward TCAACTGTTGGAAGGGCAAT 6FAM 
 reverse ctgtcttTTGCTGCGTTTTTGTTTCTG  
MS2 primary forward AGCACGACCAACAAGAGAGG  
 nested forward GAGCTAGCCAAAGGTTCAACA VIC 
 reverse ctgtcttTGGGGAGAGACTCCCTTTTC  
MS4 primary forward TAAACCCAAATGGGTAACGG  
 nested forward CGATTTACTGTTGACGCTGAA 6FAM 
 reverse ctgtcttCAAAGGAACATGCTCGATGA  
MS5 primary forward TTCGGCTGGTTTCCAATTAGG  
 nested forward CGTCCTCTATCGCGTACACA NED 
 reverse ctgtcttAAAGGGAGAGGAGCGAAAAC  
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MS6 primary forward GAGCTGCTGCTTCTATTTTGGG  
 nested forward GGTTCTTCGGTGATCTCTGC VIC 
 reverse ctgtcttGGAGGACATCAACGGGATT  
MS7 primary forward ACATCAAAGCAAAGAAGAGGG  
 nested forward TTGCAGAAAATGCAGAGAGC 6FAM 
 reverse ctgtcttAGGGTCTTCAGCGTGTTGTT  
MS8 primary forward AAACGTAAAACCTTTGGCGG  
 nested forward AGAGGAGGCAGAAATGCAGA NED 
 reverse ctgtcttAGCCCCTTTGCGTTCTTTAT  
MS9 primary forward TGAATTTCCCCATTTGCCCG  
 nested forward AGATGCCTACACGTTGACGA VIC 
 reverse ctgtcttGAAGCTGCCCATGTGGTAAT  
MS10 primary forward AGGACCAAACGGAGGACATG  
 nested forward TTATCCCTGCTGGATGTGAA 6FAM 
 reverse ctgtcttTCCTTCAGGTGGGACTTGTT  
MS12 primary forward AACGTTTCCTTGCCCACTTG  
 nested forward AATGCGCATCCTATGTCTCC NED 
 reverse ctgtcttCTGCTGTTGTTGTTGCTGCT  
MS15 primary forward CGCACTCTTCATCCTCATCG  
 nested forward TGTTTGCAAAGGAATCCACA VIC 
 reverse ctgtcttCGGCCAGATGAAAAGGATAA  
MS16 primary forward TTCCTGATGACAATTTCGACGG  
 primary reverse TCTCTTCCCATTTGAGCATCGC  
 nested forward CTTGTTGTGGTTGTTGATGGTG VIC 
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 nested reverse ctgtcttAGTACGTCAACCATGTGGGTAG  
MS20 primary forward CAAGGTGCGATGGAAGATTGG  
 nested forward GCACAACAAATGCAAGATCC VIC 
 reverse ctgtcttGTGGCAGTGGCTCATCTTCT  
Pv3.27 fwd primary TTTTTCAACTTGCTGCCCCCTG  
 fwd nested3) GGACATTCCAAATGTATGTGCAGTCG 6-FAM 
 reverse ctgtcttCGTCATCGTCATTGCTCTGGAG  
msp1F3 primary forward GGAGAACATAAGCTACCTGTCC  
 primary reverse GTTGTTACTTGGTCTTCCTCCC  
 nested forward CAAGCCTACCAAGAATTGATCCCCAA VIC 
 nested reverse ctgtcttATTACTTTGTCGTAGTCCTCGGCGTAGTCC 
 
In case of listing only one reverse primer sequence, a semi-nested protocol was used with 
identical reverse primers for both primary and nested PCR. A 7-pb tail promoting addition of a 
terminal adenine to amplification product is given in lower-case letters.  
a primer originally described in (Karunaweera, 2006). 
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Abstract 
The burden of disease caused by Plasmodium vivax is increasingly recognized. Morbidity and 
mortality are high especially in very young children. In areas where P. vivax and P. falciparum 
are co-endemic, age trends in incidence of clinical disease and prevalence differ significantly, 
with P. vivax peaking in younger children compared to P. facliparum. This suggests 
differences in the rate of acquisition of immunity. As natural immunity to malaria is acquired 
over an extended period of time and requires repeated infection, it has been suggested that 
the number of infections over time drives the speed of immunization.  
We have estimated the molecular force of infection (molFOI, i.e. the number of times an 
individual is infected per year) of P. vivax in a cohort of 264 children in Papua New Guinea. 
Children were sampled bi-monthly over a period of 16 months in an area with high prevalence 
of P. falciparum and P. vivax. In addition passive case detection was maintained. P. vivax 
incidence decreased throughout the age group, but P. falciparum incidence peaked at 3.5 
years. All P. vivax clones were genotyped using two highly polymorphic markers. The molFOI 
was estimated to 14.6 P. vivax clones per year and did not change with age. This contrasts 
earlier findings of a much lower molFOi in P. falciparum. We conclude that the different 
numbers of P. vivax and P. falciparum clones that infect children in early childhood lead to 
different speed in acquisition of immunity, and thus causes different age trends in incidence.  
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Introduction 
People who live in malaria endemic areas achieve immunity to disease after some years of 
exposure (Koch, 1900). The immunization is gradual, and the speed of acquisition of 
immunity depends on transmission intensity. While incidence and parasitemia decline fast 
under intense transmission, partial immunity will build up over several decades (if at all) in 
areas of low transmission. The rate to immune acquisition also seems to differ between 
parasite species, with immunity to P. vivax acquired faster than immunity to P. falciparum. In 
numerous field studies conducted in areas co-endemic for these species the burden of P. 
vivax infections and disease was found to peak at a younger age than that due to P. 
falciparum (Balfour, 1935; Earle, 1939; Gunewardena et al., 1994; Maitland et al., 1996; 
Mendis et al., 2001; Michon et al., 2007; Mueller et al., 2009; Phimpraphi et al., 2008). 
Similarly, during the course of malaria therapy, were neurosyphillis patients were artificially 
infected with malaria, P. vivax densities remained below the pyrogenic threshold after only a 
few doses, while each of several infections with P. falciparum induced fever (Ciuca et al., 
1934; Collins and Jeffery, 1999; Collins et al., 2004). 
Malaria infections consist of different clones (or strains) that infect individuals successively or 
in parallel. Strains can be characterized by their surface antigens (Anders et al., 1993). Their 
diversity is well documented for a number of P. falciparum antigens as well as for some P. 
vivax antigens. Examples include the circumsporozoite protein (csp) (Henry-Halldin et al., 
2011; Imwong et al., 2005), different merozoite surface proteins (msp) (Fenton et al., 1991; 
Koepfli et al., 2008; Raj et al., 2004), the apical membrane protein 1 (ama1) (Cortes et al., 
2003), or the P. vivax duffy binding protein (dbp) (Cole-Tobian and King, 2003). The large 
number of antigen variants allows parasites to escape the immune system, as newly infecting 
strains likely express different alleles as previous ones, and thus are not recognized by 
existing anti bodies (Bull and Marsh, 2002; Osier et al., 2008). As a consequence, immunity is 
thought to be largely clone specific, providing less protection against disease caused by 
heterologous clones (Ciuca et al., 1934; Cole-Tobian et al., 2009; Collins et al., 2004; Genton 
et al., 2002; Jeffery, 1966; Lyon et al., 2008; Smith et al., 1999).  
The differences in acquisition to immunity against P. falciparum and P. vivax infection 
observed in population-based studies could be caused by several factors. Biological 
differences between parasites might account for differences in immunization, such as a more 
limited antigenic repertoire of P. vivax compared to the one of P. falciparum. P. falciparum 
expresses sequentially up to 60 variants of the Erythrocyte Membrane Protein 1 (PfEMP-1) in 
a mutually exclusive manner (Voss et al., 2006) and acquisition of antibodies against broad 
repertoire of PfEMP-1.variants is thought to be key to developing anti-falciparum immunity 
(Bull et al., 1998; Dodoo et al., 2001; Giha et al., 2000). This is not the case for the P. vivax 
multi-gene vir genes, the products of which are also expressed on the surface of the host 
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reticulocyte (Fernandez-Becerra et al., 2005), but where multiple genes are concurrently 
expressed and whose function is yet to be fully understood (Bernabeu et al., 2011). Similarly, 
P. vivax relies almost fully on the Duffy receptor for invasion into the red blood cell (RBC) 
(Menard et al., 2010; Miller et al., 1976), while P. falciparum is able to invade through a 
variety of partially redundant pathways (Cowman and Crabb, 2006). Antibodies targeting 
these essential ligands can block invasion in-vitro (Chen et al., 2011; Grimberg et al., 2007; 
Jiang et al., 2011; Tham et al., 2009; Triglia et al., 2011) and are associated with significant 
protection in-vivo (King et al., 2008; Reiling et al., 2010; Richards et al., 2010). As a broad 
inhibitory response against multiple ligands may be required for effective P. falciparum 
immunity (Persson et al., 2008), different rates of immune acquisition might reflect the broader 
spectrum of P. falciparum invasion pathways.!
Immunity to malaria is poorly understood (Doolan et al., 2009; Langhorne et al., 2008). Both 
the total number of infections as well as the number of different clones seem to influence 
speed of immune acquisition (Jeffery, 1966). According to this hypothesis individuals acquire 
complete resistance against parasites once they had been infected with all parasite strains 
circulating in a population (Aguas et al., 2012; Weisman et al., 2001). As alternative to 
differences between parasite species in antigenic diversity or invasion, different numbers of 
transmitted clones could explain contrasting trends in acquisition of immunity. High numbers 
of infections per time can be the results of frequent bites of infected mosquitoes, or human 
hosts can acquire different parasite clones through a single bite of a mosquito carrying 
genetically diverse sporozoites (Annan et al., 2007; Mzilahowa et al., 2007).  
The number of infections acquired over time largely depends on transmission intensity. In the 
case of P. vivax relapsing hypnozoites add to the frequency of blood stage parasitemia. 
Relapsing parasites are mostly genetically different from parasites detected during last acute 
blood stage infection (Chen et al., 2007; Imwong et al., 2007; Restrepo et al., 2011), either 
because the relapsing clones might correspond to earlier (acute) blood stage infections, or 
because the primary and relapsing infections are genetically different clones transmitted in a 
single mosquito bite. Relapses could therefore boost existing immune responses, and 
contribute to broadening the immune repertoire, thereby contributing to the natural acquisition 
of immunity to P. vivax. 
To determine the molecular force of infection (molFOI, the number of infections acquired per 
time) under natural conditions genotyping of all parasite clones of both P. falciparum and P. 
vivax in an individual over an extended period of time is required. We have followed 264 
children aged 1 to 3 years at enrolment over 16 months in an area of comparable high 
endemicity of P. falciparum and P. vivax (Lin et al., 2010). As in earlier studies significant 
difference in age specific burden of P. vivax and P. falciparum malaria were observed during 
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follow-up: While P. vivax incidence decreased throughout the age group, P. falciparum 
incidence increased from 1 to 3.5 years with little change thereafter (Lin et al., 2010).  
In order to assess the relationship between (individual) exposure and risk of malaria, we 
genotyped all P. falciparum and P. vivax infections detected over 16 months (Koepfli et al., 
2011a; Mueller et al., submitted). By tracking msp2 PCR-fragments in consecutive infections 
we found that on average children acquired 5.9 new P. falciparum infections/child/year 
(Mueller et al., submitted). The molFOI was found to increase significant with age, was strongly 
reduced in children using insecticide treated bed nets ITNs, and showed significant spatial 
and temporal variation. Adjusting for individual differences in molFOI completely explained the 
observed age trends and effect of ITN as well as ~50% of the seasonal and almost all of the 
spatial variation in the incidence of P. falciparum malaria.  
In an earlier analysis, we have presented diversity and multiplicity of the P. vivax clones in the 
cohort (Koepfli et al., 2011a). We now present a more in-depth analysis of P. vivax 
genotyping data with the aim to estimate molFOI for P. vivax, to determine its association with 
age, ITN use and season and investigate its relationship to the age-specific burden of P. vivax 
malaria in this cohort.  
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Methods  
Ehtics statement 
Informed written consent was sought from all parents or guardians prior to recruitment of each 
child. Scientific approval and ethical clearance for the study was obtained from the Medical 
Research and Advisory Committee (MRAC 05.19) of the Ministry of Health in PNG and from 
the Ethikkommission beider Basel in Switzerland (no 03/06).  
 
Field survey and patients 
This study was conducted in Ilaita, a rural area near Maprik, East Sepik Province, Papua New 
Guinea. A detailed description of the study was given elsewhere (Lin et al., 2010). Briefly, 264 
study participants were enrolled at an age of 10 to 38 months between March and September 
2006. Following enrolment children were followed actively every 2 weeks for malaria morbidity 
for a period of up to 16 months (until July 2007). In addition, children were actively checked 
every 8 to 9 weeks for the presence of malarial infections. Except for the first and last round 
of active case detection, two consecutive blood samples were collected by finger prick at 
intervals of 24 h from each study participant at each follow-up visit. An individual thus 
contributed up to 16 samples, 14 of which were paired samples collected 24 h apart. A 
passive case detection system was maintained at the local health centre and aid post 
throughout the entire study period. At each episode of febrile illness a blood sample collected 
from all participants, a rapid diagnostic test (RDT) was performed and haemoglobin measured 
using Hemacue (Angholm, Sweden). Antimalarial treatment with Coartem® (Novartis, 
Switzerland) was administered upon a positive RDT or if haemoglobin levels were <7.5 g/dl. 
In children with negative RDT, blood slides were read within 24 h and microscopy positive 
children treated with Coartem®.  
 
Laboratory procedures 
All finger prick blood samples were separated into plasma and cells. DNA was extracted from 
cell pellets using QIAamp® 96 DNA Blood Kit (Qiagen, Australia) according to the 
manufacturerʼs instructions. 
For genotyping individual P. vivax clones, the molecular markers msp1F3 and MS16 were 
typed using capillary electrophoresis for highly precise fragment sizing, as required for 
longitudinal follow up of parasite clones. Both markers proved to be highly polymorphic in the 
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cohort with a virtual heterozygosity of 97.8% for MS16 and 88.1% for msp1F3. Details of the 
genotyping technique have been described elsewhere (Koepfli et al., 2011a). 
 
Data analysis 
In a previous analysis of the samples collected 24 hours apart we have shown that in a single 
blood sample often not all alleles of a marker are detected. Twenty-one percent of all msp1F3 
alleles and 28% of all MS16 clones were missed on a single day (Koepfli et al., 2011b). For all 
analyses we therefore used the combined genotyping data from both day 1 and day 2, except 
for enrolment and final time point where only 1 sample was available. Consequently, 
multiplicity of infection (MOI) in each host was defined as the number of different msp1F3 and 
MS16 clones, detected in the day 1 sample combined (where available) with the day 2 
sample. For all discrepancies in typing results obtained by these 2 markers, the higher MOI 
was used, because very low abundant templates cannot be consistently amplified. 
The force of new P. vivax infections (molFOI) was calculated as follows: For each interval of 8 
to 9 weeks the number of newly acquired infections was determined. New clones were 
defined as msp1F3 and MS16 alleles not present in any preceding interval. An interval started 
on the first day after a regular cross-sectional visit; it thus included all samples collected 
during passive case detection over two months plus the samples collected at the end of the 
interval. For each interval, children were considered at risk of acquiring new infection from the 
1st day after the last blood sample from the preceding interval was taken. In line with the 
pharmacokinetic properties of the drugs (Hombhanje et al., 2005; Salman et al., 2011a; 
Salman et al., 2011b), children were not considered at risk for 2 weeks after treatment with 
Coartem® and 4 weeks after treatment with amodiaquine (AQ) plus sulphadoxine-
pyramethamine (SP). The force of infection for each child and interval was subsequently 
converted into the number of new clones acquired per year-at-risk. 
As in the earlier analyses of P. falciparum molFOI (Mueller et al., submitted), longitudinal 
random-effects models, or generalized linear mixed models (GLMMs) were used for analyses 
of prevalence, multiplicity and force of infection well as for incidence of P. vivax episodes. 
These models were chosen because they allowed the fixed effects, or subject-specific 
covariates, to be specified separately from the random effects, i.e. repeated measurements 
from the same child over time and unmeasured village factors. Furthermore, unlike other 
models, the random-effects model allowed for decomposition of the random effects into 
between-village and within-village variation. 
We fitted a Poisson-Gaussian random-effects model with a log link function to relate the fixed 
and random effects to the number of clinical episodes experienced during a two month 
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interval (defined as febrile illness plus any P. vivax density or P. vivax >500 parasites/µl). 
Similarly, for the prevalence of P. vivax infection by PCR (msp1F3 and/or MS16), we fitted a 
Binomial-Gaussian random effects model with a logit link function. Covariates were selected 
based on earlier analyses of the same data (Lin et al., 2010). Exploratory data analysis 
guided the specification of the model when the relationship between the covariates and the 
outcome did not appear to be linear, such as with age, FOI rate and season. Seasonality was 
characterized by two readily interpretable parameters: the amplitude, which is traditionally half 
the range between the peak(s) and trough(s), and the phase, which is the location of the first 
zero crossing in a cycle relative to the origin in time. When included directly, these two 
parameters define a non-linear regression term. For computational convenience, they are 
usually replaced by sin and cos terms with fixed phase, which enter linearly, and whose 
coefficients (amplitudes) are thus more easily estimated together with those of other terms in 
the linear part of the model. Their coefficients are then combined via a standard trigonometric 
identity to give the original amplitude and phase parameters (Diggle, 2002). For all outcomes 
except prevalence, an offset was fit to adjust for years at risk. Estimation of these models was 
done using the LME4 package in R version 2.12. 
All point estimates except those for seasonal effects were obtained by smoothing raw raw 
data using generalized additive models. Point estimates for seasonal peaks and trough were 
obtained from the GLMM-models. 
 
The Force of Plasmodium vivax Infections in Papua New Guinean Children 
101 
Results 
A total of 264 children aged between 0.9 – 3.2 yrs of age (median 1.7, Inter-quartile range 
(IQR): [1.3, 2.4]) were enrolled and followed for up to 69 weeks. 248 of 264 (93.9%) children 
were retained until the end of the study with between 96.0% - 100.0% of children see at each 
scheduled 2-monthly survey. Over the entire follow-up the age of children thus ranged from 
0.9 to 4.5 years of age. A more detailed description of the cohort was given in (Lin et al., 
2010). 
 
Prevalence by PCR and multiplicity of P. vivax infections  
All children except 5 had at least one msp1F3 or MS16 PCR positive sample during the 16 
months follow-up. 51.6% and 52.7% of all samples collected were positive for msp1F3 or 
MS16, respectively. A prevalence of 54.8% was obtained for the two markers combined.  
P. vivax prevalence increased significantly (OR 1.44, IC95[1.17, 1.76], P < 0.001, Table 1) with 
age (at start of interval) raising from 49% in children <1 yrs to 65 - 70% in children >3yrs. 
(Figure 1). Personal ITN use (OR 0.49, IC95[0.33, 0.73], P < 0.001) and antimalarial treatment 
< 4 weeks prior (OR 0.46, IC95[0.37, 0.57], P < 0.001) were both associated with a strong 
reduction in P. vivax prevalence. When smoothing raw prevalence using non-parametric 
regression splines, P. vivax prevalence was found to increase during the first 30 weeks of 
follow-up with little change thereafter. Nevertheless, in the multivariate GLMM model (Table 1, 
Figure 2) significant seasonal (P = 0.002) and between year variation (OR 1.40, IC95[1.02, 
1.92], P = 0.03) in prevalence was detected. Based on sin/cos modelling, P. vivax prevalence 
was found to peak in week 38 (i.e. mid September / late dry season) and was lowest in week 
12 (late March / late rainy season, Figure 2). Despite adjusting for these factors, prevalence 
of infection still varied significantly between villages (P = 0.008) and among children with 
villages (P < 0.001).  
The patterns observed for multiplicity of infection paralleled those observed for prevalence. 
MOI rose significantly throughout the age range (Table 1, P < 0.001), with mean MOI 
increasing from about 2.5 in 1 year old children to 3.6 at in 4 years old children (Figure1). 
Average ITN use was associated with a significant reduction in MOI from 3.3 in non-users to 
3.0 in children always sleeping under an ITN (Figure 1, Table 1, P = 0.03). Despite small 
seasonal amplitude, average MOI also showed significant variation over time (Figure 1, Table 
2, P = 0.002) with MOI estimates to peak in week 40 (early Oct / late dry season). There was 
significant variation in MOI among children living in the same villages (Table 1, P < 0.001) but 
not between villages (p = 0.1).  
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Force of infection in 8-9 week intervals 
Excluding any period with residual drug levels from the time at risk, the average molFOI was 
14.6 new P. vivax infections per child per year.  
molFOI showed a very pronounced seasonality (Figure 2, Table 1, P < 0.0001). Based on 
GLMM modeling molFOI was estimated to peak in early January (week 53, 17 
clones/child/year) and was lowest in early July (week 27, 11 clones/child/year, Figure 2). 
molFOI was also found to be significant lower in 2007 compared to 2006 (IRR 0.84, IC95[0.77, 
0.92], P = 0.0002, Table 1, Figure 1). Regular ITN use was associated with a significant 
reduction in acquisition of new clones (IRR 0.66, IC95[0.56, 0.77], P < 0.0001, Table 1), 
whereas children with antimalarial treatment in 4 weeks prior to an interval had a higher 
molFOI (IRR 1.24, IC95[1.15, 1.33], P < 0.0001, Table 1). molFOI did however not vary 
significant with age (Figure 1, P-value (GLMM) = 0.6). As for MOI, significant variation in 
molFOI was detected among children in a village (P < 0.001) but not between villages (P = 0.3, 
Table 1). A summary of the GLMM estimates for molFOI (Fit stats) can be found in Table 1.  
 
Predictors of clinical P. vivax illness 
Over the 69 weeks of follow-up, a total of 1134 febrile episodes (incidence rate (IR) 4.60 / 
child / yr) with parasitaemia (by light microscopy) were observed (Lin et al., 2010). Overall, P. 
vivax was the 2nd most common cause of malarial illness (any density: 605 (IR 2.46), Pv > 
500/µl) after P. falciparum (any density: 630 (IR 2.56), Pf > 2,500/µl: 472 (IR 1.92)). P. 
malariae and P. ovale episodes were rare. All further analyses are done using only the more 
specific definition of P. vivax malaria (i.e. febrile illness plus parasitaemia > 500/µl) (Mueller et 
al 2009, Malaria J).  
As in earlier analyses (Lin et al., 2010), age and season were significant predictors of clinical 
episodes of P. vivax malaria (Table 2). The incidence of P. vivax malaria decreased log-
linearly with age (Figure 1,Table 2, P < 0.0001) from 2.9 episodes / child / year in children 1 
year old children to a minimum of 0.8 episodes at 3.5 years of age. The incidence of P. vivax 
malaria peaked at the beginning of rainy season (week 49, early December), and was lowest 
in the early dry season (week 23, early June, Figure 2). ITN use on the other hand showed no 
significant association with incidence of P. vivax malaria. The incidence of P. vivax malaria 
varied significantly among villages (P < 0.0001) and among children living in the same village 
(P < 0.0001). 
When molFOI was added to the model (fitted as the rate of new clones acquired per year at 
risk), molFOI was highly significantly associated with an increase in the incidence of P. vivax 
malaria (Figure 3, P < 0.0001). Adjusting for molFOI accounted for a substantial amount of 
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seasonal variation and resulted in a 45% decrease in season amplitude (Table 2, Figure 4) 
but contrary to what was observed for P. falciparum (Mueller et al., submitted) it had no effect 
at all on other factorʼs association with incidence of P. vivax malaria. 
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Discussion 
As in other regions where P. vivax and P. falciparum are co-endemic (Gunewardena et al., 
1994; Maitland et al., 1996; Phimpraphi et al., 2008), on the island of New Guinea the burden 
of P. vivax infections and illness peaks in younger children compared to P. falciparum 
(Kasehagen et al., 2006; Lin et al., 2010; Michon et al., 2007; Mueller et al., 2009). The 
increasingly appreciated burden of P. vivax associated severe morbidity and even mortality 
(Genton et al., 2008; Manning et al., in press; Poespoprodjo et al., 2009; Tjitra et al., 2008) is 
concentrated in the very youngest children (<3 yrs). This indicates a fast acquisition of 
immunity to P. vivax in individuals with life-long exposure to both P. falciparum and P. vivax 
infections. The reason for the faster acquisition of immunity to P. vivax compared to that 
against P. vivax has been unclear, but as immunity to malaria builds up gradually and is 
thought be strain specific (Ciuca et al., 1934; Jeffery, 1966), it is likely that the number of 
distinct infections acquired over an individuals lifetime is a major driving force for acquired 
immunity 
Genotyping all PCR positive infections that occurred in individual children over 16 months of 
follow-up, has revealed that children aged 0.9 - 4.5 years children indeed acquire more than 
twice as many genetically distinct P. vivax (14.6 clones/child/year) compared to P. falciparum 
blood-stage infections (5.9 clones/child/year) ((Mueller et al., submitted). In parallel with this 
higher molecular force of infection (molFOI), we also observed an increased prevalence and 
multiplicity of P. vivax infections compared to P. falciparum.  
Several reasons could account for the markedly higher P. vivax molFOI compared to that of P. 
falciparum. Genotyping techniques used for both species were comparable and experiments 
were performed in the same laboratory. Typing was based on length polymorphism in highly 
diverse marker genes as evidenced by their respective expected heterozygosity, HE. P. 
falciparum was typed using msp2 (HE=0.933) (Schoepflin et al., 2009), and MS16 (HE=0.978) 
and msp1F3 (HE=0.881) were used for P. vivax typing (Koepfli et al., 2011a). The detectability 
(the proportion of clones detected in both of two bleeds 24 h apart) of clones was 79% for 
Pfmsp2 and 61% and 73% for PvMS16 and Pmsp1F3 respectively (Koepfli et al., 2011b). 
Although P. vivax genotyping was based on two loci (and MOI and FOI were determined from 
maximal number of alleles per sample observed by any marker), the overall sensitivity seems 
comparable between single locus Pfmsp2 genotyping and two loci P. vivax typing, when 
considering the similar values for HE and detectability. 
For this study we have counted all clones detected in regular 2 monthly double bleeds, as well 
as all samples collected during febrile illness episodes detected during active and passive 
case detection. Very low-density clones are likely missed, since genotyping studies based on 
next generation sequencing technology have suggested that multiplicity of infection might be 
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several times higher than when detected by classical PCR (Campino et al., 2011; Juliano et 
al., 2010). From this and from our own previous studies on clone detectablity, we assume that 
our estimates of molFOI and MOI of both species are likely underestimates of the true burden 
and complexity of Plasmodium spp. infection in our cohort. Nevertheless, sensitivity any 
genotyping likely is imperfect. As long as comparable methodologies are used, the validity of 
the principal conclusions of epidemiological analyses presented here will not be affected. 
In PNG P. vivax and P. falciparum are transmitted by the same mosquito vectors. While no 
entomological studies were conducted concurrently with the cohort, earlier studies in different 
PNG lowlands population reported comparable sporozoite rates for P. falciparum and for P. 
vivax in the local vector populations (Benet et al., 2004; Hii et al., 2001; Michon et al., 2007). 
Although the relative prevalence of P. vivax sporozoites may rise after ITN introduction 
(Bockarie and Dagoro, 2006), it is nevertheless unlikely that the differences in molFOI could 
be explained solely by different EIRs (entomological inoculation rates) for the two species. 
However, 75% of all P. vivax positive individuals in our cohort carried multiple clone 
infections, but only 33% of all P. falciparum positive children (Koepfli et al., 2011a) and Sonja 
Schoepflin, unpublished results). This increases the chance that mosquitoes will concurrently 
ingest gametocytes from more than one P. vivax clones, which in turn increases the likelihood 
that individuals become infected with multiple P. vivax clones by a single mosquito bite.  
Finally, P. vivax parasites detected in the blood stream do not always derive from a recent 
mosquito bite, but can also be the result of relapsing hypnozoites from an earlier bite. New 
Guinea P. vivax strains were found to relapse very rapidly and 63% of 1 - 5 yr old children had 
a recurrent parasitemia within 6 weeks after treatment with Coartem (Barnadas et al., 2011). 
Two thirds of these recurrent infections (all post 28 days) were of a different genotype. 
Although genotyping cannot differentiate between true new infections and relapses of a 
different genotype as seen in the last infection, relapsing P. vivax infections likely contribute 
significantly to the higher molFOI. In summary, molFOI of P.falciparum and P. vivax measure 
different epidemiological parameters: while molFOI of P. falciparum is directly linked to 
transmission by mosquitoes, molFOI of P. vivax measures both, mosquito-borne transmission 
intensity and frequency and genetic complexity of relapsing parasites. 
Whereas P. falciparum molFOI was found to be strongly age dependent and to increase from 3 
clones per year in children <1 year to 8 clones per year in those >4 (Mueller et al., submitted), 
P. vivax molFOI does not change significantly with age. We thus estimate that during the first 
years of life, the children in our cohort were infected with three to four times more genetically 
distinct P. vivax than P. falciparum clones. This large difference in molFOI, and thus the overall 
genetic diversity to which children are exposed in early childhood, has dramatic impacts on 
the age specific burden with P. vivax and P. falciparum malaria. Although a higher molFOI was 
associated with a significant increase in incidence of clinical disease in both species (Mueller 
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et al., submitted), the incidence of P. vivax decreased significantly across the entire age 
range, while the incidence of P. falciparum malaria increased with the age. This suggests that 
between the age of 1 to 4 years children have been exposed to a sufficient number of P. vivax 
infections to acquire high level of clinical immunity to this parasite.  
Such an exposure may even be sufficient for children to acquire a certain degree of sterile 
immunity against P. vivax infection. Mosquito biting rates are known to increase proportional 
to host body size (Port et al., 1980). Therefore, as children grow in size, their exposure to 
malarial infection also increases, as confirmed by the strong age-dependence of P. falciparum 
molFOI. P. vivax molFOI did not change with age. This suggests that in older children some of 
the transmitted P. vivax sporozoites do not succeed to establish detectable blood stage 
infections.  
In conclusion, we propose that the number of infections acquired over time is a mayor 
determinant of immunity against clinical malaria. Although we can not rule out that generic 
differences exist between P. falciparum and P. vivax with respect to the nature of immune 
responses elicited and immune acquisition by their hosts, the observed differences in molFOI 
can largely explain the striking differences in incidence trends between the two species. The 
faster acquisition of immunity against P. vivax disease results in a marked decrease in 
incidence with increasing age, despite a constant number of blood stage infections. 
The Force of Plasmodium vivax Infections in Papua New Guinean Children 
107 
References 
Aguas, R., Ferreira, M.U., and Gomes, M.G. (2012). Modeling the effects of relapse in the 
transmission dynamics of malaria parasites. J Parasitol Res 2012, 921715. 
Anders, R.F., McColl, D.J., and Coppel, R.L. (1993). Molecular variation in Plasmodium 
falciparum: polymorphic antigens of asexual erythrocytic stages. Acta Trop 53, 239-253. 
Annan, Z., Durand, P., Ayala, F.J., Arnathau, C., Awono-Ambene, P., Simard, F., 
Razakandrainibe, F.G., Koella, J.C., Fontenille, D., and Renaud, F. (2007). Population genetic 
structure of Plasmodium falciparum in the two main African vectors, Anopheles gambiae and 
Anopheles funestus. Proc Natl Acad Sci USA 104, 7987-7992. 
Balfour, M.C. (1935). Malaria studies in Greece. Am J Trop Med Hyg 15, 301-329. 
Barnadas, C., Koepfli, C., Karunajeewa, H.A., Siba, P.M., Davis, T.M.E., and Mueller, I. 
(2011). Characterization of Treatment Failure in Efficacy Trials of Drugs against Plasmodium 
vivax by Genotyping Neutral and Drug Resistance-Associated Markers. Antimicrob Agents 
Chemother 55, 4479-4481. 
Benet, A., Mai, A., Bockarie, F., Lagog, M., Zimmerman, P., Alpers, M.P., Reeder, J.C., and 
Bockarie, M.J. (2004). Polymerase chain reaction diagnosis and the changing pattern of 
vector ecology and malaria transmission dynamics in Papua New Guinea. Am J Trop Med 
Hyg 71, 277-284. 
Bernabeu, M., Lopez, F., Ferrer, M., Martin-Jaular, L., Razaname, A., Corradin, G., Maier, A., 
Del Portillo, H., and Fernandez-Becerra, C. (2011). Functional analysis of Plasmodium vivax 
VIR proteins reveals different subcellular localizations and cytoadherence to the ICAM-1 
endothelial receptor. Cell Microbiol. 
Bockarie, M.J., and Dagoro, H. (2006). Are insecticide-treated bednets more protective 
against Plasmodium falciparum than Plasmodium vivax-infected mosquitoes? Malar J 5, 15. 
Bull, P.C., Lowe, B.S., Kortok, M., Molyneux, C.S., Newbold, C.I., and Marsh, K. (1998). 
Parasite antigens on the infected red cell surface are targets for naturally acquired immunity 
to malaria. Nat Med 4, 358-360. 
Bull, P.C., and Marsh, K. (2002). The role of antibodies to Plasmodium falciparum-infected-
erythrocyte surface antigens in naturally acquired immunity to malaria. Trends Microbiol 10, 
55-58. 
Campino, S., Auburn, S., Kivinen, K., Zongo, I., Ouedraogo, J.B., Mangano, V., Djimde, A., 
Doumbo, O.K., Kiara, S.M., Nzila, A., et al. (2011). Population genetic analysis of 
Plasmodium falciparum parasites using a customized Illumina GoldenGate genotyping assay. 
PLoS ONE 6, e20251. 
Chen, L., Lopaticki, S., Riglar, D.T., Dekiwadia, C., Uboldi, A.D., Tham, W.H., O'Neill, M.T., 
Richard, D., Baum, J., Ralph, S.A., et al. (2011). An EGF-like protein forms a complex with 
PfRh5 and is required for invasion of human erythrocytes by Plasmodium falciparum. PLoS 
Pathog 7, e1002199. 
Chen, N., Auliff, A., Rieckmann, K., Gatton, M., and Cheng, Q. (2007). Relapses of 
Plasmodium vivax infection result from clonal hypnozoites activated at predetermined 
intervals. J Infect Dis 195, 934-941. 
Ciuca, M., Ballif, L., and Chelarescu-Vieru, M. (1934). Immunity in malaria. Transactions of 
the Royal Society of Tropical Medicine and Hygiene 27, 4. 
The Force of Plasmodium vivax Infections in Papua New Guinean Children 
108 
Cole-Tobian, J., and King, C.L. (2003). Diversity and natural selection in Plasmodium vivax 
Duffy binding protein gene. Mol Biochem Parasitol 127, 121-132. 
Cole-Tobian, J.L., Michon, P., Biasor, M., Richards, J.S., Beeson, J.G., Mueller, I., and King, 
C.L. (2009). Strain-specific duffy binding protein antibodies correlate with protection against 
infection with homologous compared to heterologous plasmodium vivax strains in Papua New 
Guinean children. Infect Immun 77, 4009-4017. 
Collins, W.E., and Jeffery, G.M. (1999). A retrospective examination of secondary sporozoite- 
and trophozoite-induced infections with Plasmodium falciparum: development of parasitologic 
and clinical immunity following secondary infection. Am J Trop Med Hyg 61, 20-35. 
Collins, W.E., Jeffery, G.M., and Roberts, J.M. (2004). A retrospective examination of 
reinfection of humans with Plasmodium vivax. Am J Trop Med Hyg 70, 642-644. 
Cortes, A., Mellombo, M., Mueller, I., Benet, A., Reeder, J.C., and Anders, R.F. (2003). 
Geographical structure of diversity and differences between symptomatic and asymptomatic 
infections for Plasmodium falciparum vaccine candidate AMA1. Infect Immun 71, 1416-1426. 
Cowman, A.F., and Crabb, B.S. (2006). Invasion of red blood cells by malaria parasites. Cell 
124, 755-766. 
Diggle, P. (2002). Analysis of longitudinal data, 2nd edn (Oxford ; New York, Oxford 
University Press). 
Dodoo, D., Staalsoe, T., Giha, H., Kurtzhals, J.A., Akanmori, B.D., Koram, K., Dunyo, S., 
Nkrumah, F.K., Hviid, L., and Theander, T.G. (2001). Antibodies to variant antigens on the 
surfaces of infected erythrocytes are associated with protection from malaria in Ghanaian 
children. Infect Immun 69, 3713-3718. 
Doolan, D.L., Dobano, C., and Baird, J.K. (2009). Acquired immunity to malaria. Clin Microbiol 
Rev 22, 13-36, Table of Contents. 
Earle, W.C. (1939). Epidemiology of malaria in Puerto Rico. Puerto Rico J Pub Health Trop 
Med 15, 3-27. 
Fenton, B., Clark, J.T., Khan, C.M., Robinson, J.V., Walliker, D., Ridley, R., Scaife, J.G., and 
McBride, J.S. (1991). Structural and antigenic polymorphism of the 35- to 48-kilodalton 
merozoite surface antigen (MSA-2) of the malaria parasite Plasmodium falciparum. Mol Cell 
Biol 11, 963-971. 
Fernandez-Becerra, C., Pein, O., de Oliveira, T.R., Yamamoto, M.M., Cassola, A.C., Rocha, 
C., Soares, I.S., de Braganca Pereira, C.A., and del Portillo, H.A. (2005). Variant proteins of 
Plasmodium vivax are not clonally expressed in natural infections. Mol Microbiol 58, 648-658. 
Genton, B., Betuela, I., Felger, I., Al-Yaman, F., Anders, R.F., Saul, A., Rare, L., Baisor, M., 
Lorry, K., Brown, G.V., et al. (2002). A recombinant blood-stage malaria vaccine reduces 
Plasmodium falciparum density and exerts selective pressure on parasite populations in a 
phase 1-2b trial in Papua New Guinea. J Infect Dis 185, 820-827. 
Genton, B., D'Acremont, V., Rare, L., Baea, K., Reeder, J.C., Alpers, M.P., and Muller, I. 
(2008). Plasmodium vivax and mixed infections are associated with severe malaria in 
children: a prospective cohort study from Papua New Guinea. PLoS Med 5, e127. 
Giha, H.A., Staalsoe, T., Dodoo, D., Roper, C., Satti, G.M., Arnot, D.E., Hviid, L., and 
Theander, T.G. (2000). Antibodies to variable Plasmodium falciparum-infected erythrocyte 
surface antigens are associated with protection from novel malaria infections. Immunol Lett 
71, 117-126. 
The Force of Plasmodium vivax Infections in Papua New Guinean Children 
109 
Grimberg, B.T., Udomsangpetch, R., Xainli, J., McHenry, A., Panichakul, T., Sattabongkot, J., 
Cui, L., Bockarie, M., Chitnis, C., Adams, J., et al. (2007). Plasmodium vivax invasion of 
human erythrocytes inhibited by antibodies directed against the Duffy binding protein. PLoS 
Med 4, e337. 
Gunewardena, D.M., Carter, R., and Mendis, K.N. (1994). Patterns of acquired anti-malarial 
immunity in Sri Lanka. Mem Inst Oswaldo Cruz 89 Suppl 2, 63-65. 
Henry-Halldin, C.N., Sepe, D., Susapu, M., McNamara, D.T., Bockarie, M., King, C.L., and 
Zimmerman, P.A. (2011). High-throughput molecular diagnosis of circumsporozoite variants 
VK210 and VK247 detects complex Plasmodium vivax infections in malaria endemic 
populations in Papua New Guinea. Infect Genet Evol 11, 391-398. 
Hii, J.L., Smith, T., Vounatsou, P., Alexander, N., Mai, A., Ibam, E., and Alpers, M.P. (2001). 
Area effects of bednet use in a malaria-endemic area in Papua New Guinea. 
TransRSocTropMedHyg 95, 7-13. 
Hombhanje, F.W., Hwaihwanje, I., Tsukahara, T., Saruwatari, J., Nakagawa, M., Osawa, H., 
Paniu, M.M., Takahashi, N., Lum, J.K., Aumora, B., et al. (2005). The disposition of oral 
amodiaquine in Papua New Guinean children with falciparum malaria. Br J Clin Pharmacol 
59, 298-301. 
Imwong, M., Pukrittayakamee, S., Gruner, A.C., Renia, L., Letourneur, F., Looareesuwan, S., 
White, N.J., and Snounou, G. (2005). Practical PCR genotyping protocols for Plasmodium 
vivax using Pvcs and Pvmsp1. Malar J 4, 20. 
Imwong, M., Snounou, G., Pukrittayakamee, S., Tanomsing, N., Kim, J.R., Nandy, A., 
Guthmann, J.P., Nosten, F., Carlton, J., Looareesuwan, S., et al. (2007). Relapses of 
Plasmodium vivax infection usually result from activation of heterologous hypnozoites. J Infect 
Dis 195, 927-933. 
Jeffery, G.M. (1966). Epidemiological significance of repeated infections with homologous and 
heterologous strains and species of Plasmodium. Bull World Health Organ 35, 873-882. 
Jiang, L., Gaur, D., Mu, J., Zhou, H., Long, C.A., and Miller, L.H. (2011). Evidence for 
erythrocyte-binding antigen 175 as a component of a ligand-blocking blood-stage malaria 
vaccine. Proc Natl Acad Sci U S A 108, 7553-7558. 
Juliano, J.J., Porter, K., Mwapasa, V., Sem, R., Rogers, W.O., Ariey, F., Wongsrichanalai, C., 
Read, A., and Meshnick, S.R. (2010). Exposing malaria in-host diversity and estimating 
population diversity by capture-recapture using massively parallel pyrosequencing. Proc Natl 
Acad Sci USA 107, 20138-20143. 
Kasehagen, L.J., Mueller, I., McNamara, D.T., Bockarie, M.J., Kiniboro, B., Rare, L., Lorry, K., 
Kastens, W., Reeder, J.C., Kazura, J.W., et al. (2006). Changing patterns of Plasmodium 
blood-stage infections in the Wosera region of Papua New Guinea monitored by light 
microscopy and high throughput PCR diagnosis. Am J Trop Med Hyg 75, 588-596. 
King, C.L., Michon, P., Shakri, A.R., Marcotty, A., Stanisic, D., Zimmerman, P.A., Cole-
Tobian, J.L., Mueller, I., and Chitnis, C.E. (2008). Naturally acquired Duffy-binding protein-
specific binding inhibitory antibodies confer protection from blood-stage Plasmodium vivax 
infection. Proc Natl Acad Sci U S A 105, 8363-8368. 
Koch, R. (1900). Dritter Bericht über die Tätigkeit der Malariaexpedition. Deutsche 
Medizinische Wochenschrift 17. 
Koepfli, C., Mueller, I., Marfurt, J., Goroti, M., Sie, A., Oa, O., Genton, B., Beck, H.-P., and 
Felger, I. (2008). Evaluation of Plasmodium vivax genotyping markers for molecular 
monitoring in clinical trials. J Infect Dis. 
The Force of Plasmodium vivax Infections in Papua New Guinean Children 
110 
Koepfli, C., Ross, A., Kiniboro, B., Smith, T.A., Zimmerman, P.A., Siba, P., Mueller, I., and 
Felger, I. (2011a). Multiplicity and diversity of Plasmodium vivax infections in a highly endemic 
region in Papua New Guinea. . PLoS Negl Trop Dis In press. 
Koepfli, C., Schoepflin, S., Bretscher, M., Lin, E., Kiniboro, B., Zimmerman, P.A., Siba, P., 
Smith, T.A., Mueller, I., and Felger, I. (2011b). How much remains undetected? Probability of 
molecular detection of human plasmodia in the field. PLoS ONE 6, e19010. 
Langhorne, J., Ndungu, F.M., Sponaas, A.M., and Marsh, K. (2008). Immunity to malaria: 
more questions than answers. Nat Immunol 9, 725-732. 
Lin, E., Kiniboro, B., Gray, L., Dobbie, S., Robinson, L., Laumaea, A., Schopflin, S., Stanisic, 
D., Betuela, I., Blood-Zikursh, M., et al. (2010). Differential patterns of infection and disease 
with P. falciparum and P. vivax in young Papua New Guinean children. PLoS One 5, e9047. 
Lyon, J.A., Angov, E., Fay, M.P., Sullivan, J.S., Girourd, A.S., Robinson, S.J., Bergmann-
Leitner, E.S., Duncan, E.H., Darko, C.A., Collins, W.E., et al. (2008). Protection induced by 
Plasmodium falciparum MSP1(42) is strain-specific, antigen and adjuvant dependent, and 
correlates with antibody responses. PLoS ONE 3, e2830. 
Maitland, K., Williams, T.N., Bennett, S., Newbold, C.I., Peto, T.E., Viji, J., Timothy, R., Clegg, 
J.B., Weatherall, D.J., and Bowden, D.K. (1996). The interaction between Plasmodium 
falciparum and P. vivax in children on Espiritu Santo island, Vanuatu. Trans R Soc Trop Med 
Hyg 90, 614-620. 
Manning, L., Laman, M., Law, I., Bona, C., Aipit, S., Teine, D., Warrell, J., Rosanas-Urgell, A., 
Lin, E., Kiniboro, B., et al. (in press). Features and prognosis of severe malaria caused by 
Plasmodium falciparum, Plasmodium vivax and mixed Plasmodium species in Papua New 
Guinean children. PLoS One. 
Menard, D., Barnadas, C., Bouchier, C., Henry-Halldin, C., Gray, L.R., Ratsimbasoa, A., 
Thonier, V., Carod, J.F., Domarle, O., Colin, Y., et al. (2010). Plasmodium vivax clinical 
malaria is commonly observed in Duffy-negative Malagasy people. Proc Natl Acad Sci U S A 
107, 5967-5971. 
Mendis, K., Sina, B.J., Marchesini, P., and Carter, R. (2001). The neglected burden of 
Plasmodium vivax malaria. Am J Trop Med Hyg 64, 97-106. 
Michon, P., Cole-Tobian, J.L., Dabod, E., Schoepflin, S., Igu, J., Susapu, M., Tarongka, N., 
Zimmerman, P.A., Reeder, J.C., Beeson, J.G., et al. (2007). The risk of malarial infections 
and disease in Papua New Guinean children. Am J Trop Med Hyg 76, 997-1008. 
Miller, L.H., Mason, S.J., Clyde, D.F., and McGinniss, M.H. (1976). The resistance factor to 
Plasmodium vivax in blacks. The Duffy-blood-group genotype, FyFy. N Engl J Med 295, 302-
304. 
Mueller, I., Schoepflin, S., Smith, T.A., Benton, K.L., Bretscher, M., Lin, E., Kiniboro, B., 
Zimmerman, P.A., Speed, T., Siba, P., et al. (submitted). The Force of Infection: Key to 
understanding the epidemiology of Plasmodium falciparum malaria in Papua New Guinean 
children. Proc Natl Acad Sci USA. 
Mueller, I., Widmer, S., Michel, D., Maraga, S., McNamara, D.T., Kiniboro, B., Sie, A., Smith, 
T.A., and Zimmerman, P.A. (2009). High sensitivity detection of Plasmodium species reveals 
positive correlations between infections of different species, shifts in age distribution and 
reduced local variation in Papua New Guinea. Malar J 8, 41. 
Mzilahowa, T., McCall, P.J., and Hastings, I.M. (2007). "Sexual" population structure and 
genetics of the malaria agent P. falciparum. PLoS ONE 2, e613. 
The Force of Plasmodium vivax Infections in Papua New Guinean Children 
111 
Osier, F.H., Fegan, G., Polley, S.D., Murungi, L., Verra, F., Tetteh, K.K., Lowe, B., Mwangi, 
T., Bull, P.C., Thomas, A.W., et al. (2008). Breadth and magnitude of antibody responses to 
multiple Plasmodium falciparum merozoite antigens are associated with protection from 
clinical malaria. Infect Immun 76, 2240-2248. 
Persson, K.E., McCallum, F.J., Reiling, L., Lister, N.A., Stubbs, J., Cowman, A.F., Marsh, K., 
and Beeson, J.G. (2008). Variation in use of erythrocyte invasion pathways by Plasmodium 
falciparum mediates evasion of human inhibitory antibodies. J Clin Invest 118, 342-351. 
Phimpraphi, W., Paul, R.E., Yimsamran, S., Puangsa-art, S., Thanyavanich, N., 
Maneeboonyang, W., Prommongkol, S., Sornklom, S., Chaimungkun, W., Chavez, I.F., et al. 
(2008). Longitudinal study of Plasmodium falciparum and Plasmodium vivax in a Karen 
population in Thailand. Malar J 7, 99. 
Poespoprodjo, J.R., Fobia, W., Kenangalem, E., Lampah, D.A., Hasanuddin, A., Warikar, N., 
Sugiarto, P., Tjitra, E., Anstey, N.M., and Price, R.N. (2009). Vivax malaria: a major cause of 
morbidity in early infancy. Clin Infect Dis 48, 1704-1712. 
Port, G.R., Boreham, P.F.L., and Bryan, J.H. (1980). The relationship of host size to feeding 
by mosquitos of the Anopheles gambiae Giles complex (Diptera, Culicidae). Bull Entomol Res 
70, 133-144. 
Raj, D.K., Das, B.R., Dash, A.P., and Supakar, P.C. (2004). Genetic diversity in the merozoite 
surface protein 1 gene of Plasmodium falciparum in different malaria-endemic localities. Am J 
Trop Med Hyg 71, 285-289. 
Reiling, L., Richards, J.S., Fowkes, F.J., Barry, A.E., Triglia, T., Chokejindachai, W., Michon, 
P., Tavul, L., Siba, P.M., Cowman, A.F., et al. (2010). Evidence that the erythrocyte invasion 
ligand PfRh2 is a target of protective immunity against Plasmodium falciparum malaria. J 
Immunol 185, 6157-6167. 
Restrepo, E., Imwong, M., Rojas, W., Carmona-Fonseca, J., and Maestre, A. (2011). High 
genetic polymorphism of relapsing P. vivax isolates in northwest Colombia. Acta Trop 119, 
23-29. 
Richards, J.S., Stanisic, D.I., Fowkes, F.J., Tavul, L., Dabod, E., Thompson, J.K., Kumar, S., 
Chitnis, C.E., Narum, D.L., Michon, P., et al. (2010). Association between naturally acquired 
antibodies to erythrocyte-binding antigens of Plasmodium falciparum and protection from 
malaria and high-density parasitemia. Clin Infect Dis 51, e50-60. 
Salman, S., Kose, K., Griffin, S., Baiwog, F., Winmai, J., Kandai, J., Siba, P., Ilett, K.F., 
Mueller, I., and Davis, T.M.E. (2011a). The pharmacokinetic properties of standard and 
double-dose sulfadoxine-pyrimethamine in infants. Antimicrob Agents Chemother 55, 1693–
1700. 
Salman, S., Page-Sharp, M., Griffin, S., Kose, K., Siba, P.M., Ilett, K.F., Mueller, I., and Davis, 
T.M. (2011b). Population pharmacokinetics of artemether, lumefantrine, and their respective 
metabolites in Papua New Guinean children with uncomplicated malaria. Antimicrobial agents 
and chemotherapy 55, 5306-5313. 
Schoepflin, S., Valsangiacomo, F., Lin, E., Kiniboro, B., Mueller, I., and Felger, I. (2009). 
Comparison of Plasmodium falciparum allelic frequency distribution in different endemic 
settings by high-resolution genotyping. Malar J 8, 250. 
Smith, T., Felger, I., Tanner, M., and Beck, H.P. (1999). Premunition in Plasmodium 
falciparum infection: insights from the epidemiology of multiple infections. Trans R Soc Trop 
Med Hyg 93 Suppl 1, 59-64. 
The Force of Plasmodium vivax Infections in Papua New Guinean Children 
112 
Tham, W.H., Wilson, D.W., Reiling, L., Chen, L., Beeson, J.G., and Cowman, A.F. (2009). 
Antibodies to reticulocyte binding protein-like homologue 4 inhibit invasion of Plasmodium 
falciparum into human erythrocytes. Infect Immun 77, 2427-2435. 
Tjitra, E., Anstey, N.M., Sugiarto, P., Warikar, N., Kenangalem, E., Karyana, M., Lampah, 
D.A., and Price, R.N. (2008). Multidrug-resistant Plasmodium vivax associated with severe 
and fatal malaria: a prospective study in Papua, Indonesia. PLoS Med 5, e128. 
Triglia, T., Chen, L., Lopaticki, S., Dekiwadia, C., Riglar, D.T., Hodder, A.N., Ralph, S.A., 
Baum, J., and Cowman, A.F. (2011). Plasmodium falciparum merozoite invasion is inhibited 
by antibodies that target the PfRh2a and b binding domains. PLoS Pathog 7, e1002075. 
Voss, T.S., Healer, J., Marty, A.J., Duffy, M.F., Thompson, J.K., Beeson, J.G., Reeder, J.C., 
Crabb, B.S., and Cowman, A.F. (2006). A var gene promoter controls allelic exclusion of 
virulence genes in Plasmodium falciparum malaria. Nature 439, 1004-1008. 
Weisman, S., Wang, L., Billman-Jacobe, H., Nhan, D.H., Richie, T.L., and Coppel, R.L. 
(2001). Antibody responses to infections with strains of Plasmodium falciparum expressing 
diverse forms of merozoite surface protein 2. Infect Immun 69, 959-967. 
 
 
!
!
!
The Force of Plasmodium vivax Infections in Papua New Guinean Children 
113 
 
Figure 1: Age and seasonal patterns of prevalence, multiplicity (MOI), force-of-infection 
(molFOI) and incidence of P. vivax malaria. Spline smoothed raw data and 95% confidence 
intervals. 
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Figure 2: Effect of ITN use on prevalence, multiplicity (MOI) and force (FOI) of P. vivax 
infection and incidence of clinical episodes.  
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Figure 3: Association between force-of-infection (molFOI) and incidence of P. vivax malaria. 
A) Spline smoothed raw data. B) Incidence rate ratio adjusted for seasonal difference from GLMM 
model. Predicted means and 95% confidence intervals 
 
 
Figure 4: Predicted associations of seasonality with P. vivax molecular epidemiology 
endpoints: A) seasonal patters in prevalence, MOI and molFOI, B) seasonal effects on incidence 
of P. vivax (>500/µl) before (blue) and after adjusting for difference in molFOI (red). 
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Table 1: Parameter estimates GLMM models for prevalence, multiplicity of infection 
(MOI) and force of P. vivax infections (molFOI).  
Fixed 
effects 
Prevalence 
ORa LCL UCL P MOI RRb LCL UCL P FOI IRRc LCL UCL P 
Age 1.44 1.17 1.76 0.0006 1.15 1.09 1.22 <.0001     
Sin(week) 0.72 0.6 0.86 0.92 0.88 0.97 0.99 0.93 1.05 
Cos(week) 0.95 0.8 1.12 
0.002f 
1.01 0.96 1.06 
0.002 
1.23 1.18 1.29 
<.0001 
Average 
ITN used 0.49 0.33 0.73 0.0004 0.89 0.8 0.98 0.03 0.66 0.56 0.77 <.0001 
Treatede 0.46 0.37 0.57 <.0001     1.24 1.16 1.33 <.0001 
Year 2007 1.4 1.02 1.92 0.03     0.84 0.77 0.92 0.0002 
Random effects            
village 0.12   0.008 0.006   0.1 0.007   0.3 
child 0.68   <.0001 0.03   <.0001 0.2   <.0001 
Seasonal stats            
betaSin 
-
0.328504067    
-
0.083381609    
-
0.010050336    
betaCos 
-
0.051293294    0.009950331    0.207014169    
Amplitude 0.33    0.08    0.21    
offset 11.71811035    
-
12.01702659    
-
0.401479259    
peak week 38    40    1    
trough 
week 12    14    27    
Month of 
Peak 
late 
September    
early 
October    
early 
January    
Month of 
Trough late March    early April    early July    
a OR: Odds ratio, LCL: lover confidence level, UCL: upper confidence level 
b RR: Rate ratio 
c IRR: incidence rate ratio, CI95: 95% confidence interval.  
d insecticide treated net use: 0% vs 100% use 
e Treated with antimalarials within 28days prior to start of interval. 
f joint p-value for sin and cos 
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Table 2: Incidence of P. vivax malaria 
Fixed 
effects 
PvAll 
IRR LCL UCL P 
PvAll+ 
FOI LCL UCL P 
Pv 
500 LCL UCL P 
Pv 
500+ 
FOI LCL UCL P 
Age 0.72 0.63 0.83 <.0001 0.68 0.6 0.78 <.0001 0.55 0.46 0.67 <.0001 0.52 0.44 0.62 <.0001 
Sin (week) 0.88 0.78 0.99 0.92 0.82 1.03 0.89 0.77 1.03 0.94 0.81 1.09 
Cos (week) 1.48 1.31 1.66 
<.0001a 
1.29 1.14 1.45 
<.0001 
1.45 1.25 1.67 
<.0001 
1.24 1.07 1.44 
0.01 
FOI^1/3 NA NA NA NA 1.88 1.74 2.03 <.0001 NA NA NA NA 1.99 1.8 2.19 <.0001 
Random 
effects                 
village 0.08   0.002 0.17   <.0001 0.2   0.0001 0.35   <.0001 
child 0.33   <.0001 0.11   0.003 0.56   <.0001 0.28   <.0001 
Seasonal 
stats                 
betaSin 
-
0.128    -0.083    -0.117    
-
0.062    
betaCos 0.392    0.255    0.372    0.215    
Amplitude 0.41    0.27    0.39    0.22    
offset 
-
2.609    -2.619    -2.515    
-
2.318    
peak week 49    49    49    49    
trough 
week 23    23    23    23    
Month of 
Peak 
early 
Dec.    
early 
Dec.    
early 
Dec.    
early 
Dec.    
Month of 
Trough 
early 
June    
early 
June    
early 
June    
early 
June    
Fit stats                 
log 
likelihood -843    -684    -669    -551    
AICb 1699    1382    1349    1115    
a joint p-value for sin and cos   b Akaike Information Criterium
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Supplementary Table 1: Parameter estimates for multiple random effects models predicting 
the number of incident clinical episodes of P. vivax malaria with any parasites density with 
and without adjustment for molFOI 
           Base model  molFOI adjusted 
  IRR CI95 p - value  IRR CI95 p - value 
         
Age (at interval) 
 
0.72 
[0.62, 
0.83] 
<0.0001  0.69 
[0.60, 
0.78] 
0.3 
         
Sin (week) 
 
0.88 
[0.78, 
0.99] 
 0.92 
[0.82, 
1.03] 
Cos (week) 
 
1.48 
[1.31, 
1.66] 
<0.0001e 
 1.28 
[1.14, 
1.45] 
<0.0001e 
         
FOI 
 
- - -  1.89 
[1.74, 
2.04] 
< 0.0001 
         Random effects:         
   Village  0.08  < 0.01  0.14  <0.001 
   Child within 
village 
 
0.33  < 0.001  0.11  <0.01 
Log likelihood  -843    -683   
AIC  1701    1382   
Seasonal effects         
Amplitude 
 
0.41 
[0.37, 
0.51] 
  0.26 
[0.24, 
0.37] 
 
Peak (week)  49    49   
Trough (week)  23    23   
 
aIRR: incidence rate ratio, CI95: 95% confidence interval. b insecticide treated net use: 0% vs 100% use 
c Force of infection (# new clonse per year-at-risk), cub-root transformed. 
d Akaike Information Criterium 
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General Discussion 
 
The Complex Pattern of Malaria Infection and Disease 
The epidemiology of malaria is the result of a complex interplay of the parasites, their human 
hosts and the mosquito vector. During its life cycle the parasite passes from the mosquito 
salivary glands through the human skin to the liver, and then invades red blood cells in 
continuous cycles. A small proportion of parasites transform into sexual forms, gametocytes, 
and once taken up during a mosquito blood meal they undergo recombination and migrate to 
the salivary glands, where the sporozoites start the cycle again (reviewed in (Bousema and 
Drakeley, 2011; Prudencio et al., 2006).  
All clinical symptoms are caused by the red blood cell cycle, while sporozoite invasion and the 
liver stage do not cause disease. P. vivax parasites can appear in the blood stream after 
relapses of hypnozoites, i.e. liver stages that stay dormant for an extended period of time 
after mosquito transmission. These relapsing parasites can induce clinical disease, however 
the onset and frequency of malaria depends not only on transmission intensity and relapses, 
but is also strongly influenced by acquired immunity, which develops in areas of intense 
transmission after a few years (Koch, 1900).  
 
P. vivax and Malaria Elimination 
Understanding the factors influencing transmission and immunization will become 
increasingly important in the upcoming era of malaria eradication. In this context, the specific 
biological characteristics of P. vivax are of particular relevance, as antimalarial interventions 
might not affect all Plasmodium species similarly. Interventions already led to a decrease of 
malaria in many places of the world. In several countries, however, this was accompanied by 
a shift in predominance from P. falciparum to P. vivax. Such results were obtained from the 
highlands of Papua New Guinea (Mueller et al., 2005), Colombia (Rodriguez et al., 2011), 
Cambodia, Laos or eastern Thailand (Cui et al., 2011).  
The elimination of P. vivax is complicated by several specific characteristics of this parasiteʼs 
biology. Firstly, hypnozoites that relapse after an unpredictable period of time require long-
term surveillance of patients after clearance of acute blood stage parasitemia. This effort is 
required even in regions of very low transmission and thus a low risk of re-infection. Secondly, 
P. vivax parasitemia is generally lower than that of P. falciparum. This might lead to 
underestimation of P. vivax infections by standard light microscopy. Thirdly, fast acquisition of 
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semi-immunity leads to a large number of asymptomatic P. vivax carriers, all potentially 
contributing to transmission.  As a consequence of these discrepancies to P. falciparum, the 
need for P. vivax specific research for malaria elimination has been addressed (Feachem et 
al., 2010; Mueller et al., 2009), as well as the need for new drugs targeting hypnozoites (Wells 
et al., 2010). 
Feasibility of elimination of malaria in a country depends on the epidemiological situation, 
including the level of transmission and the risk of reintroduction of malaria due to migration, 
as well as on the health infrastructure, the political situation and the commitment of the 
government towards malaria elimination. In a recent report, Tatem and coworkers have 
indentified PNG among the countries with the poorest health infrastructure, when comparing 
all malaria endemic countries (Tatem et al., 2010). Given the high prevalence of P. vivax, the 
report ranked PNG as one of the countries facing the biggest difficulties to eliminate P. vivax 
malaria (Tatem et al., 2010). In the same report the north coast of PNG was identified as one 
of the few regions outside sub-Saharan Africa, where transmission needs to be reduced by 
more than 90% in order to eliminate malaria (Tatem et al., 2010). 
 
P. vivax Epidemiology in Papua New Guinea 
This thesis addresses a number of questions related to P. vivax epidemiology and population 
genetics in Papua New Guinea (PNG). Samples were collected in a previously described 
cohort study in PNG in an area with high prevalence of around 50% for P. vivax as well as P. 
falciparum. Children aged 1 to 4.5 years were followed up in two-monthly cross-sectional 
surveys and during all febrile episodes (Lin et al., 2010). To gain a more comprehensive view 
of P. vivax populations in PNG, P. vivax clones from three other sites in PNG were typed and 
population structure was assessed.  
In preceding molecular-epidemiological studies, Sonja Schoepflin had genotyped all P. 
falciparum clones using the marker msp2 (Schoepflin et al., 2009). In the total sample set, 
over 3000 samples were positive for P. vivax. In the course of this thesis all P. vivax positive 
samples were genotyped for the markers msp1F3 and MS16. Both markers showed high 
numbers of alleles. The virtual heterozygosity (the chance that two individual clones carry 
different alleles of a marker) was 88.1% for msp1F3 and 97.1% for MS16 (details given in 
chapter 3). By using both highly polymorphic markers in combination only a small number of 
parasite clones will be missed due to the fact that two concurrent infections within one host 
share the same marker allele.  
Parasite diversity as well as prevalence may be underestimated owing to imperfect 
detectability of all parasite clones present in a host. One reason for imperfect detection 
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probably is a parasite density below the detection limit of PCR. While the limits of microscopic 
detection are well known, the detection limit of PCR based techniques is less acknowledged. 
Repeated analysis of the same individual can be applied to investigate sensitivity in field 
samples of very low parasite density. Different factors may cause low densities, or densities 
changing from one day to another. Host immunity, or in the case of P. vivax, the host cell 
preference for reticulocytes, results in overall low parasite density. The effects of 
synchronized schizogony, and thus a marked increase in parasite numbers in 48 hour 
intervals, and in the case of P. falciparum sequestration, resulting in absence of parasites 
from the blood stream for part of the red blood cell cycle, can cause dramatical fluctuation in 
parasite density in the blood stream within a short period of time. 
Molecular epidemiological studies rely on a reliable detection of parasites. As we were 
especially interested in age trends and differences between parasite species, we estimated 
the proportion of infections missed in a single blood sample for both species, P. falciparum 
and P. vivax, using data collected over 12 months. To this aim, we have compared blood 
samples taken from the same individual in a 24-hour interval. Within one day no gain or loss 
of an infection is expected. Therefore we concluded that parasites, observed only on one day, 
must have been below the detection limit on the other day.  
The microscopy and genotyping results from over 1ʼ000 paired blood samples showed that 
the impact of repeated sampling on prevalence is moderate: only around 10% of all parasite 
positive samples were missed by sampling once only. The only exception to a generally low 
impact of single sampling was observed for the microscopical detection of P. falciparum, 
where 22% of infections were missed when sampling on a single day only. The effect is more 
pronounced when individual clones are studied, with 18% of all P. falciparum and, depending 
on the marker, 22% to 28% of all P. vivax clones being missed by sampling only once. We did 
not observe an effect of age on detectability, however, with increasing multiplicity of infection 
(MOI) the detectability decreased. There were no pronounced differences between 
Plasmodium species, suggesting that the generally lower P. vivax densities balance the 
reduction of detectability in P. falciparum caused by sequestration and synchronized 
schizogony. 
Chapter 3 of this thesis describes in detail the diversity of P. vivax clones and MOI in the 
cohort study in PNG. Diversity was very high with 154 different two-loci haplotypes detected 
in 219 single clone infections. No haplotypes were predominant. Mean MOI was 2.7 with a 
slight increase with age, while P. falciparum MOI was only 1.5. No seasonal trend in MOI was 
observed; likely relapses added to MOI in times of less mosquito transmission. 
Plasmodium parasites live in a highly structured environment in their hosts and sexual 
recombination in the mosquito midgut is only possible if different gametocytes are taken up 
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(Mzilahowa et al., 2007). This is the case if human hosts are infected simultaneously with 
different clones and if more than one clone produce gametocytes. High MOI is thus expected 
to be associated with high recombination between different parasites, and as a consequence, 
with low levels of linkage disequilibrium (LD). It has been shown in P. falciparum that LD 
decreases with increasing transmission intensity and with a high proportion of human hosts 
carrying multiple clone infections (Mu et al., 2005). 
The extent of LD, as well as the parasite population structure, influence the spread of drug 
resistant parasites. High gene flow, resulting in little differences between geographically 
separated parasite populations, leads to high admixture and thus low LD. In such situations 
linkage between mutated loci that confer resistance to antimalarial drugs, is expected to be 
low (Talisuna et al., 2003). If a single gene confers drug resistance, the resistance trait likely 
spreads faster if gene flow is high (Talisuna et al., 2003). This is for example the case for 
resistance to sulphadoxine-pyrimethamine caused by mutations in the dihydrofolate 
reductase (dhfr) gene (Peterson et al., 1990).  
Marked population differences and high levels of LD were shown in P. vivax populations from 
regions of low to moderate transmission in Latin America and Asia (Gunawardena et al., 
2010; Imwong et al., 2007a; Van den Eede et al., 2010). Also P. falciparum in PNG shows a 
moderate level of population structure (Schultz et al., 2010). To compare these previous 
results from P. falciparum from PNG or P. vivax from other endemic settings, with P. vivax 
populations from in PNG, we have genotyped a subset of the samples from our cohort study 
and samples from 3 other locations in PNG for 13 additional neutral markers (chapter four). 
We did not detect population genetic differences between sites or LD, not even in the 
highlands, where substantially lower P. vivax transmission was expected. Together with the 
finding of a high MOI, our popuation genetic analyses indicated a panmictic population 
structure for P. vivax in PNG. This all implies that interventions to reduce transmission are not 
feasible in a restricted area due to high numbers of immigrating parasites. 
The outcome of disease is strongly influenced by the acquisition of immunity to malaria. The 1 
to 4.5 year old children in our cohort showed contrasting trends in episodes caused by P. 
falciparum and P. vivax. Incidence caused by P. vivax decreased over the whole age group 
from approximately 3.5 to 1.5 clinical episodes per child per year (Lin et al., 2010). In contrast, 
P. falciparum incidence rose from 1.2 clinical episodes per year in children aged 1 year to 3.5 
episodes per year in 3-year-old children. Afterwards incidence decreases. It is generally 
observed that P. vivax causes disease mainly in very young children, while immunity to P. 
falciparum is acquired more slowly and thus P. falciparum causes episodes also in older 
children (Gunewardena et al., 1994; Mendis et al., 2001; Michon et al., 2007).  
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Laboratory experiments have shown that acquired immunity to malaria is largely clone-
specific, i.e. immunity is less effective against infections with heterologous strains (Jeffery, 
1966; Lyon et al., 2008). It has been speculated that the total number of infections acquired 
over time is a driving force behind the speed of acquisition of immunity (Weisman et al., 
2001). In chapter five we have estimated the molecular force of infection (molFOI, the number 
of infections acquired per time) in our cohort. On average, a child was infected with more than 
14 P. vivax clones per year, more than twice the number of P. falciparum clones acquired per 
year (Mueller et al., manuscript in preparation). P. vivax FOI did not change with age, 
indicating the decrease in P. vivax incidence indeed is a result of acquired immunity and is 
not caused by a decrease in numbers of new infections. We therefore suggest that the higher 
number of P. vivax infections acquired over time, as compared to the number of P. falciparum 
infections, leads to immunity in a shorter time than for P. falciparum. The same argument is 
true for the higher P. vivax MOI. 
While P. falciparum molFOI was found to be a direct measure for transmission (Mueller et al., 
manuscript in preparation), any P. vivax parasite detected in the blood stream could also be 
the result of relapsing hypnozoites. Longitudinal sampling in P. vivax patients has 
demonstrated that the genotype of relapsing parasites differs to the one in the last blood 
stage infection in most of the cases (Imwong et al., 2007b; Restrepo et al., 2011). Thus 
relapses further increase molFOI. It is however not known whether the relapsing clone had 
been present as blood stage infection at an earlier time point. The answer to this question 
would require studies with infection of P. vivax naïve individuals in a setting where re-infection 
can be excluded, and subsequent genotyping of all blood stage parasites over several 
months. 
molFOI is a central epidemiological parameter, and is of great relevance to monitor 
interventions, such as bed nets, which aim at lowering the number of infections acquired. 
Indeed, use of bed nets has led to a decrease of P. falciparum molFOI and incidence (Mueller 
et al., manuscript in preparation). This effect of bed nets is less clear for P. vivax incidence, 
most likely because of relapses that occur independent of bed net use. The higher P. vivax 
MOI and molFOI in comparison to the corresponding P. falciparum parameters certainly can be 
attributed to relapses. But also a higher transmission of P. vivax, e.g. due to different vector 
preference of P. vivax and P. falciparum, might play a role. No entomological studies were 
undertaken in parallel to our cohort, thus we cannot provide information on entomological 
inoculations rates for P. vivax and P. falciparum. 
Due to the high diversity of P. vivax clones and the high level of gene flow between villages, 
children are infected within their first years of life with a large number of different genotypes. 
These infections cause a peak P. vivax morbidity in early childhood, and in parallel, a fast 
acquisition of immunity against disease. 
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Technical Considerations 
Genotyping P. vivax using size polymorphic markers 
For all studies presented in this thesis parasites were genotyped by PCR amplification of 
length polymorphic DNA markers followed by sizing of PCR products by capillary 
electrophoresis (CE). Length polymorphic markers have been used to genotype Plasmodium 
species since early molecular-epidemiological studies in the 1990s. Early genotyping 
protocols for P. vivax used PCR followed by restriction fragment length polymorphism (RFLP) 
to study the diversity of parasites, including the number of strains in a population or the 
multiplicity of infection (Bruce et al., 1999; Imwong et al., 2005).  PCR-RFLP also proved 
useful to classify the outcome of drug treatment by comparing parasites at day 0 with 
parasites at day of recurrent parasitemia, and thus differentiating between new infection and 
treatment failure (Ohrt et al., 1997).  
Given the relatively low level of technical equipment needed for PCR-RFLP experiments, the 
method has proven useful in endemic countries until now (Mbacham et al., 2010; Zhong et al., 
2011). Nevertheless, the method has some disadvantages: Analysis of PCR or restriction 
fragments on agarose gels can be difficult, especially if alleles of a given marker differ by only 
a few base pairs (as it is usually observed in microsatellite typing).  The number of size 
variant alleles that can be acurately discriminated by gel electophoresis clearly is limited, in 
particular if for larger fragment lengths. Further problems arise in case of multiple clone 
infections, when the analysis of large numbers of bands after restriction digest of different 
clones can be extremely difficult. Finally, minority clones representing only a small fraction of 
the entire PCR product are likely overseen on a gel. 
CE overcomes several of these problems. PCR products differing as little as 2 or 3 base pairs 
in size can be reliably differentiated, allowing discrimination of a large number of alleles for a 
single marker. Multiclonal infections can easily be identified. However, rules and cut offs need 
to be defined to distinguish true, but low intensity signals from background noise. Other 
authors have suggested to define a threshold of one quarter or one third of the intensity of the 
mayor peak in a sample, and to count minor peaks only if their intensity reaches at least this 
intensity (Havryliuk and Ferreira, 2009). However, in natural infections densities of concurrent 
parasite clones within a host might differ by several orders of magnitude, and the intrinsic 
ratios of peak intensities of two amplification products are still reflected even after nested 
PCR (Hunt et al., 2005). Applying a threshold as suggested would eliminate a considerable 
number of minority clones in a blood sample.  We have thus defined a fixed threshold, 
independent of the intensity of the predominant clone.  
In this context it should be noted that clones sharing markers of identical lengths will not be 
resolved by capillary sizing of fragments, but could be differentiated by sequencing. Thus, it is 
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important to consider that estimates of multiplicity obtained by PCR-CE are useful 
epidemiological parameter, but do not necessarily measure absolute MOI. 
 
Outlook: next generation sequencing 
Next generation sequencing technologies offer new opportunities and might overcome some 
of the limitations mentioned above. They require, however, sophisticated laboratory facilities 
as well as sound bioinformatics skills to analyse huge amounts of data produced. Both these 
factors are in high demand in particular in endemic countries. Analysis of large sample sets 
obtained in field studies or in the course of drug efficacy trials by next generation sequencing 
approaches is not yet done, but might become the method of choice in the future. 
These technologies have already given interesting insights and helped to interprete field data. 
Recently Juliano and coworkers did massively parallel pyrosequencing of the P. falciparum 
msp1 and msp2 genes in field patient isolates. By analysing on average over 1300 reads per 
patient, they were able to detect low density variants, and indeed they found up to six times 
more clones per patient as determined by PCR combined with gel electrophoresis (Juliano et 
al., 2010). Likewise, whole genome SNP-typing proved useful for population genetic analysis. 
Campino et al. have genotyped over 300 single nucleotide polymorphis (SNPs) in several P. 
falciparum strains applying an Illumina genotyping assay. They were able to distinguish 
strains of different geographical origin and confirmed population structure obtained in 
previous studies (Campino et al., 2011). Typing SNPs rather than length polymorphism in 
microsatellites makes it possible to analyze further aspects of parasite biology and evolution. 
By assessing the rate of dN/dS, i.e. the rate of non-synonymous (dN) mutations per 
synonymous (dS) mutation, loci under selection (characterized by high values of dN/dS) can 
be identified. In case of field samples carrying multiple-clone infections, however, 
reconstruction of multi-locus haplotypes is currently impossible. 
An increasing number of new technologies for genotyping and genome analysis are made 
available, and the initially high costs decreased dramatically over the past few years. They 
overcome some of the limitations of more traditional approaches, but might also lead to 
disproportional high complexity of laboratory and data analysis methods. For future studies 
the methods to apply need to be evaluated carefully and selected in accordance with the 
prime research questions. 
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Conclusions 
We have for the first time genotyped a large number of P. vivax clones from a cohort of 264 
children in an area highly endemic for P. vivax and P. falciparum (Lin et al., 2010). Our choice 
of two highly polymorphic markers allows discrimination of clones with a high resolution, and 
thus we could assess multiplicity (MOI) and molecular force of infection (molFOI). All P. 
falciparum clones detected in this cohort have been genotyped previously, allowing 
comparisons of Plasmodium species. Most likely the values measured are underestimates 
because a proportion of clones was missed as a result of imperfect detectability of low density 
clones. However, as detectability does not differ between parasite species or age groups, 
comparisons and age trends of MOI and FOI were possible. We detected substantially higher 
P. vivax MOI and FOI compared to P. falciparum, most likely caused by relapses. High MOI 
increases recombination and thus seemed to eliminate population substructuring, in contrast 
to a moderate population structuring of P. falciparum in PNG (Schultz et al., 2010) P. vivax 
allelic composition does not differ between sites in PNG. High MOI and molFOI as well as high 
levels of gene flow imply great resilience of P. vivax towards antimalarial interventions 
(Mendis et al., 2001). 
P. vivax mol FOI was twice as high as that of P. falciparum (Schoepflin et al., manuscript in 
preparation), which likely leads to faster immunization and could therefore  explain the 
differences in  the age distribution of P. vivax versus  P. falciparum incidence  (Lin et al., 
2010).  
This thesis can serve as a reference for molecular epidemiology of P. vivax in high 
transmission areas and might be useful for future comparisons with P. falciparum. Control of 
P. vivax malaria is complicated by the large reservoir of dormant liver stages that relapse 
independently of mosquito transmission. The absence of population structuring implies 
intensive migration of parasites and affects the spread of drug resistance. P. vivax will thus 
present a major challenge on the way towards control and future elimination of malaria in 
PNG. 
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Plasmodium vivax intervention trials customarily report uncorrected treatment failure rates. Application of
recrudescence-reinfection genotyping and drug resistance single-nucleotide polymorphism typing to a 4-arm
comparative efficacy trial illustrated that molecular approaches can assist in understanding the relative
contributions of true drug resistance (recurrent with same genotype) and new infections to treatment failure.
The PCR-corrected adequate clinical and parasitologic response may constitute an informative secondary
endpoint in future P. vivax drug trials.
Approximately 40% of the world’s population is at risk of
vivax malaria (7). Recent interest in this infection has been
heightened by the emergence of chloroquine (CQ) resistance
in 1989 (21) and subsequent reports of severe disease (6, 25).
There has been a resultant increase in monitoring of Plasmo-
dium vivax drug sensitivity through efficacy trials (2, 12, 19, 20,
22) and identification of molecular markers of resistance (1, 8,
16, 24).
Recurrent P. vivax parasitemia in intervention trials may
indicate not only treatment failure but also activation of liver-
stage hypnozoites (relapses) or a new infection (17). Two stud-
ies of patients not at risk of reinfection found that most re-
lapses were genetically distinct from the primary infections (4,
10). Standardized genotyping protocols characterizing treat-
ment failure have not yet been developed for antimalarial trials
for vivax malaria. However, candidate markers on genes cod-
ing for surface proteins (2, 9, 14) or neutral markers such as
microsatellites (10, 13, 14) could, if sufficiently polymorphic,
allow discrimination between strains in assessing posttreat-
ment recurrence in a way analogous to that established for
falciparum malaria (26). In a recent study of small numbers of
children in Papua New Guinea (PNG) treated with amodi-
aquine or CQ plus sulfadoxine-pyrimethamine (SP), the au-
thors recommended use of two highly polymorphic markers
associated with a very low probability of independent infec-
tions carrying the same alleles (14). We have utilized this
approach in a retrospective analysis of samples taken from a
larger number of PNG children participating in an efficacy trial
comparing CQ-SP and three artemisinin combination thera-
pies (ACTs) (12), and we performed a complementary analysis
of 4-aminoquinoline and SP drug resistance markers (3, 5,
15, 24).
The study was conducted in Madang and East Sepik Prov-
inces between 2005 and 2007 (12) and involved 195 children
aged 0.5 to 5 years with !250 P. vivax asexual forms/"l and no
features of severe malaria who were randomly assigned to
CQ-SP, artesunate-SP (ARTS-SP), dihydroartemisinin-piper-
aquine (DHA-PIP), or artemether-lumefantrine (AL) arms of
the trial. The non-PCR-corrected clinical and parasitologic
failure rates were 49.0%, 48.7%, 15.8%, and 51.5%, respec-
tively, after 28 days of follow-up and 87.0%, 66.7%, 30.6%, and
69.7% after 42 days. There was no difference between the rate
of recurrent P. vivax parasitemia between the CQ-SP, ARTS-
SP, and AL arms (P # 0.28, log rank test) (Fig. 1A).
Genotyping based on length polymorphism of a region of
msp1 (msp1F3) and a microsatellite, MS16, was performed;
this combination has a probability of $0.25% for two isolates
to carry the same alleles (14). Recurrent infections occurring
during 42 days of follow-up that contained at least one geno-
type present at baseline were classified as recurrent infections
with the same genotype, and recurrences with a different ge-
notype were classified as new infections. Since P. vivax geno-
typing was not prespecified and in view of limited sample
volumes, usable blood samples on the day of recurrent para-
sitemia were available for 70.1% and 70.3% of the samples to
days 28 and 42, respectively. The present substudy was ap-
proved by the PNG IMR Institutional Review Board (approval
1029).
During 28 days of follow-up, there were no significant dif-
ferences between CQ-SP, ARTS-SP, or AL in the rates of
either recurrent parasitemia with the same genotype (Fig. 1B)
(P# 0.74) or new infections (Fig. 1C) (P# 0.59). Up to day 42,
there were significantly more cases of recurrent parasitemia
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with the same genotype in the CQ-SP arm but not in the
number of new infections (Table 1). At days 28 and 42, fewer
infections with either the same or different genotypes were
observed after DHA-PIP (Table 1). Day 42 treatment failure
rates were 87.0%, 66.7%, 69.7%, and 30.6% for CQ-SP,
ARTS-SP, AL, and DHA-PIP, respectively, and 51.4%, 28.1%,
22.2%, and 9.7% after PCR correction.
To better understand these differences, we screened muta-
tions in two P. vivax genes related to SP or 4-aminoquinoline
resistance, namely, dhfr (5) and mdr1 (3, 23). Of patients allo-
cated to the CQ-SP or ARTS-SP groups, 32 (69.6%) and 38
(71.8%), respectively, were infected with at least one triple or
quadruple dhfrmutant parasite at enrolment (57L, 58R, and 61
M, ! 117T). While the small sample size did not allow firm
conclusions regarding selection of mutant parasites, an in-
crease in the frequency of triple/quadruple dhfr mutants was
observed in the recurrent parasitemias with the same genotype
(based on msp1/MS16 genotyping) in the CQ-SP (15/18;
83.3%) and ARTS-SP (9/9; 100%) arms. No such increase was
observed in the AL arm (20/32 [62.5%] versus 4/6 [66.7%]). In
the CQ-SP arm, the presence of parasites with triple/quadruple
dhfr (57L, 58R, 61M/117T) plusmdr1 976F was associated with
treatment failure (recurrent parasitemia with same genotype)
with an odds ratio of 3.9 (95% confidence interval, 0.6–28.2;
P" 0.08). Given the overall high levels of triple/quadruple dhfr
mutants, this adds to emerging evidence that mdr1 (976F)
mutations may be involved in reduced P. vivax CQ sensitivity
(16, 24).
Despite comparable non-PCR-corrected adequate clinical
and parasitologic responses (ACPRs), the genotyping/molecu-
lar marker data reveal between-treatment differences in recur-
rent parasitemia that reflect the pharmacodynamic and phar-
macokinetic profiles of the antimalarial drugs (11, 18, 27).
Given the high prevalence of quadruple dhfr mutant parasites
and the relatively short elimination half-lives of the compo-
nents, SP is likely to have contributed little to either initial
parasite clearance or to prevention of new (or relapsing) in-
fections during follow-up in the CQ-SP and ARTS-SP arms.
FIG. 1. Kaplan-Meier curves for time to first recurrent P. vivax
infection during 6 weeks of follow-up. (A) Time to any recurrent P.
vivax parasitemia; (B) time to recurrent infection with the same geno-
type; (C) time to recurrent infection with a new genotype.
TABLE 1. Genotyping results of recurrent parasitemia during 6 weeks of follow-up
Follow-up period, genotyping
method, and result
No. of patients in assessment group and no. (%) with indicated result P valuea
CQ-SP ART-SP AL DHA-PIP
3 single
arms
DHA vs
combined
28-day assessment 51 39 33 38
Noncorrected ACPR 26 (51.0) 20 (51.3) 16 (48.5) 32 (84.2) 0.97 #0.001
Evaluable by PCR 44 34 29 34
No recurrent parasitemia 26 (59.1) 20 (58.8) 16 (55.2) 32 (94.1)
Same genotype 10 (22.7) 4 (11.8) 6 (20.7) 1 (2.9) 0.44 0.03
New infection 8 (18.2) 10 (29.4) 7 (22.6) 1 (2.9) 0.51 0.005
PCR-corrected ACPRb 34 (77.3) 30 (88.2) 23 (79.3) 33 (97.1) 0.44 0.03
42-day assessment 46 39 33 36
Noncorrected ACPR 6 (13.0) 13 (33.3) 10 (30.3) 25 (69.4) 0.03 #0.001
Evaluable by PCR 35 32 27 31
No recurrent parasitemia 6 (17.1) 13 (40.6) 10 (37.0) 25 (80.6)
Same genotype 18 (51.4) 9 (28.1) 6 (22.2) 3 (9.7) 0.03 0.01
New infection 11 (31.4) 10 (31.3) 11 (40.7) 3 (9.7) 0.94 0.03
PCR-corrected ACPRb 17 (48.6) 23 (71.9) 21 (77.8) 28 (90.3) 0.03 0.01
a Based on a chi-squared test, with P values for the CQ-SP, ART-SP, and AL treatments arms (single arms) or for DHA-PIP and the other three arms combined
(“combined”).
b PCR-corrected ACPR, the sum of no recurrent parasitemia and new infections.
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Thus, ARTS would have been primarily responsible for suc-
cessful initial clearance in the latter arm. The predominantly
late occurrence of recurrent parasitemia irrespective of origin
in the CQ-SP arm indicates that CQ remained partially effec-
tive despite the positive selection of mdr1 mutant (976F) par-
asites. The difference in efficacy between DHA-PIP and AL
may largely reflect the terminal elimination half-lives of PIP (3
to 4 weeks) and lumefantrine (4 to 6 days), with long-lasting
PIP suppression of reinfections and relapses regardless of ge-
notype and plasma lumefantrine concentrations beyond 2
weeks posttreatment that were insufficient to prevent recur-
rence (20).
The present preliminary data highlight the important poten-
tial contribution that genotyping/molecular marker typing can
make to improved characterization of recurrent parasitemia in
P. vivax intervention trials. Since genotyping cannot differen-
tiate between true failures and relapses with the same geno-
type, the primary endpoint should remain ACPR without
genotyping. However, ACPR after genotyping based on epi-
demiologically appropriate markers could be added as a sec-
ondary endpoint. Further research may promote harmoniza-
tion of P. vivax genotyping protocols and the adoption of
consensus recommendations.
The intervention trial was sponsored by WHO Western Pacific Re-
gion, Rotary Against Malaria (PNG), and the National Health and
Medical Research Council (NHMRC) of Australia (grant 353663).
The present substudy was funded by NHMRC project grant 1010203.
T.M.E.D. was supported by an NHMRC Practitioner fellowship.
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